[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1408
1. Tanaka T: Colorectal carcinogenesis: Review of human and experimental animal studies. J Carcinog; 2009;8:5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The focus is on human and murine colorectal carcinogenesis and the histogenesis of this malignant disorder.
  • A summary of a model of colitis-associated colon tumorigenesis (an AOM/DSS model) will also be presented.
  • The earliest phases of colorectal oncogenesis occur in the normal mucosa, with a disorder of cell replication.
  • The large majority of colorectal malignancies develop from an adenomatous polyp (adenoma).
  • Carcinomas usually originate from pre-existing adenomas, but this does not imply that all polyps undergo malignant changes and does not exclude de novo oncogenesis.
  • Besides adenomas, there are other types of pre-neoplasia, which include hyperplastic polyps, serrated adenomas, flat adenomas and dysplasia that occurs in the inflamed colon in associated with inflammatory bowel disease.
  • Colorectal neoplasms and/or pre-neoplasms can be prevented by interfering with the various steps of oncogenesis, which begins with uncontrolled epithelial cell replication, continues with the formation of adenomas and eventually evolves into malignancy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Drug Metab Rev. 1998 May;30(2):405-19 [9606610.001]
  • [Cites] Science. 1993 Jun 11;260(5114):1658-61 [8503013.001]
  • [Cites] Nature. 1993 Jul 22;364(6435):352-5 [8332195.001]
  • [Cites] Int J Cancer. 1993 Jan 21;53(2):260-3 [7678832.001]
  • [Cites] Cell. 1993 Nov 19;75(4):817-25 [8242752.001]
  • [Cites] Cell. 1993 Nov 19;75(4):805-16 [8242751.001]
  • [Cites] Mol Cell Biol. 1993 Jul;13(7):4242-50 [8321226.001]
  • [Cites] Biochemistry. 1991 May 14;30(19):4637-48 [2029511.001]
  • [Cites] Hum Mol Genet. 1992 Sep;1(6):387-90 [1338760.001]
  • [Cites] Gut. 1992 Apr;33(4):524-9 [1316306.001]
  • [Cites] Carcinogenesis. 1992 Sep;13(9):1509-12 [1394832.001]
  • [Cites] Nature. 1992 Sep 17;359(6392):235-7 [1528264.001]
  • [Cites] Cancer Res. 1991 Mar 1;51(5):1564-7 [1997197.001]
  • [Cites] Am J Clin Nutr. 1991 Jan;53(1 Suppl):226S-237S [1985392.001]
  • [Cites] Cancer Res. 1990 Dec 15;50(24):7937-41 [2253235.001]
  • [Cites] N Engl J Med. 1990 Nov 1;323(18):1228-33 [2215606.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] Prog Clin Biol Res. 1988;279:319-33 [2847199.001]
  • [Cites] Pathology. 1989 Apr;21(2):138-42 [2812873.001]
  • [Cites] Cancer. 1989 Sep 1;64(5):1138-46 [2758387.001]
  • [Cites] Cancer. 1989 Aug 15;64(4):950-5 [2743285.001]
  • [Cites] Cancer. 1988 Dec 1;62(11):2373-7 [3179952.001]
  • [Cites] Cancer Res. 1988 Jul 15;48(14):4121-6 [3383201.001]
  • [Cites] Cancer. 1988 Feb 15;61(4):829-34 [3338040.001]
  • [Cites] Int Rev Cytol. 1984;90:309-73 [6389415.001]
  • [Cites] Cancer Lett. 1987 Oct 30;37(2):147-51 [3677050.001]
  • [Cites] Cancer Res. 1985 Jan;45(1):1-8 [3880665.001]
  • [Cites] Dis Colon Rectum. 1985 Nov;28(11):847-51 [4053897.001]
  • [Cites] Gastroenterology. 1990 Mar;98(3):694-702 [1688816.001]
  • [Cites] Cell. 1990 Jun 1;61(5):759-67 [2188735.001]
  • [Cites] Am J Surg Pathol. 1990 Jun;14(6):524-37 [2186644.001]
  • [Cites] Science. 1990 Jan 5;247(4938):49-56 [2294591.001]
  • [Cites] J Cancer Res Clin Oncol. 1984;108(1):129-34 [6430908.001]
  • [Cites] Cancer Invest. 1983;1(1):41-7 [6667399.001]
  • [Cites] J Clin Pathol. 1982 Aug;35(8):830-41 [7107955.001]
  • [Cites] Gastroenterology. 1981 Mar;80(3):578-84 [7450448.001]
  • [Cites] Cancer. 1977 Nov;40(5 Suppl):2436-45 [200341.001]
  • [Cites] Cancer Res. 1977 Nov;37(11):4182-9 [198131.001]
  • [Cites] Virchows Arch B Cell Pathol. 1978 Dec 21;29(3):211-23 [104430.001]
  • [Cites] Biochem Pharmacol. 1977 Oct 1;26(19):1763-8 [907715.001]
  • [Cites] Lab Invest. 1974 Apr;30(4):505-13 [4363166.001]
  • [Cites] J Natl Cancer Inst. 1973 Sep;51(3):1029-39 [4355212.001]
  • [Cites] Nat Rev Cancer. 2002 Aug;2(8):594-604 [12154352.001]
  • [Cites] J Biol Chem. 2002 Jul 19;277(29):26281-5 [12011067.001]
  • [Cites] Lancet Oncol. 2002 Feb;3(2):83-8 [11905459.001]
  • [Cites] Clin Cancer Res. 2002 Feb;8(2):314-46 [11839647.001]
  • [Cites] Gut. 2001 Apr;48(4):526-35 [11247898.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3416-21 [11248093.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2640-5 [11226292.001]
  • [Cites] BMJ. 2000 Oct 7;321(7265):886-9 [11021873.001]
  • [Cites] Drugs Aging. 2000 May;16(5):329-34 [10917070.001]
  • [Cites] Mol Med Today. 2000 Dec;6(12):462-9 [11099951.001]
  • [Cites] Chirurg. 2000 Oct;71(10):1230-4; discussion 1234-5 [11077584.001]
  • [Cites] Nature. 2000 Nov 16;408(6810):307-10 [11099028.001]
  • [Cites] Am J Pathol. 2000 Sep;157(3):737-45 [10980113.001]
  • [Cites] Cancer Res. 2000 Jul 1;60(13):3333-7 [10910033.001]
  • [Cites] Cancer Res. 2000 Jul 1;60(13):3323-7 [10910031.001]
  • [Cites] Gut. 2000 Jul;47(1):43-9 [10861263.001]
  • [Cites] Mt Sinai J Med. 2000 May;67(3):227-40 [10828908.001]
  • [Cites] Dis Colon Rectum. 2000 Jun;43(6):782-7 [10859077.001]
  • [Cites] Science. 2000 May 12;288(5468):1053-8 [10807576.001]
  • [Cites] Oncol Rep. 2000 May-Jun;7(3):501-8 [10767359.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Mar;9(3):239-47 [10750661.001]
  • [Cites] Toxicol Lett. 2000 Mar 15;112-113:395-402 [10720758.001]
  • [Cites] Carcinogenesis. 2000 Mar;21(3):469-76 [10688867.001]
  • [Cites] Oncogene. 2000 Jan 27;19(4):546-55 [10698524.001]
  • [Cites] Carcinogenesis. 2009 Feb;30(2):183-96 [19037092.001]
  • [Cites] Gastroenterology. 2009 Feb;136(2):542-50.e6 [19103203.001]
  • [Cites] CA Cancer J Clin. 2009 Jan-Feb;59(1):27-41 [19147867.001]
  • [Cites] Cancer Prev Res (Phila). 2008 Dec;1(7):562-7 [19139006.001]
  • [Cites] Chem Biol Interact. 2009 Jan 27;177(2):128-36 [19028472.001]
  • [Cites] Gastroenterology. 2009 Mar;136(3):780-98 [19263594.001]
  • [Cites] Int J Cancer. 2009 Jan 15;124(2):264-71 [19003968.001]
  • [Cites] World J Gastroenterol. 2008 Nov 21;14(43):6632-5 [19034964.001]
  • [Cites] Br J Cancer. 1998 Feb;77(4):588-94 [9484816.001]
  • [Cites] Br J Cancer. 1998;77(3):466-71 [9472645.001]
  • [Cites] Dis Colon Rectum. 1997 Oct;40(10 Suppl):S80-5 [9378018.001]
  • [Cites] Am J Pathol. 1997 Mar;150(3):833-9 [9060821.001]
  • [Cites] Am J Gastroenterol. 1997 Feb;92(2):204-11 [9040192.001]
  • [Cites] Science. 1997 Feb 14;275(5302):967-9 [9020077.001]
  • [Cites] Cell. 1997 Feb 7;88(3):323-31 [9039259.001]
  • [Cites] Nat Genet. 1996 Nov;14(3):255-7 [8896552.001]
  • [Cites] Cell. 1996 Dec 13;87(6):1001-14 [8978605.001]
  • [Cites] Biochem Biophys Res Commun. 1996 Oct 14;227(2):553-7 [8878551.001]
  • [Cites] Cell. 1996 Oct 18;87(2):175-85 [8861902.001]
  • [Cites] Cell. 1996 Oct 18;87(2):159-70 [8861899.001]
  • [Cites] Oncogene. 1996 Aug 15;13(4):787-95 [8761300.001]
  • [Cites] Nat Genet. 1996 Jul;13(3):343-6 [8673134.001]
  • [Cites] Am J Surg Pathol. 1994 Jun;18(6):559-68 [7513966.001]
  • [Cites] Nature. 1994 Jun 2;369(6479):411-4 [8196769.001]
  • [Cites] Science. 1994 Jun 3;264(5164):1463-7 [7811320.001]
  • [Cites] Cancer Lett. 1995 Jun 29;93(1):55-71 [7600544.001]
  • [Cites] Cell. 1995 Jan 27;80(2):293-9 [7834749.001]
  • [Cites] Science. 1995 Jun 2;268(5215):1336-8 [7761852.001]
  • [Cites] Cancer Res. 1994 Nov 1;54(21):5527-30 [7923190.001]
  • [Cites] Cell. 1994 Aug 12;78(3):409-24 [8062384.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Sep 15;90(18):8683-6 [8378348.001]
  • [Cites] Carcinogenesis. 2006 Jan;27(1):162-9 [16081511.001]
  • [Cites] Int J Cancer. 2006 Jan 1;118(1):25-34 [16049979.001]
  • [Cites] Oncogene. 1999 Apr 29;18(17):2747-54 [10348349.001]
  • [Cites] Oncogene. 1999 Apr 22;18(16):2599-606 [10353603.001]
  • [Cites] Hematol Oncol Clin North Am. 1998 Oct;12(5):963-73 [9888016.001]
  • [Cites] Biochemistry (Mosc). 1998 Jul;63(7):854-65 [9721338.001]
  • [Cites] Nature. 1998 Oct 22;395(6704):801-4 [9796814.001]
  • [Cites] N Engl J Med. 1998 Oct 29;339(18):1277-84 [9791143.001]
  • [Cites] Gastroenterology. 1997 Oct;113(4):1146-58 [9322509.001]
  • [Cites] J Pathol. 1998 Jul;185(3):246-55 [9771477.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 1998 Jun 29;353(1370):821-30 [9684279.001]
  • [Cites] Asian Pac J Cancer Prev. 2006 Jul-Sep;7(3):495-501 [17059355.001]
  • [Cites] Cancer Lett. 2006 Jul 8;238(1):69-75 [16046055.001]
  • [Cites] Surg Endosc. 2006 Feb;20(2):270-3 [16341566.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jan 17;103(3):714-9 [16407113.001]
  • [Cites] Curr Biol. 2002 Feb 19;12(4):253-65 [11864565.001]
  • [Cites] Cancer Res. 2001 Dec 15;61(24):8664-7 [11751382.001]
  • [Cites] Cancer Res. 2001 Dec 1;61(23):8408-11 [11731419.001]
  • [Cites] Mol Cell. 2001 Mar;7(3):683-94 [11463392.001]
  • [Cites] Mol Cell. 2001 Mar;7(3):673-82 [11463391.001]
  • [Cites] Clin Cancer Res. 2001 Jun;7(6):1523-32 [11410486.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):1874-8 [11280741.001]
  • [Cites] Curr Gastroenterol Rep. 2005 Oct;7(5):389-95 [16168238.001]
  • [Cites] Chem Biol Interact. 2005 Jun 30;155(1-2):1-9 [15904905.001]
  • [Cites] Cancer Res. 1976 May;36(5):1585-92 [178424.001]
  • [Cites] Cancer Res. 1975 Nov;35(11 Pt 1):2962-8 [1182690.001]
  • [Cites] Nature. 2005 Apr 14;434(7035):843-50 [15829953.001]
  • [Cites] Histol Histopathol. 2005 Apr;20(2):483-92 [15736053.001]
  • [Cites] J Pathol. 2005 Jan;205(2):130-44 [15641015.001]
  • [Cites] Carcinogenesis. 2005 Jan;26(1):229-38 [15459021.001]
  • [Cites] Nature. 1999 Apr 1;398(6726):422-6 [10201372.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):4997-5002 [9560217.001]
  • [Cites] Nat Genet. 1999 Oct;23(2):176-84 [10508513.001]
  • [Cites] Br J Cancer. 1975 Jul;32(1):60-77 [1174451.001]
  • [Cites] Cancer. 1975 Feb;35(2):413-8 [1111917.001]
  • [Cites] Cancer Sci. 2004 Sep;95(9):721-7 [15471557.001]
  • [Cites] Mutat Res. 2004 Nov 2;555(1-2):107-19 [15476855.001]
  • [Cites] Mol Cell Biol. 2004 Sep;24(17):7598-611 [15314168.001]
  • [Cites] J Mol Med (Berl). 2004 Jul;82(7):434-48 [15175863.001]
  • [Cites] Environ Mol Mutagen. 2004;44(1):26-35 [15199544.001]
  • [Cites] Cancer Sci. 2004 Jun;95(6):475-80 [15182426.001]
  • [Cites] Int J Colorectal Dis. 2004 Jul;19(4):308-15 [14605835.001]
  • [Cites] Curr Cancer Drug Targets. 2004 Feb;4(1):29-42 [14965265.001]
  • [Cites] Cancer Sci. 2003 Nov;94(11):965-73 [14611673.001]
  • [Cites] Cancer Res. 2003 Jul 1;63(13):3819-25 [12839979.001]
  • [Cites] Cancer Res. 2003 May 15;63(10):2388-92 [12750256.001]
  • [Cites] Mod Pathol. 2003 Apr;16(4):347-58 [12692200.001]
  • [Cites] Carcinogenesis. 2003 Mar;24(3):353-62 [12663492.001]
  • [Cites] Gastroenterology. 2003 Mar;124(3):762-77 [12612914.001]
  • [Cites] Cell. 2002 Oct 18;111(2):241-50 [12408868.001]
  • [Cites] Scand J Gastroenterol Suppl. 2002;(236):48-53 [12408504.001]
  • [Cites] Am J Pathol. 2002 Sep;161(3):1051-60 [12213734.001]
  • [Cites] J Gastroenterol Hepatol. 2002 Oct;17(10):1078-83 [12201867.001]
  • [Cites] Annu Rev Genomics Hum Genet. 2002;3:101-28 [12142355.001]
  • [Cites] Nutr Cancer. 2008;60 Suppl 1:70-80 [19003583.001]
  • [Cites] Nutr Cancer. 2008;60(5):675-84 [18791932.001]
  • [Cites] Carcinogenesis. 2008 May;29(5):1057-63 [18375960.001]
  • [Cites] Eur J Cancer. 2008 Jul;44(10):1345-89 [18280139.001]
  • [Cites] J Cell Mol Med. 2008 Jan-Feb;12(1):67-96 [18053092.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Future Oncol. 2008 Feb;4(1):93-102 [18241004.001]
  • [Cites] World J Gastroenterol. 2008 Jan 21;14(3):378-89 [18200660.001]
  • [Cites] Acta Pharmacol Sin. 2008 Jan;29(1):1-20 [18158862.001]
  • [Cites] Cancer Res. 2007 Oct 1;67(19):9568-76 [17909068.001]
  • [Cites] Int J Cancer. 2007 Oct 15;121(8):1659-64 [17557291.001]
  • [Cites] Cancer Biomark. 2007;3(3):135-40 [17611304.001]
  • [Cites] BMC Cancer. 2007;7:84 [17506908.001]
  • [Cites] Subcell Biochem. 2007;42:213-25 [17612053.001]
  • [Cites] Adv Exp Med Biol. 2007;595:213-26 [17569213.001]
  • [Cites] Cancer Cell Int. 2007;7:2 [17362521.001]
  • [Cites] Environ Health Perspect. 2007 Jan;115(1):165-71 [17366838.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Cell. 2006 Nov 3;127(3):469-80 [17081971.001]
  • [Cites] Nature. 2002 May 23;417(6887):443-7 [11986622.001]
  • [Cites] Nat Rev Cancer. 2001 Oct;1(1):55-67 [11900252.001]
  • (PMID = 19332896.001).
  • [ISSN] 1477-3163
  • [Journal-full-title] Journal of carcinogenesis
  • [ISO-abbreviation] J Carcinog
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2678864
  •  go-up   go-down


2. Gordon PV, Paxton JB, Fox NS: A methodology for distinguishing divergent cell fates within a common progenitor population: adenoma- and neuroendocrine-like cells are confounders of rat ileal epithelial cell (IEC-18) culture. BMC Cell Biol; 2005;6(1):2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A methodology for distinguishing divergent cell fates within a common progenitor population: adenoma- and neuroendocrine-like cells are confounders of rat ileal epithelial cell (IEC-18) culture.
  • BACKGROUND: IEC-18 cells are a non-transformed, immortal cell line derived from juvenile rat ileal crypt cells.
  • We then confirmed the cell-specific phenotype by immunolocalization of proteins corresponding to those genes.
  • The majority of IEC-18 cells in SFM alone had a loss in expression of the adenomatous polyposis coli (APC) gene at the mRNA and protein levels, consistent with adenoma-like transformation.
  • The most common fate switch that we were able to detect correlates with a down regulation of the APC gene and transformation into an adenoma-like phenotype.
  • [MeSH-minor] Adenoma / pathology. Animals. Carcinoma, Neuroendocrine / pathology. Gene Expression Profiling. Gene Expression Regulation. Genes, APC. Methods. Phenotype. Rats

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Physiol. 1999 Nov;277(5 Pt 1):G1027-40 [10564109.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4368-74 [12907606.001]
  • [Cites] J Biol Chem. 2001 Aug 31;276(35):32419-22 [11445558.001]
  • [Cites] Brain Res Mol Brain Res. 2002 Jan 31;98(1-2):81-92 [11834298.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2002 May;282(5):G877-93 [11960784.001]
  • [Cites] Nat Genet. 2002 Dec;32 Suppl:469-73 [12454640.001]
  • [Cites] Nat Genet. 2002 Dec;32 Suppl:490-5 [12454643.001]
  • [Cites] Bioinformatics. 2004 Jan 1;20(1):105-14 [14693816.001]
  • [Cites] Neurosci Lett. 2004 Jan 23;355(1-2):89-92 [14729242.001]
  • [Cites] Am J Pathol. 2004 Apr;164(4):1369-77 [15039224.001]
  • [Cites] Dis Colon Rectum. 2004 Feb;47(2):219-26 [15043293.001]
  • [Cites] Arch Biochem Biophys. 2004 Sep 1;429(1):100-5 [15288813.001]
  • [Cites] Oncogene. 2004 Sep 16;23(42):7144-8 [15273719.001]
  • [Cites] Proc Natl Acad Sci U S A. 1978 Nov;75(11):5548-52 [103096.001]
  • [Cites] J Natl Cancer Inst. 1981 Dec;67(6):1353-62 [6273638.001]
  • [Cites] FEBS Lett. 1989 Sep 25;255(2):423-6 [2792386.001]
  • [Cites] J Lab Clin Med. 1992 Aug;120(2):329-41 [1500831.001]
  • [Cites] J Clin Invest. 1995 Oct;96(4):1759-67 [7560067.001]
  • [Cites] Genomics. 1998 Jul 1;51(1):27-34 [9693030.001]
  • [Cites] Aliment Pharmacol Ther. 1999 May;13 Suppl 2:15-30 [10429737.001]
  • [Cites] J Gastroenterol. 2000;35(8):575-82 [10955595.001]
  • (PMID = 15656904.001).
  • [ISSN] 1471-2121
  • [Journal-full-title] BMC cell biology
  • [ISO-abbreviation] BMC Cell Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC547914
  •  go-up   go-down


3. Freeman HJ: Heterogeneity of colorectal adenomas, the serrated adenoma, and implications for screening and surveillance. World J Gastroenterol; 2008 Jun 14;14(22):3461-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heterogeneity of colorectal adenomas, the serrated adenoma, and implications for screening and surveillance.
  • Current algorithms for screening and surveillance for colon cancer are valuable, but may be limited by the underlying nature of the targeted neoplastic lesions.
  • Although part of the success of adenoma removal relates to interruption of so-called "adenoma-carcinoma sequence", an alternate serrated pathway to colon cancer may pose difficulties with the ultimate results achieved by traditional colonoscopic methods.
  • The endpoint carcinoma in this unique pathway may be derived from a dysplastic serrated adenoma.
  • These tend to be located primarily in the right colon, especially in females, and are frequently associated with co-existent colon cancer.
  • Unfortunately, however, there are few, if any, other identifiable risk factors, including age or family history of colon polyps or colon cancer.
  • Moreover, this alternate serrated pathway may itself also be quite biologically heterogeneous as reflected in sessile serrated adenomas (SSA) with virtually exclusive molecular signatures defined by the presence of either BRAF or KRAS mutations.
  • Screening algorithms in the future may need to be modified and individualized, depending on new information that likely will emerge on the natural history of these biologically heterogeneous lesions that differs from traditional adenomatous polyps.
  • [MeSH-major] Adenoma / diagnosis. Algorithms. Colorectal Neoplasms / diagnosis. Mass Screening / methods

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2001 Feb;25(2):177-84 [11176066.001]
  • [Cites] Gastroenterol Clin North Am. 2008 Mar;37(1):129-60, vii-viii [18313544.001]
  • [Cites] Am J Surg Pathol. 1990 Jun;14(6):524-37 [2186644.001]
  • [Cites] Gastroenterology. 1996 Mar;110(3):748-55 [8608884.001]
  • [Cites] Am J Clin Pathol. 2005 Sep;124(3):380-91 [16191506.001]
  • [Cites] Gastroenterology. 2006 Nov;131(5):1631-4 [17067594.001]
  • [Cites] Gastroenterology. 2006 Nov;131(5):1400-7 [17101316.001]
  • [Cites] Am J Surg Pathol. 2006 Dec;30(12):1491-501 [17122504.001]
  • [Cites] Am J Gastroenterol. 2006 Dec;101(12):2711-6 [17227517.001]
  • [Cites] Gut. 2007 Mar;56(3):373-9 [17005766.001]
  • [Cites] Arch Pathol Lab Med. 2007 Mar;131(3):440-5 [17516746.001]
  • [Cites] Gastroenterol Clin North Am. 2007 Dec;36(4):947-68, viii [17996799.001]
  • [Cites] Gut. 2008 Jan;57(1):59-64 [17681999.001]
  • [Cites] Am J Surg Pathol. 2008 Jan;32(1):21-9 [18162766.001]
  • [Cites] Am J Surg Pathol. 2008 Jan;32(1):30-5 [18162767.001]
  • [Cites] Am J Surg Pathol. 2008 Feb;32(2):296-303 [18223333.001]
  • [Cites] J Gastroenterol. 2008;43(1):45-50 [18297435.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • (PMID = 18567071.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 3.6.5.2 / ras Proteins
  • [Other-IDs] NLM/ PMC2716605
  •  go-up   go-down


Advertisement
4. Toth B, Coles M: Inhibition of large intestinal cancers by celecoxib using a serial sacrifice technique. In Vivo; 2006 Jul-Aug;20(4):453-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histopathologically, the tumors were diagnosed as polypoid adenomas and adenocarcinomas of the cecum, colon and rectum.
  • [MeSH-minor] 1,2-Dimethylhydrazine / administration & dosage. 1,2-Dimethylhydrazine / pharmacology. Adenocarcinoma / chemically induced. Adenocarcinoma / pathology. Adenoma / chemically induced. Adenoma / pathology. Administration, Oral. Animals. Animals, Outbred Strains. Anti-Inflammatory Agents, Non-Steroidal / administration & dosage. Carcinogens / administration & dosage. Carcinogens / pharmacology. Celecoxib. Female. Incidence. Injections, Subcutaneous. Mice. Survival Rate. Time Factors

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CELECOXIB .
  • Hazardous Substances Data Bank. 1,2-DIMETHYLHYDRAZINE .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16900774.001).
  • [ISSN] 0258-851X
  • [Journal-full-title] In vivo (Athens, Greece)
  • [ISO-abbreviation] In Vivo
  • [Language] eng
  • [Grant] United States / NCCIH NIH HHS / AT / 1R21 AT001739
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Carcinogens; 0 / Cyclooxygenase Inhibitors; 0 / Pyrazoles; 0 / Sulfonamides; IX068S9745 / 1,2-Dimethylhydrazine; JCX84Q7J1L / Celecoxib
  •  go-up   go-down


5. Dubé C, Rostom A, Lewin G, Tsertsvadze A, Barrowman N, Code C, Sampson M, Moher D, U.S. Preventive Services Task Force: The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med; 2007 Mar 6;146(5):365-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DATA SYNTHESIS: Regular use of aspirin reduced the incidence of colonic adenomas in RCTs (relative risk [RR], 0.82 [95% CI, 0.7 to 0.95]), case-control studies (RR, 0.87 [CI, 0.77 to 0.98]), and cohort studies (RR, 0.72 [CI, 0.61 to 0.85]).
  • CONCLUSIONS: Aspirin appears to be effective at reducing the incidence of colonic adenoma and colorectal cancer, especially if used in high doses for more than 10 years.
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Aspirin / therapeutic use. Colorectal Neoplasms / prevention & control. Primary Prevention
  • [MeSH-minor] Adenoma / prevention & control. Adult. Cardiovascular Diseases / chemically induced. Colonic Polyps / prevention & control. Female. Gastrointestinal Diseases / chemically induced. Humans. Incidence. Male. United States / epidemiology

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .
  • PubMed Health. DARE review .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] ACP J Club. 2007 Jul-Aug;147(1):15-6 [17608380.001]
  • [CommentIn] Gastroenterology. 2007 Aug;133(2):717-8 [17681190.001]
  • [CommentIn] Ann Intern Med. 2007 Nov 6;147(9):674; author reply 674-5 [17975195.001]
  • [SummaryForPatientsIn] Ann Intern Med. 2007 Mar 6;146(5):I35 [17339615.001]
  • (PMID = 17339622.001).
  • [ISSN] 1539-3704
  • [Journal-full-title] Annals of internal medicine
  • [ISO-abbreviation] Ann. Intern. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; R16CO5Y76E / Aspirin
  • [Number-of-references] 61
  •  go-up   go-down


6. Croce MV, Sálice VC, Lacunza E, Segal-Eiras A: Alpha 1-acid glycoprotein (AGP): a possible carrier of sialyl lewis X (slewis X) antigen in colorectal carcinoma. Histol Histopathol; 2005 01;20(1):91-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: tissue and serum samples from 88 patients with colorectal cancer, 22 adenomas and 23 normal were included.
  • [MeSH-minor] Adenoma / immunology. Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / immunology. Colon / immunology. Colon / metabolism. Female. Humans. Immunohistochemistry. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15578427.001).
  • [ISSN] 0213-3911
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / 5-acetylneuraminyl-(2-3)-galactosyl-(1-4)-(fucopyranosyl-(1-3))-N-acetylglucosamine; 0 / Antibodies, Monoclonal; 0 / Oligosaccharides; 0 / Orosomucoid
  •  go-up   go-down


7. Oset P, Jasińska A, Szcześniak P, Orszulak-Michalak D, Talar-Wojnarowska R, Małecka-Panas E: [Analysis of serum gastrin levels in patients with adenomatous polyps of the colon]. Pol Merkur Lekarski; 2009 May;26(155):458-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of serum gastrin levels in patients with adenomatous polyps of the colon].
  • Adenomatous polyps are known risk factor of colon cancer.
  • Gastrin is a peptide hormone involved in the growth of both normal and malignant intestinal tissue, which probably may promote progression through the adenoma-carcinoma sequence.
  • AIM OF OUR STUDY: To assess the association between serum gastrin levels and size, type and localization of colonic adenomas.
  • MATERIAL AND METHODS: The study included 60 patients with adenomatous polyps of the colon and 30 healthy volunteers.
  • RESULTS: We observed higher serum gastrin levels in patients with colonic adenomas compared to control group (59.65 pg/ml vs. 46.89 pg/ml; p < 0.05).
  • There was no association between gastrin levels and size, number, localisation and histologic type of polyps (p > 0.05).
  • CONCLUSION: Despite of elevated serum levels in patients with colonic adenomas we did not observe the association between gastrin levels and size, grade of dysplasia and histologic type of polyps.
  • The exact role of hipergastrinemia in process of colon carcinogenesis remains to be determined.
  • [MeSH-major] Adenomatous Polyps / blood. Gastrins / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19606697.001).
  • [ISSN] 1426-9686
  • [Journal-full-title] Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
  • [ISO-abbreviation] Pol. Merkur. Lekarski
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Gastrins
  •  go-up   go-down


8. Ono S, Fujishiro M, Goto O, Kodashima S, Omata M: Submerging endoscopic submucosal dissection leads to successful en bloc resection of colonic laterally spreading tumor with submucosal fat. Gut Liver; 2008 Dec;2(3):209-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Submerging endoscopic submucosal dissection leads to successful en bloc resection of colonic laterally spreading tumor with submucosal fat.
  • A 72-year-old female with a colonic laterally spreading tumor (LST) was referred to our department.
  • A total colonoscopy revealed a large nongranular LST, 30 mm in diameter, in the ascending colon.
  • The lesion was successfully resected en bloc without complications.
  • The pathological examination indicated the curative resection of a tubulovillous adenoma.
  • We propose that a submerged ESD could also be an effective procedure for colonic neoplasms with submucosal fat by avoiding blurring of the endoscopic view.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Gastroenterol Hepatol. 2007 Jun;5(6):678-83; quiz 645 [17466600.001]
  • [Cites] AJR Am J Roentgenol. 2003 Sep;181(3):781-4 [12933481.001]
  • [Cites] Endoscopy. 1998 May;30(4):351-5 [9689507.001]
  • [Cites] Gastrointest Endosc. 2006 Jan;63(1):178-83 [16377346.001]
  • (PMID = 20485649.001).
  • [ISSN] 2005-1212
  • [Journal-full-title] Gut and liver
  • [ISO-abbreviation] Gut Liver
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2871645
  • [Keywords] NOTNLM ; Adipose tissue / Colonic neoplasms / Colonoscopy / Resection / Submucosa
  •  go-up   go-down


9. Ye C, Shrubsole MJ, Cai Q, Ness R, Grady WM, Smalley W, Cai H, Washington K, Zheng W: Promoter methylation status of the MGMT, hMLH1, and CDKN2A/p16 genes in non-neoplastic mucosa of patients with and without colorectal adenomas. Oncol Rep; 2006 Aug;16(2):429-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Promoter methylation status of the MGMT, hMLH1, and CDKN2A/p16 genes in non-neoplastic mucosa of patients with and without colorectal adenomas.
  • CpG island methylation has been observed in aberrant crypt foci (ACF) and adenomas in the colon, implicating it in the earliest aspects of colon cancer formation.
  • In addition, some investigators have identified an age-related increase in DNA methylation of the ESR1 locus in the colon mucosa, suggesting that DNA methylation may be a pre-neoplastic change that increases the risk of colon adenomas and colon cancer.
  • We investigated the methylation status in the promoter regions of the CDKN2A/p16, hMLH1, and MGMT genes in human non-neoplastic rectal mucosa and evaluated whether these methylation markers may predict the presence of adenomatous polyps in the colon.
  • The promoter methylation patterns of these genes were examined in rectal biopsies (mucosa samples) of 97 colorectal adenoma cases and 94 healthy controls using methylation-specific PCR (MSP) assays.
  • The methylation status of these genes in rectal mucosa biopsies detected by MSP assays may not distinguish between patients with and without adenomas in the colon.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16820927.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA095103; United States / NCI NIH HHS / CA / R01 CA097386; United States / NCI NIH HHS / CA / P50 CA95103; United States / NCI NIH HHS / CA / R01CA97386
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Carrier Proteins; 0 / MLH1 protein, human; 0 / Nuclear Proteins; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase
  •  go-up   go-down


10. Bouzourene H, Sandmeier D: [Sessile serrated adenoma: an underdiagnosed colonic polyp]. Rev Med Suisse; 2007 Jul 4;3(118):1702-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Sessile serrated adenoma: an underdiagnosed colonic polyp].
  • [Transliterated title] L'adénome dentelé sessile, un polype colique à ne pas méconnaître.
  • Serrated polyps of the colon represent a large morphological spectrum of lesions.
  • They comprise the hyperplastic polyp considered as an innocuous lesion for many years, the traditional serrated adenoma presenting a potential of cancerisation and the recently described the sessile serrated adenoma which seems to be a potential precursor of colonic cancer with microsatellite instability and which probably uses an alternate polyp-neoplasia pathway in addition to the classical adenoma-carcinoma sequence.
  • The aims of this article intend to inform of new concept of colonic carcinogenesis, to be aware of a serrated colonic polyp entity recently described and to use a same nomenclature to facilitate the dialogue between pathologists and clinicians.
  • [MeSH-major] Adenoma / pathology. Colonic Neoplasms / pathology. Colonic Polyps / pathology

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17726906.001).
  • [ISSN] 1660-9379
  • [Journal-full-title] Revue médicale suisse
  • [ISO-abbreviation] Rev Med Suisse
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 10
  •  go-up   go-down


11. Tan KL, Wilson S, O'Neill C, Gordon D, Napier S: Something not quite right: Gardner syndrome diagnosed by multiple cutaneous lesions and genetic testing. Surgeon; 2005 Dec;3(6):412-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gardner syndrome is a variant of familial adenomatous polyposis characterized by intestinal adenomatous polyps, which can progress to adenocarcinoma, and a variety of extraintestinal manifestations, including skin cysts, osteomas, soft tissue fibrous tumours and a characteristic ocular lesion.
  • Gardner syndrome was considered only after excision of subcutaneous fibrous tumours from the mastoid region and paraspinal area and was confirmed by genetic testing in spite of the patient's refusal to undergo colonic endoscopic examination.
  • Subsequent resection revealed approximately 70 adenomatous colonic polyps in the colon and rectum but no invasive tumour, highlighting the benefits of genetic testing in treatment planning.

  • Genetic Alliance. consumer health - Gardner Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16353862.001).
  • [ISSN] 1479-666X
  • [Journal-full-title] The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland
  • [ISO-abbreviation] Surgeon
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


12. Sacher-Huvelin S, Coron E, Gaudric M, Planche L, Benamouzig R, Maunoury V, Filoche B, Frédéric M, Saurin JC, Subtil C, Lecleire S, Cellier C, Coumaros D, Heresbach D, Galmiche JP: Colon capsule endoscopy vs. colonoscopy in patients at average or increased risk of colorectal cancer. Aliment Pharmacol Ther; 2010 Nov;32(9):1145-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colon capsule endoscopy vs. colonoscopy in patients at average or increased risk of colorectal cancer.
  • BACKGROUND: Colon capsule endoscopy (CCE) is a new, non-invasive technology.
  • Colon cleanliness was excellent or good in 52% of cases at CCE.
  • CCE accuracy for the detection of polyps ≥ 6 mm was 39% (95% CI 30-48) for sensitivity, 88% (95% CI 85-91) for specificity, 47% (95% CI 37-57) for positive predictive value and 85% (95% CI 82-88) for negative predictive value.
  • CCE accuracy was better for the detection of advanced adenoma, in patients with good or excellent cleanliness and after re-interpretation of the CCE videos by an independent expert panel.
  • Further studies should pay attention to colonic preparation (Clinicaltrial.gov number NCT00436514).

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Blackwell Publishing Ltd.
  • (PMID = 21039676.001).
  • [ISSN] 1365-2036
  • [Journal-full-title] Alimentary pharmacology & therapeutics
  • [ISO-abbreviation] Aliment. Pharmacol. Ther.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00436514
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


13. Galamb O: [mRNA expression analysis and classification of colonic biopsy samples using oligonucleotide and cDNA microarray techniques]. Orv Hetil; 2008 Jul 20;149(29):1373-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [mRNA expression analysis and classification of colonic biopsy samples using oligonucleotide and cDNA microarray techniques].
  • We have shown that the sequential overexpression of osteopontin and osteonectin mRNAs and proteins significantly correlates with the progression of the colorectal adenoma-dysplasia-carcinoma sequence.
  • We have identified and validated ten novel markers with continuously increasing mRNA expression in line with the adenoma-dysplasia-carcinoma transition.
  • We have identified the top 27, 13 and 10 genes associated with adenoma, colorectal cancer, and inflammatory bowel diseases.
  • [MeSH-major] Biopsy. Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / metabolism. Colon / metabolism. Oligonucleotide Array Sequence Analysis. Osteonectin / metabolism. Osteopontin / metabolism. RNA, Messenger / metabolism
  • [MeSH-minor] Adenoma / genetics. Adenoma / metabolism. Carcinoma / genetics. Carcinoma / metabolism. Colorectal Neoplasms / genetics. Colorectal Neoplasms / metabolism. Gene Expression. Humans. Inflammatory Bowel Diseases / genetics. Inflammatory Bowel Diseases / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Sequence Analysis, DNA. Up-Regulation

  • MedlinePlus Health Information. consumer health - Biopsy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18617470.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Osteonectin; 0 / RNA, Messenger; 106441-73-0 / Osteopontin
  •  go-up   go-down


14. Ragupathi M, Ramos-Valadez DI, Pedraza R, Haas EM: Robotic-assisted single-incision laparoscopic partial cecectomy. Int J Med Robot; 2010 Sep;6(3):362-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Single-incision laparoscopic surgery is an emerging approach in the field of minimally invasive colon and rectal surgery.
  • Pathology revealed a sessile tubular adenoma of the cecum.
  • [MeSH-major] Cecum / surgery. Intestinal Polyps / surgery. Laparoscopy / methods. Robotics / instrumentation. Robotics / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 John Wiley & Sons, Ltd.
  • (PMID = 20665713.001).
  • [ISSN] 1478-596X
  • [Journal-full-title] The international journal of medical robotics + computer assisted surgery : MRCAS
  • [ISO-abbreviation] Int J Med Robot
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


15. Hu Y, Lu X, Luo G: Effect of Recql5 deficiency on the intestinal tumor susceptibility of Apc(min) mice. World J Gastroenterol; 2010 Mar 28;16(12):1482-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Recql5 deficiency in Apc(min/+) mice resulted in a significant increase in the tumor incidence in both the colon (P = 0.0162) and the small intestine (P < 0.01).
  • Importantly, since mouse Recql5 and human RECQL5 are highly conserved, these findings also suggest that RECQL5 may be a tumor suppressor for human colon cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Genet. 2001 Mar;2(3):196-206 [11256071.001]
  • [Cites] J Biol Chem. 2009 Aug 28;284(35):23197-203 [19570979.001]
  • [Cites] Semin Cancer Biol. 2002 Aug;12(4):261-6 [12147207.001]
  • [Cites] Nat Rev Cancer. 2002 Dec;2(12):910-7 [12459729.001]
  • [Cites] Nat Med. 2004 Aug;10(8):789-99 [15286780.001]
  • [Cites] Annu Rev Cell Dev Biol. 2004;20:337-66 [15473844.001]
  • [Cites] Trends Genet. 1993 Apr;9(4):138-41 [8516849.001]
  • [Cites] Cell. 1996 Oct 18;87(2):159-70 [8861899.001]
  • [Cites] Nature. 1997 Apr 24;386(6627):761, 763 [9126728.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 1998 Jun 29;353(1370):915-23 [9684289.001]
  • [Cites] Nature. 1998 Dec 17;396(6712):643-9 [9872311.001]
  • [Cites] Hum Mol Genet. 2005 Mar 15;14(6):813-25 [15703196.001]
  • [Cites] Mol Cell Biol. 2005 May;25(9):3431-42 [15831450.001]
  • [Cites] Nat Rev Cancer. 2005 Oct;5(10):773-85 [16195750.001]
  • [Cites] Genes Dev. 2007 Dec 1;21(23):3073-84 [18003859.001]
  • [Cites] Biochem J. 2008 Aug 1;413(3):505-16 [18419580.001]
  • [Cites] Pathol Res Pract. 2008;204(7):479-90 [18538487.001]
  • [Cites] Mol Biol Cell. 2009 Jan;20(1):114-23 [18987339.001]
  • [Cites] Trends Mol Med. 2002 Apr;8(4):179-86 [11927276.001]
  • (PMID = 20333788.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P20 CA103736; United States / NCI NIH HHS / CA / R01 CA88939
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Suppressor Proteins; EC 3.6.4.12 / RecQ Helicases; EC 5.99.- / Recql5 protein, mouse
  • [Other-IDs] NLM/ PMC2846253
  •  go-up   go-down


16. Khoo RE: Transanal excision of a rectal adenoma using single-access laparoscopic port. Dis Colon Rectum; 2010 Jul;53(7):1078-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transanal excision of a rectal adenoma using single-access laparoscopic port.
  • Through this port, insufflation with gas maintained exposure of the surgical site, a 30-degree 5-mm camera, a grasper, and electrocautery were used to remove a large villous adenoma.
  • [MeSH-major] Adenoma, Villous / surgery. Colectomy / methods. Laparoscopes. Laparoscopy / methods. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20551763.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Boissan M, De Wever O, Lizarraga F, Wendum D, Poincloux R, Chignard N, Desbois-Mouthon C, Dufour S, Nawrocki-Raby B, Birembaut P, Bracke M, Chavrier P, Gespach C, Lacombe ML: Implication of metastasis suppressor NM23-H1 in maintaining adherens junctions and limiting the invasive potential of human cancer cells. Cancer Res; 2010 Oct 1;70(19):7710-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We silenced NM23-H1 expression in human hepatoma and colon carcinoma cells and methodologically investigated effects on cell-cell adhesion, migration, invasion, and signaling linked to cancer progression.
  • Analysis of NM23-H1 expression in clinical specimens revealed high expression in premalignant lesions (liver cirrhosis and colon adenoma) and the central body of primary liver or colon tumors, but downregulation at the invasive front of tumors.
  • [MeSH-minor] Actins / metabolism. Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Breast Neoplasms / genetics. Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Carcinoma, Hepatocellular / genetics. Carcinoma, Hepatocellular / metabolism. Carcinoma, Hepatocellular / pathology. Cell Line, Tumor. Cell Movement / genetics. Colonic Neoplasms / genetics. Colonic Neoplasms / metabolism. Colonic Neoplasms / pathology. Cytoskeleton / metabolism. Cytoskeleton / pathology. Gene Silencing. Humans. Liver Neoplasms / genetics. Liver Neoplasms / metabolism. Liver Neoplasms / pathology. Matrix Metalloproteinase 14 / metabolism. Neoplasm Invasiveness. Wnt Proteins / metabolism


18. Van Gossum A, Munoz-Navas M, Fernandez-Urien I, Carretero C, Gay G, Delvaux M, Lapalus MG, Ponchon T, Neuhaus H, Philipper M, Costamagna G, Riccioni ME, Spada C, Petruzziello L, Fraser C, Postgate A, Fitzpatrick A, Hagenmuller F, Keuchel M, Schoofs N, Devière J: Capsule endoscopy versus colonoscopy for the detection of polyps and cancer. N Engl J Med; 2009 Jul 16;361(3):264-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Capsule endoscopy versus colonoscopy for the detection of polyps and cancer.
  • BACKGROUND: An ingestible capsule consisting of an endoscope equipped with a video camera at both ends was designed to explore the colon.
  • This study compared capsule endoscopy with optical colonoscopy for the detection of colorectal polyps and cancer.
  • METHODS: We performed a prospective, multicenter study comparing capsule endoscopy with optical colonoscopy (the standard for comparison) in a cohort of patients with known or suspected colonic disease for the detection of colorectal polyps or cancer.
  • Patients underwent an adapted colon preparation, and colon cleanliness was graded from poor to excellent.
  • We computed the sensitivity and specificity of capsule endoscopy for polyps, advanced adenoma, and cancer.
  • The sensitivity and specificity of capsule endoscopy for detecting polyps that were 6 mm in size or bigger were 64% (95% confidence interval [CI], 59 to 72) and 84% (95% CI, 81 to 87), respectively, and for detecting advanced adenoma, the sensitivity and specificity were 73% (95% CI, 61 to 83) and 79% (95% CI, 77 to 81), respectively.
  • For all lesions, the sensitivity of capsule endoscopy was higher in patients with good or excellent colon cleanliness than in those with fair or poor colon cleanliness.
  • Mild-to-moderate adverse events were reported in 26 patients (7.9%) and were mostly related to the colon preparation.
  • CONCLUSIONS: The use of capsule endoscopy of the colon allows visualization of the colonic mucosa in most patients, but its sensitivity for detecting colonic lesions is low as compared with the use of optical colonoscopy. (ClinicalTrials.gov number, NCT00604162. )
  • [MeSH-major] Capsule Endoscopy. Colonic Polyps / diagnosis. Colonoscopy. Colorectal Neoplasms / diagnosis


19. Pandak N, Tomić-Paradzik M, Krizanović B, Fornet-Sapcevski J: [The importance of Streptococcus bovis systemic infections]. Lijec Vjesn; 2006 Jul-Aug;128(7-8):206-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • He was an older man, who had undergone prostatectomy due prostatic adenoma several years before.
  • Colon endoscopy was performed in both patients and it revealed colon polyps.
  • Since Streptococcus bovis infections are associated with colon carcinoma, it is imperative to perform colonoscopy in each patient suffering infection with this germ, and to consider him as a high risk patient for developing colon cancer.

  • MedlinePlus Health Information. consumer health - Streptococcal Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17087134.001).
  • [ISSN] 0024-3477
  • [Journal-full-title] Lijec̆nic̆ki vjesnik
  • [ISO-abbreviation] Lijec Vjesn
  • [Language] hrv
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


20. Schick V, Franzius C, Beyna T, Oei ML, Schnekenburger J, Weckesser M, Domschke W, Schober O, Heindel W, Pohle T, Juergens KU: Diagnostic impact of 18F-FDG PET-CT evaluating solid pancreatic lesions versus endosonography, endoscopic retrograde cholangio-pancreatography with intraductal ultrasonography and abdominal ultrasound. Eur J Nucl Med Mol Imaging; 2008 Oct;35(10):1775-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PET-CT revealed cervical lymphonodal metastasis from occult bronchogenic carcinoma and a tubular colon adenoma with intermediate dysplasia on polypectomy, respectively.

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Ultrasound.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Gastroenterol. 2006 Nov-Dec;40(10 ):923-9 [17063113.001]
  • [Cites] J Gastrointest Surg. 2005 Jan;9(1):22-8; discussion 28-9 [15623441.001]
  • [Cites] Dtsch Med Wochenschr. 2007 Aug;132(33):1696-700 [17713866.001]
  • [Cites] Ann Intern Med. 2004 Nov 16;141(10 ):753-63 [15545675.001]
  • [Cites] J Clin Ultrasound. 1986 Jun;14(5):339-53 [3088049.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2008 Mar;35(3):527-31 [17960376.001]
  • [Cites] World J Surg. 2001 Sep;25(9):1134-9 [11571948.001]
  • [Cites] Gastrointest Endosc. 2005 May;61(6):700-8 [15855975.001]
  • [Cites] Br J Surg. 1999 Feb;86(2):194-9 [10100786.001]
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]
  • [Cites] AJR Am J Roentgenol. 1998 Dec;171(6):1565-70 [9843289.001]
  • [Cites] Am J Gastroenterol. 2002 Jun;97(6):1386-91 [12094855.001]
  • [Cites] Gastrointest Endosc. 2000 Sep;52(3):367-71 [10968852.001]
  • [Cites] Gastrointest Endosc. 2001 Jun;53(7):722-7 [11375578.001]
  • [Cites] Aliment Pharmacol Ther. 2006 Jul 1;24(1):87-94 [16803606.001]
  • [Cites] Ann Intern Med. 2001 Mar 20;134(6):459-64 [11255521.001]
  • [Cites] Lancet. 2004 Mar 27;363(9414):1049-57 [15051286.001]
  • [Cites] Ann Surg. 1999 May;229(5):729-37; discussion 737-8 [10235532.001]
  • [Cites] Surg Endosc. 2005 Mar;19(3):369-73 [15624058.001]
  • [Cites] Endoscopy. 2006 Dec;38(12):1246-9 [17163327.001]
  • [Cites] Am J Gastroenterol. 2004 Sep;99(9):1684-9 [15330902.001]
  • [Cites] JOP. 2003 Jan;4(1):68-74 [12555018.001]
  • [Cites] JOP. 2004 Jul;5(4):289-303 [15254364.001]
  • [Cites] Rofo. 2007 Jul;179(7):693-702 [17592808.001]
  • [Cites] Eur J Nucl Med. 1997 Jun;24(6):678-82 [9169578.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Mar;2(3):252-61 [15017610.001]
  • [Cites] Oncology (Williston Park). 2002 Jan;16(1):29-38, 43; discussion 44, 47-9, 53-6 [11831609.001]
  • [Cites] Radiology. 1991 Feb;178(2):328-30 [1987587.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2004;11(1):4-10 [15747028.001]
  • [Cites] AJR Am J Roentgenol. 2003 Feb;180(2):475-80 [12540455.001]
  • [Cites] Radiographics. 2005 Nov-Dec;25(6):1451-68; discussion 1468-70 [16284127.001]
  • [Cites] World J Gastroenterol. 2007 Jul 21;13(27):3662-6 [17659723.001]
  • [Cites] Med Phys. 1998 Oct;25(10 ):2046-53 [9800714.001]
  • [Cites] J Nucl Med. 2001 May;42(5 Suppl):1S-93S [11483694.001]
  • [Cites] Dig Surg. 2005;22(1-2):55-61; discussion 62 [15838173.001]
  • [Cites] Rofo. 2007 Jan;179(1):72-9 [17146750.001]
  • [Cites] Semin Nucl Med. 2006 Jul;36(3):248-56 [16762614.001]
  • [Cites] J Gastrointest Surg. 2004 Mar-Apr;8(3):280-8 [15019924.001]
  • [Cites] Chang Gung Med J. 2005 May;28(5):274-83 [16086542.001]
  • [Cites] Cancer. 2000 Dec 15;89(12 ):2547-54 [11135214.001]
  • [Cites] Eur J Cancer. 2001 Oct;37 Suppl 8:S4-66 [11602373.001]
  • [Cites] Pancreas. 2005 Aug;31(2):192-4 [16025008.001]
  • [Cites] Ann Nucl Med. 2003 Jul;17 (5):421-6 [12971645.001]
  • [Cites] J Nucl Med. 2004 Aug;45(8):1279-86 [15299049.001]
  • [Cites] Ann Surg. 2005 Aug;242(2):235-43 [16041214.001]
  • [Cites] J Nucl Med. 2002 Feb;43(2):173-80 [11850481.001]
  • [Cites] Scand J Gastroenterol. 2002 Nov;37(11):1313-20 [12465731.001]
  • [Cites] J Natl Cancer Inst. 1997 Mar 19;89(6):442-6 [9091646.001]
  • [Cites] World J Surg. 2000 Sep;24(9):1121-9 [11036292.001]
  • [Cites] N Engl J Med. 2004 Mar 18;350(12):1200-10 [15028824.001]
  • [Cites] Pancreas. 2006 Oct;33(3):211-20 [17003640.001]
  • [Cites] Pancreatology. 2005;5(4-5):398-402 [15985763.001]
  • (PMID = 18481063.001).
  • [ISSN] 1619-7070
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


21. Matsumoto T, Esaki M, Fujisawa R, Nakamura S, Yao T, Iida M: Chromoendoscopy, narrow-band imaging colonoscopy, and autofluorescence colonoscopy for detection of diminutive colorectal neoplasia in familial adenomatous polyposis. Dis Colon Rectum; 2009 Jun;52(6):1160-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromoendoscopy, narrow-band imaging colonoscopy, and autofluorescence colonoscopy for detection of diminutive colorectal neoplasia in familial adenomatous polyposis.
  • METHODS: Thirteen patients with adenomatous polyposis were examined by total colonoscopy using an instrument that incorporated both narrow-band and autofluorescence imaging.
  • Narrow-band imaging depicted a greater number of lesions than did white light in the transverse colon, descending colon, and rectum.
  • CONCLUSION: Chromoendoscopy is superior to white light colonoscopy, autofluorescence imaging, and narrow-band imaging for detection of diminutive colorectal lesions in adenomatous polyposis.
  • [MeSH-major] Adenomatous Polyposis Coli / diagnosis. Colonoscopy / methods. Colorectal Neoplasms / diagnosis. Microscopy, Fluorescence / methods. Precancerous Conditions / diagnosis
  • [MeSH-minor] Adenoma / diagnosis. Adolescent. Adult. Colonoscopes. Coloring Agents. Cross-Sectional Studies. Diagnosis, Differential. Female. Humans. Image Processing, Computer-Assisted. Male. Middle Aged


22. Tzouvala M, Lazaris AC, Papatheodoridis GV, Kouvidou C, Papathomas TG, Kavantzas N, Elemenoglou I, Karamanolis DG, Agapitos E: Potential role of apoptosis and apoptotic regulatory proteins in colorectal neoplasia: correlations with clinico-pathological parameters and survival. Dig Dis Sci; 2008 Feb;53(2):451-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Biopsies from 46 colorectal cancers, 121 adenomas, and 25 controls were studied using monoclonal antibodies against p53, bcl-2, mdm2 and the terminal deoxynucleotidyl-transferase-mediated dUTP nick end labeling (TUNEL) method for apoptosis.
  • P53 and bcl2 protein expression was higher in adenomas >or=1 cm (P < 0.03) and tubulovillous-villous adenomas (P < 0.03), and correlated with dysplasia (P < 0.03).
  • In conclusion, both bcl-2 and p53 immunohistochemical profiles may be useful adjuncts in detecting adenomas with a malignant potential, whereas bcl-2 could be used in combination with Dukes' stage as a predictor of prognosis in colorectal cancer.
  • [MeSH-major] Adenoma / metabolism. Apoptosis / physiology. Colorectal Neoplasms / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1994 Jul 28;331(4):213-21 [8015568.001]
  • [Cites] Cancer Res. 1994 Jun 15;54(12):3131-5 [8205530.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2000 Sep;8(3):175-82 [10981868.001]
  • [Cites] Mol Pathol. 1998 Feb;51(1):26-9 [9624416.001]
  • [Cites] Neoplasma. 2002;49(6):387-93 [12584586.001]
  • [Cites] Anticancer Res. 1999 Jan-Feb;19(1B):727-30 [10216484.001]
  • [Cites] J Gastroenterol Hepatol. 2006 Jul;21(7):1108-14 [16824061.001]
  • [Cites] Cancer Res. 1994 Apr 15;54(8):2095-7 [8174112.001]
  • [Cites] Hum Pathol. 1996 Mar;27(3):225-33 [8600035.001]
  • [Cites] Arch Intern Med. 2003 Feb 24;163(4):413-20 [12588199.001]
  • [Cites] J Pathol. 1996 May;179(1):10-4 [8691332.001]
  • [Cites] Hum Pathol. 2001 Oct;32(10):1029-38 [11679935.001]
  • [Cites] Clin Cancer Res. 2001 May;7(5):1118-26 [11350874.001]
  • [Cites] Anticancer Res. 1997 Jul-Aug;17 (4A):2615-9 [9252690.001]
  • [Cites] Oncogene. 1994 Jun;9(6):1799-805 [8183579.001]
  • [Cites] Histol Histopathol. 2000 Jul;15(3):667-72 [10963109.001]
  • [Cites] Oncogene. 1996 Apr 18;12(8):1707-13 [8622891.001]
  • [Cites] Eur J Biochem. 1998 Feb 15;252(1):1-15 [9523706.001]
  • [Cites] Aust N Z J Surg. 1999 Feb;69(2):88-94 [10030808.001]
  • [Cites] Virchows Arch. 1998 Dec;433(6):523-7 [9870685.001]
  • [Cites] Gut. 2003 Mar;52(3):398-403 [12584223.001]
  • [Cites] Hum Pathol. 1995 May;26(5):534-40 [7750937.001]
  • [Cites] BMC Cancer. 2006 Jul 13;6:187 [16839413.001]
  • [Cites] Pathobiology. 1997;65(3):140-5 [9309780.001]
  • [Cites] Dis Colon Rectum. 1997 Jul;40(7):785-90 [9221853.001]
  • [Cites] N Engl J Med. 1992 Mar 5;326(10):658-62 [1736104.001]
  • [Cites] J Pathol. 2001 Aug;194(4):436-43 [11523051.001]
  • [Cites] J Natl Cancer Inst. 1994 Apr 6;86(7):499-504 [8133533.001]
  • [Cites] Ann Oncol. 2004 Dec;15(12):1849-50 [15550595.001]
  • [Cites] J Gastrointest Surg. 2000 Jan-Feb;4(1):109-14 [10631371.001]
  • [Cites] Jpn J Cancer Res. 1994 Jun;85(6):584-91 [8063611.001]
  • [Cites] Dig Dis Sci. 2003 Oct;48(10):1990-7 [14627346.001]
  • [Cites] Br J Cancer. 1996 Apr;73(8):889-95 [8611422.001]
  • [Cites] Hippokratia. 2006 Jul;10(3):116-9 [20351806.001]
  • [Cites] Gut. 2002 Jun;50(6):834-9 [12010886.001]
  • [Cites] Eur J Cancer. 1999 Jul;35(7):1083-8 [10533452.001]
  • [Cites] Oncology. 2002;62(3):278-85 [12065876.001]
  • [Cites] Clin Mol Pathol. 1995 Feb;48(1):M12-6 [16695968.001]
  • [Cites] World J Surg Oncol. 2005 Jul 19;3:47 [16029489.001]
  • [Cites] J Gen Intern Med. 2003 Feb;18(2):128-37 [12542588.001]
  • [Cites] Clin Cancer Res. 1995 Oct;1(10):1103-10 [9815900.001]
  • [Cites] Am J Pathol. 1994 Nov;145(5):1191-8 [7977649.001]
  • [Cites] Cell. 1993 Aug 27;74(4):609-19 [8358790.001]
  • [Cites] Am J Gastroenterol. 1996 Sep;91(9):1809-13 [8792703.001]
  • [Cites] J Pathol. 1999 Jan;187(1):127-37 [10341713.001]
  • (PMID = 17562177.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53; EC 2.3.2.27 / MDM2 protein, human; EC 2.3.2.27 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


23. Yuri M, Sasahira T, Nakai K, Ishimaru S, Ohmori H, Kuniyasu H: Reversal of expression of 15-lipoxygenase-1 to cyclooxygenase-2 is associated with development of colonic cancer. Histopathology; 2007 Oct;51(4):520-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reversal of expression of 15-lipoxygenase-1 to cyclooxygenase-2 is associated with development of colonic cancer.
  • AIMS: Two different pathways of linoleic acid (LA) metabolism have opposite effects on the development of colonic cancer: a protumoral prostaglandin cascade metabolized by cyclooxygenase (COX)-2, and an antitumoral peroxisome proliferator-activated receptor (PPAR)-gamma ligands metabolized by 15-lipooxygenase (LOX)-1.
  • The aim was to examine the switching of the two LA metabolic pathways in colonic adenomas and carcinomas.
  • MATERIALS AND METHODS: The expression of 15LOX-1 mRNA and COX-2 protein was examined in 54 adenomas, 21 pTis carcinoma-in-adenoma lesions and 36 pT3/p Stage II carcinomas of the colon by in-situ hybridization and immunohistochemistry, respectively.
  • RESULTS: 15LOX-1 expression was found in 89% (48 of 54) of adenomas, 43% (nine of 21) of adenomas and 10% (two of 21) of carcinomas in carcinoma-in-adenoma lesions, but not in pT3 carcinomas (P < 0.0001).
  • In contrast, COX-2 production was found in 11% (six of 54) of adenomas, 52% (11 of 21) of adenomas and 71% (15 of 21) of carcinomas in carcinoma-in-adenoma lesions, and 92% (33 of 36) of pT3 carcinomas (P < 0.0001).
  • Concurrence of 15LOX-1 down-regulation and COX-2 up-regulation was found in 6% (three of 54) of adenomas, 33% (seven of 21) of adenomas and 71% (15 of 21) of carcinomas in carcinoma-in-adenoma lesions, and 92% (33 of 36) of pT3 carcinomas (P < 0.0001).
  • CONCLUSIONS: These results suggest that switching of LA metabolism by reversal of the expression of 15LOX-1 and COX-2 is associated with acquisition of malignant potential in colonic neoplasia.
  • [MeSH-major] Adenoma / metabolism. Arachidonate 15-Lipoxygenase / metabolism. Carcinoma / metabolism. Colonic Neoplasms / metabolism. Cyclooxygenase 2 / metabolism

  • Hazardous Substances Data Bank. LINOLEIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17711445.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; 9KJL21T0QJ / Linoleic Acid; EC 1.13.11.33 / Arachidonate 15-Lipoxygenase; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


24. Grau MV, Sandler RS, McKeown-Eyssen G, Bresalier RS, Haile RW, Barry EL, Ahnen DJ, Gui J, Summers RW, Baron JA: Nonsteroidal anti-inflammatory drug use after 3 years of aspirin use and colorectal adenoma risk: observational follow-up of a randomized study. J Natl Cancer Inst; 2009 Feb 18;101(4):267-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nonsteroidal anti-inflammatory drug use after 3 years of aspirin use and colorectal adenoma risk: observational follow-up of a randomized study.
  • BACKGROUND: Frequent use of nonsteroidal anti-inflammatory drugs (NSAIDs) has been shown to reduce the risk of colorectal adenomas in randomized trials.
  • METHODS: We used data from the Aspirin/Folate Polyp Prevention Study (AFPPS), in which 1121 subjects were randomly assigned to receive placebo or aspirin (81 or 325 mg/d) for 3 years.
  • The primary outcomes were all adenomas and advanced lesions.
  • The protective effect of 81 mg of aspirin for colorectal adenomas persisted with continued posttreatment NSAID use.
  • The risk of any adenoma among frequent NSAID users was 26.8% vs 39.9% among placebo subjects who later used NSAIDs sporadically (adjusted relative risk = 0.62, 95% confidence interval [CI] = 0.39 to 0.98; P(trend) with NSAID use frequency = .03).
  • [MeSH-major] Adenoma / prevention & control. Anti-Inflammatory Agents, Non-Steroidal / administration & dosage. Anticarcinogenic Agents / administration & dosage. Aspirin / administration & dosage. Colorectal Neoplasms / prevention & control

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1998 Feb;77(4):573-80 [9484814.001]
  • [Cites] Yonsei Med J. 1998 Aug;39(4):287-95 [9752793.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 21;90(20):1529-36 [9790545.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Apr;8(4 Pt 1):311-5 [10207634.001]
  • [Cites] J Exp Med. 1999 Aug 16;190(4):445-50 [10449515.001]
  • [Cites] Oncol Rep. 2005 Apr;13(4):559-83 [15756426.001]
  • [Cites] JAMA. 2005 Aug 24;294(8):914-23 [16118381.001]
  • [Cites] J Natl Cancer Inst. 2006 Jun 7;98(11):736-47 [16757698.001]
  • [Cites] Trends Mol Med. 2006 Jun;12(6):240-4 [16650804.001]
  • [Cites] Crit Rev Oncol Hematol. 2006 Jul;59(1):51-64 [16531064.001]
  • [Cites] Biotechnol Lett. 2006 Aug;28(16):1263-70 [16819585.001]
  • [Cites] Br J Cancer. 2006 Nov 6;95(9):1277-9 [17060932.001]
  • [Cites] Gastroenterology. 2006 Dec;131(6):1674-82 [17087947.001]
  • [Cites] Annu Rev Med. 2007;58:239-52 [17100552.001]
  • [Cites] J Natl Cancer Inst. 2007 Jan 17;99(2):129-36 [17227996.001]
  • [Cites] Drugs. 2007;67(6):821-45 [17428102.001]
  • [Cites] J Natl Cancer Inst. 2007 Apr 18;99(8):608-15 [17440162.001]
  • [Cites] Eur J Pharmacol. 2007 Jun 1;563(1-3):49-60 [17341418.001]
  • [Cites] Lancet. 2007 May 12;369(9573):1603-13 [17499602.001]
  • [Cites] JAMA. 2007 Jun 6;297(21):2351-9 [17551129.001]
  • [Cites] Subcell Biochem. 2007;42:213-25 [17612053.001]
  • [Cites] Cancer Lett. 2007 Oct 28;256(2):246-58 [17707579.001]
  • [Cites] Int J Epidemiol. 2007 Oct;36(5):962-5 [17954716.001]
  • [Cites] J Gastrointest Surg. 2000 Mar-Apr;4(2):150-61 [10675238.001]
  • [Cites] Eur J Cancer. 2000 Mar;36(5):664-74 [10738133.001]
  • [Cites] J Natl Cancer Inst. 2002 Feb 20;94(4):252-66 [11854387.001]
  • [Cites] Gastroenterology. 2002 Mar;122(3):641-5 [11874996.001]
  • [Cites] Curr Pharm Des. 2002;8(12):1021-34 [11945149.001]
  • [Cites] Br J Surg. 2002 Jul;89(7):845-60 [12081733.001]
  • [Cites] Gastroenterology. 2002 Dec;123(6):1770-7 [12454832.001]
  • [Cites] N Engl J Med. 2003 Mar 6;348(10):883-90 [12621132.001]
  • [Cites] N Engl J Med. 2003 Mar 6;348(10):891-9 [12621133.001]
  • [Cites] Prog Exp Tumor Res. 2003;37:1-24 [12795046.001]
  • [Cites] Gastroenterology. 2003 Aug;125(2):328-36 [12891533.001]
  • [Cites] Curr Opin Pharmacol. 2003 Aug;3(4):352-61 [12901943.001]
  • [Cites] Cancer Causes Control. 2003 Jun;14(5):403-11 [12946034.001]
  • [Cites] Br J Cancer. 2004 Jan 12;90(1):224-9 [14710233.001]
  • [Cites] Dis Colon Rectum. 2004 May;47(5):665-73 [15054679.001]
  • [Cites] BMC Cancer. 2003 Oct 31;3:28 [14588079.001]
  • [Cites] N Engl J Med. 1993 May 6;328(18):1313-6 [8385741.001]
  • [Cites] N Engl J Med. 1995 Sep 7;333(10):609-14 [7637720.001]
  • [Cites] Biochem Pharmacol. 1998 Jan 1;55(1):53-64 [9413930.001]
  • (PMID = 19211442.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 098286; United States / NCI NIH HHS / CA / P30 CA023108; United States / NCI NIH HHS / CA / CA 046927; United States / NCI NIH HHS / CA / U01 CA046927; United States / NCI NIH HHS / CA / R01 CA059005
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Anticarcinogenic Agents; R16CO5Y76E / Aspirin
  • [Other-IDs] NLM/ PMC2644329
  •  go-up   go-down


25. Zhang X, Leav I, Revelo MP, Deka R, Medvedovic M, Jiang Z, Ho SM: Deletion hotspots in AMACR promoter CpG island are cis-regulatory elements controlling the gene expression in the colon. PLoS Genet; 2009 Jan;5(1):e1000334
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Deletion hotspots in AMACR promoter CpG island are cis-regulatory elements controlling the gene expression in the colon.
  • Alpha-methylacyl-coenzyme A racemase (AMACR) regulates peroxisomal beta-oxidation of phytol-derived, branched-chain fatty acids from red meat and dairy products -- suspected risk factors for colon carcinoma (CCa).
  • By using a panel of immunostained-laser-capture-microdissected clinical samples comprising the entire colon adenoma-carcinoma sequence, we show that deregulation of AMACR during colon carcinogenesis involves two nonrandom events, resulting in the mutually exclusive existence of double-deletion at CG3 and CG10 and deletion of CG12-16 in a newly identified CpG island within the core promoter of AMACR.
  • It existed in histologically normal colonic glands and tubular adenomas with low AMACR expression and was absent in villous adenomas and all CCas expressing variable levels of AMACR.
  • Our findings identified key in vivo events and novel transcription factors responsible for AMACR regulation in CCas and suggested these AMACR deletions may have diagnostic/prognostic value for colon carcinogenesis.
  • [MeSH-major] Colon / enzymology. Colonic Neoplasms / genetics. CpG Islands / genetics. Gene Expression Regulation, Neoplastic. Promoter Regions, Genetic. Racemases and Epimerases / genetics
  • [MeSH-minor] Adenoma, Villous / genetics. Adenoma, Villous / metabolism. Adenoma, Villous / pathology. Base Sequence. Binding Sites. Cell Differentiation. Cell Line, Tumor. Humans. Molecular Sequence Data. Polymorphism, Genetic. Repressor Proteins / metabolism. Sequence Deletion / genetics. Transcription, Genetic

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Methods Mol Biol. 2000;132:365-86 [10547847.001]
  • [Cites] Cancer Res. 2000 Mar 15;60(6):1677-82 [10749139.001]
  • [Cites] J Biol Chem. 2000 May 26;275(21):15685-90 [10748193.001]
  • [Cites] Am J Pathol. 2001 Jul;159(1):79-92 [11438457.001]
  • [Cites] Am J Surg Pathol. 2001 Nov;25(11):1397-404 [11684956.001]
  • [Cites] J Lipid Res. 2002 Mar;43(3):438-44 [11893780.001]
  • [Cites] JAMA. 2002 Apr 3;287(13):1662-70 [11926890.001]
  • [Cites] Cancer Res. 2002 Apr 15;62(8):2220-6 [11956072.001]
  • [Cites] Am J Surg Pathol. 2002 Jul;26(7):926-31 [12131161.001]
  • [Cites] Am J Pathol. 2002 Sep;161(3):841-8 [12213712.001]
  • [Cites] Science. 2002 Sep 13;297(5588):1807-8; discussion 1807-8 [12229925.001]
  • [Cites] Hum Pathol. 2003 Mar;34(3):228-33 [12673556.001]
  • [Cites] J Lipid Res. 2003 May;44(5):968-77 [12611910.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Aug;12(8):775-83 [12917210.001]
  • [Cites] Hum Pathol. 2003 Aug;34(8):792-6 [14506641.001]
  • [Cites] Cancer Detect Prev. 2003;27(6):422-6 [14642549.001]
  • [Cites] J Cell Biochem. 2004 Jan 1;91(1):47-53 [14689581.001]
  • [Cites] Am J Pathol. 2004 Mar;164(3):787-93 [14982833.001]
  • [Cites] Histopathology. 2004 Sep;45(3):218-25 [15330799.001]
  • [Cites] Cell. 1980 Oct;21(3):653-68 [6985477.001]
  • [Cites] Cell. 1990 Jun 1;61(5):759-67 [2188735.001]
  • [Cites] Int J Cancer. 1992 May 28;51(3):386-9 [1592529.001]
  • [Cites] Genome Res. 2007 Jun;17(6):807-17 [17567999.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Aug;16(8):1536-42 [17684125.001]
  • [Cites] Prostate. 2007 Oct 1;67(14):1487-97 [17680641.001]
  • [Cites] Prostate. 2007 Oct 1;67(14):1507-13 [17683075.001]
  • [Cites] Oncogene. 2007 Nov 15;26(52):7346-54 [17525739.001]
  • [Cites] Environ Health Perspect. 2008 Jun;116(6):769-76 [18560533.001]
  • [Cites] Genome Res. 2008 Nov;18(11):1763-77 [18836037.001]
  • [Cites] Curr Top Microbiol Immunol. 2006;301:259-81 [16570852.001]
  • [Cites] Am J Hum Genet. 1992 Dec;51(6):1325-33 [1463014.001]
  • [Cites] Hum Mol Genet. 1997 Jun;6(6):881-5 [9175734.001]
  • [Cites] Br J Cancer. 1999 Mar;79(7-8):1283-7 [10098773.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Feb 22;102(8):2970-4 [15710887.001]
  • [Cites] Mol Cancer Res. 2005 Feb;3(2):110-8 [15755877.001]
  • [Cites] Prostate. 2005 Jun 1;63(4):316-23 [15599942.001]
  • [Cites] Prostate. 2005 Jun 1;63(4):341-6 [15602744.001]
  • [Cites] Bioinformatics. 2005 Jul 1;21(13):2933-42 [15860560.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2005 Sep;13(3):252-5 [16082251.001]
  • [Cites] J Gastroenterol Hepatol. 2005 Sep;20(9):1410-5 [16105129.001]
  • [Cites] Clin Transl Oncol. 2006 Jun;8(6):391-8 [16790391.001]
  • [Cites] Atherosclerosis. 2006 Sep;188(1):43-50 [16289551.001]
  • [Cites] Cancer Causes Control. 2007 Feb;18(1):41-50 [17315319.001]
  • [Cites] Hum Pathol. 2007 Jun;38(6):850-6 [17442371.001]
  • [Cites] J Med Chem. 2007 May 31;50(11):2700-7 [17477519.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2007 Jun;15(2):175-80 [17525630.001]
  • (PMID = 19148275.001).
  • [ISSN] 1553-7404
  • [Journal-full-title] PLoS genetics
  • [ISO-abbreviation] PLoS Genet.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA112532; United States / NCI NIH HHS / CA / R01 CA112532; United States / NIEHS NIH HHS / ES / P30 ES006096; United States / NCI NIH HHS / CA / R01 CA015776; United States / NCI NIH HHS / CA / CA015776; United States / NCI NIH HHS / CA / R01 CA062269; United States / NCI NIH HHS / CA / CA062269
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Repressor Proteins; 0 / ZNF202 protein, human; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  • [Other-IDs] NLM/ PMC2613032
  •  go-up   go-down


26. Wada R: Proposal of a new hypothesis on the development of colorectal epithelial neoplasia: nonspecific inflammation--colorectal Paneth cell metaplasia--colorectal epithelial neoplasia. Digestion; 2009;79 Suppl 1:9-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Colorectal epithelial neoplasia (CR-EN), both adenoma and adenocarcinoma, may develop from the essential tubules of the colorectum.
  • In order to conclude the carcinogenesis of the colorectal cancer more clearly, the biological features including the genetic abnormality of the nonneoplastic mucosal epithelium of colon and rectum, which coexist in connection with CR-EN, should be investigated.
  • In this review, the importance of Paneth cell metaplasia of colorectum as one of the original mucosal regions of the development of CR-EN, and the new hypothesis on the development of CR-EN (nonspecific inflammation - colorectal Paneth cell metaplasia - colorectal epithelial neoplasia) are examined.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma / pathology. Colorectal Neoplasms / pathology. Paneth Cells / pathology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19153484.001).
  • [ISSN] 1421-9867
  • [Journal-full-title] Digestion
  • [ISO-abbreviation] Digestion
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 19
  •  go-up   go-down


27. Tomita T: Immunocytochemical localization of lymphatic and venous vessels in colonic polyps and adenomas. Dig Dis Sci; 2008 Jul;53(7):1880-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunocytochemical localization of lymphatic and venous vessels in colonic polyps and adenomas.
  • Using lymphatic vessels endothelial hyaluronan receptor-1 (LYVE-1) immunocytochemical staining, hyperplastic polyps, tubular adenomas to villous adenomas, were investigated for lymphatic vessels compared with immunostained blood vessels using factor-8.
  • Four cases each of hyperplastic polyps, tubular adenomas to villous adenomas, were routinely fixed in formalin and embedded in paraffin and were immunostained using goat anti-LYVE-1 for lymphatic vessels and rabbit anti-factor-8 for blood vessels.
  • In normal colon and hyperplastic polyps, slender lymphatic vessels were noted in muscularis mucosa, which spread into the base of colonic crypt, whereas round venous vessels, they extend into lamina propria.
  • In tubular adenomas, small lymphatic and venous vessels were noted in broad fibrous stalks.
  • In villous adenomas, smaller lymphatic and venous vessels were noted in fine intervillous stroma.
  • In normal colon and hyperplastic polyps, slender, irregularly shaped lymphatic vessels were present in muscularis mucosa, spreading into the base of the colonic crypt.
  • In tubular adenomas, small lymphatic and venous vessels were noted in fibrous stalks.
  • In villous adenomas, smaller lymphatic and venous vessels were noted in intervillous stroma.
  • There are no increased lymphatic and venous vessels in intermucosal stroma and stalks of adenomas compared with normal colon.
  • [MeSH-major] Adenoma / blood supply. Colonic Neoplasms / blood supply. Colonic Polyps. Immunohistochemistry / methods. Lymphatic Vessels. Veins

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1998 Apr 15;58(8):1599-604 [9563467.001]
  • [Cites] Clin Exp Med. 2006 Jun;6(2):65-71 [16820993.001]
  • [Cites] Lymphology. 1995 Mar;28(1):4-20 [7791375.001]
  • [Cites] Cancer. 1998 Sep 1;83(5):825-9 [9731879.001]
  • [Cites] Cell Tissue Res. 2007 May;328(2):317-28 [17265066.001]
  • [Cites] Int J Oncol. 2003 Aug;23(2):533-9 [12851706.001]
  • [Cites] Cell. 1999 Sep 17;98(6):769-78 [10499794.001]
  • [Cites] Lymphology. 2003 Jun;36(2):52-61 [12926829.001]
  • [Cites] Am J Pathol. 2006 Mar;168(3):1045-53 [16507917.001]
  • [Cites] Int J Mol Med. 2004 Feb;13(2):211-4 [14719125.001]
  • [Cites] J Clin Pathol. 2005 Feb;58(2):202-6 [15677543.001]
  • [Cites] Oncol Rep. 2004 Jan;11(1):47-50 [14654901.001]
  • [Cites] Dig Dis Sci. 1995 May;40(5):996-1004 [7729290.001]
  • [Cites] Am J Pathol. 2004 Oct;165(4):1187-97 [15466385.001]
  • [Cites] Pancreas. 2007 Nov;35(4):e18-22 [18090227.001]
  • (PMID = 17990106.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / LYVE1 protein, human; 0 / Vesicular Transport Proteins
  •  go-up   go-down


28. Lansdorp-Vogelaar I, Kuntz KM, Knudsen AB, Wilschut JA, Zauber AG, van Ballegooijen M: Stool DNA testing to screen for colorectal cancer in the Medicare population: a cost-effectiveness analysis. Ann Intern Med; 2010 Sep 21;153(6):368-77
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • LIMITATION: No pathways other than the traditional adenoma-carcinoma sequence were modeled.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Bowel Movement.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Planning and Implementing Cervical Cancer Prevention and Control Programs: A Manual for Managers .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2009 Jun 1;115(11):2410-9 [19288570.001]
  • [Cites] Am J Gastroenterol. 2008 Nov;103(11):2862-70 [18759824.001]
  • [Cites] Gastroenterology. 2004 May;126(5):1270-9 [15131787.001]
  • [Cites] J Mol Diagn. 2004 Nov;6(4):386-95 [15507679.001]
  • [Cites] Cancer. 1979 May;43(5):1847-57 [445371.001]
  • [Cites] Cancer. 1982 Feb 15;49(4):819-25 [7055790.001]
  • [Cites] Gut. 1982 Oct;23(10):835-42 [7117903.001]
  • [Cites] Int J Cancer. 1985 Aug 15;36(2):179-86 [4018911.001]
  • [Cites] Int J Cancer. 1986 Aug 15;38(2):173-6 [3733258.001]
  • [Cites] Cancer. 1988 Apr 1;61(7):1472-6 [3345499.001]
  • [Cites] Scand J Gastroenterol. 1989 Sep;24(7):799-806 [2799283.001]
  • [Cites] Gastroenterology. 1990 Feb;98(2):371-9 [2403953.001]
  • [Cites] Gut. 1992 Nov;33(11):1508-14 [1452076.001]
  • [Cites] Comput Biomed Res. 1999 Feb;32(1):13-33 [10066353.001]
  • [Cites] J Natl Cancer Inst. 1999 Mar 3;91(5):434-7 [10070942.001]
  • [Cites] Ann Surg. 1963 Feb;157:223-6 [14020146.001]
  • [Cites] Dis Colon Rectum. 1964 Jul-Aug;7:249-61 [14176135.001]
  • [Cites] N Engl J Med. 2004 Dec 23;351(26):2704-14 [15616205.001]
  • [Cites] Am J Prev Med. 2005 Feb;28(2):208-14 [15710277.001]
  • [Cites] Gastroenterology. 2005 Aug;129(2):422-8 [16083699.001]
  • [Cites] Cancer. 2006 Jan 15;106(2):277-83 [16342248.001]
  • [Cites] CA Cancer J Clin. 2006 Jan-Feb;56(1):11-25; quiz 49-50 [16449183.001]
  • [Cites] Am J Gastroenterol. 2006 Feb;101(2):343-50 [16454841.001]
  • [Cites] Gastroenterology. 2006 May;130(6):1872-85 [16697750.001]
  • [Cites] BMC Cancer. 2006;6:136 [16723013.001]
  • [Cites] J Natl Cancer Inst. 2000 Apr 5;92(7):557-63 [10749911.001]
  • [Cites] N Engl J Med. 2000 Jul 20;343(3):162-8 [10900274.001]
  • [Cites] JAMA. 2000 Oct 18;284(15):1954-61 [11035892.001]
  • [Cites] N Engl J Med. 2000 Nov 30;343(22):1603-7 [11096167.001]
  • [Cites] JAMA. 2002 May 8;287(18):2428-9 [11988064.001]
  • [Cites] Gastroenterology. 2002 Dec;123(6):1786-92 [12454834.001]
  • [Cites] Gastroenterology. 2003 Feb;124(2):544-60 [12557158.001]
  • [Cites] Clin Colorectal Cancer. 2003 May;3(1):47-53 [12777192.001]
  • [Cites] N Engl J Med. 2006 Nov 2;355(18):1863-72 [17079760.001]
  • [Cites] Ann Intern Med. 2006 Dec 19;145(12):880-6 [17179057.001]
  • [Cites] Histopathology. 2007 Jan;50(1):113-30 [17204026.001]
  • [Cites] Clin Gastroenterol Hepatol. 2007 Jan;5(1):111-7 [17161655.001]
  • [Cites] Endoscopy. 2007 Feb;39(2):168-73 [17327977.001]
  • [Cites] Am J Manag Care. 2007 Jul;13(7):393-400 [17620034.001]
  • [Cites] Am J Gastroenterol. 2007 Oct;102(10):2259-64 [17617203.001]
  • [Cites] J Natl Cancer Inst. 2007 Oct 3;99(19):1462-70 [17895475.001]
  • [Cites] J Natl Cancer Inst. 2008 May 7;100(9):630-41 [18445825.001]
  • [Cites] Gastroenterology. 2008 May;134(5):1570-95 [18384785.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Jul;17(7):1623-30 [18628413.001]
  • [Cites] Ann Intern Med. 2008 Oct 7;149(7):441-50, W81 [18838724.001]
  • [Cites] Ann Intern Med. 2008 Oct 7;149(7):509-10 [18838731.001]
  • [Cites] Ann Intern Med. 2008 Nov 4;149(9):627-37 [18838716.001]
  • [Cites] Ann Intern Med. 2009 Jun 16;150(12):849-57, W152 [19528563.001]
  • (PMID = 20855801.001).
  • [ISSN] 1539-3704
  • [Journal-full-title] Annals of internal medicine
  • [ISO-abbreviation] Ann. Intern. Med.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA115953; United States / NCI NIH HHS / CA / U01 CA097426; United States / NCI NIH HHS / CA / P30 CA008748; United States / PHS HHS / / HHSP233200700196P; United States / PHS HHS / / HHSP233200700350P; United States / NCI NIH HHS / CA / U01-CA-115953; United States / NCI NIH HHS / CA / U01-CA-088204; United States / PHS HHS / / HHSP233200700123P; United States / NCI NIH HHS / CA / U01 CA088204; United States / NCI NIH HHS / CA / U01-CA-097426
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  • [Other-IDs] NLM/ NIHMS438539; NLM/ PMC3578600
  •  go-up   go-down


29. Ashktorab H, Brim H, Al-Riyami M, Date A, Al-Mawaly K, Kashoub M, Al-Mjeni R, Smoot DT, Al-Moundhri M, Al-Hashemi S, Ganguly SS, Raeburn S: Sporadic colon cancer: mismatch repair immunohistochemistry and microsatellite instability in Omani subjects. Dig Dis Sci; 2008 Oct;53(10):2723-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sporadic colon cancer: mismatch repair immunohistochemistry and microsatellite instability in Omani subjects.
  • We assessed colonic cancers in an attempt to identify tumors with DNA MMR deficiency and microsatellite instability (MSI).
  • Colon cancer tissue was assayed using immunohistochemistry for expression of hMLH1 and hMSH2, and a panel of five pairs of microsatellite primers (NR21, NR22, NR24, BAT25, and BAT26) for MSI-H analysis and additional dinucleotide markers (D17S250, D5S346, and D2S123) used for MSI-L.
  • The methylation status of the p16 promoter was determined by methylation-specific polymerase chain reaction (PCR).
  • The information currently available indicates that there is an incidence of 4.7% colon cancer (49/1036) and 12.1% (126/1290) colon adenoma among the cases who underwent colonoscopy at these centers.
  • [MeSH-major] Adenoma / genetics. Colonic Neoplasms / genetics. Colorectal Neoplasms / genetics. DNA Mismatch Repair. Microsatellite Instability

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gut. 2001 Jun;48(6):821-9 [11358903.001]
  • [Cites] Eur J Cancer Prev. 1993 Mar;2(2):105-15 [8461861.001]
  • [Cites] Am J Hum Genet. 2004 Mar;74(3):532-44 [14973781.001]
  • [Cites] Clin Cancer Res. 2005 Aug 1;11(15):5410-6 [16061855.001]
  • [Cites] Cancer Res. 1998 Aug 1;58(15):3455-60 [9699680.001]
  • [Cites] Am J Pathol. 1994 Jul;145(1):148-56 [8030745.001]
  • [Cites] CA Cancer J Clin. 2002 Jan-Feb;52(1):23-47 [11814064.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10 (1 Pt 1):191-5 [14734469.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5248-57 [9823339.001]
  • [Cites] Int J Cancer. 2003 Aug 10;106(1):66-73 [12794758.001]
  • [Cites] Cancer Res. 1999 Mar 1;59(5):1090-5 [10070967.001]
  • [Cites] Cancer. 1999 Feb 15;85(4):779-85 [10091754.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5635-43 [16110022.001]
  • [Cites] Gastroenterology. 2005 Sep;129(3):837-45 [16143123.001]
  • [Cites] Science. 1993 May 7;260(5109):812-6 [8484121.001]
  • [Cites] Histopathology. 2007 Jan;50(1):113-30 [17204026.001]
  • [Cites] Cancer Res. 1997 Mar 1;57(5):808-11 [9041175.001]
  • [Cites] Gastroenterology. 1999 Jul;117(1):123-31 [10381918.001]
  • [Cites] Cancer Res. 1998 Apr 15;58(8):1713-8 [9563488.001]
  • [Cites] Cancer Res. 1997 Nov 1;57(21):4749-56 [9354436.001]
  • [Cites] Cancer Res. 1996 Dec 1;56(23):5470-4 [8968103.001]
  • [Cites] Cancer. 1988 Jan 15;61(2):386-95 [3422035.001]
  • [Cites] Gastroenterology. 2002 Dec;123(6):1804-11 [12454837.001]
  • [Cites] Surgery. 2001 Jul;130(1):17-20 [11436007.001]
  • [Cites] Cancer. 1999 Apr 15;85(8):1670-6 [10223559.001]
  • [Cites] Int J Cancer. 2005 Oct 10;116(6):914-9 [15856472.001]
  • [Cites] Cancer. 2005 Sep 1;104(5):952-61 [16015629.001]
  • [Cites] Cancer Res. 1993 Dec 15;53(24):5849-52 [8261392.001]
  • [Cites] Gastroenterology. 2004 Feb;126(2):394-401 [14762775.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):6991-5 [11585722.001]
  • [Cites] J Clin Oncol. 2004 Nov 15;22(22):4584-94 [15542810.001]
  • [Cites] N Engl J Med. 1998 May 21;338(21):1481-7 [9593786.001]
  • [Cites] Clin Cancer Res. 2003 Mar;9(3):1112-7 [12631615.001]
  • [Cites] J Clin Oncol. 2002 Feb 15;20(4):1043-8 [11844828.001]
  • [Cites] Clin Chem Lab Med. 2001 Feb;39(2):121-8 [11341745.001]
  • [Cites] Int J Cancer. 1997 Dec 19;74(6):664-9 [9421366.001]
  • [Cites] Isr Med Assoc J. 2005 Aug;7(8):520-4 [16106779.001]
  • (PMID = 18299982.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA102681
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / MLH1 protein, human; 0 / Mucins; 0 / Nuclear Proteins; EC 3.6.1.3 / MSH2 protein, human; EC 3.6.1.3 / MutL Protein Homolog 1; EC 3.6.1.3 / MutS Homolog 2 Protein
  •  go-up   go-down


30. Fujimoto T, Yoshimatsu K, Watanabe K, Yokomizo H, Otani T, Matsumoto A, Osawa G, Onda M, Ogawa K: Overexpression of human X-box binding protein 1 (XBP-1) in colorectal adenomas and adenocarcinomas. Anticancer Res; 2007 Jan-Feb;27(1A):127-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of human X-box binding protein 1 (XBP-1) in colorectal adenomas and adenocarcinomas.
  • Recently, overexpression of XBP-1 has been reported in breast cancer including non-invasive carcinomas, and was suggested to play an important role in breast carcinogenesis.
  • To investigate the involvement of XBP-1 in colorectal tumorigenecity, the expression of XBP-1 was examined in four colon cancer cell lines, six colorectal polyps and five colorectal carcinomas.
  • MATERIALS AND METHODS: The study population consisted of eleven patients who had undergone resection for colorectal cancer or adenoma from 2000 to 2002.
  • Four colon cancer cell lines, DLD1, SW480, HCT15 and WiDr, were also analyzed for expression of XBP-1.
  • Reverse transcription-polymerase chain reaction was performed using eleven primary colon tumors.
  • RESULTS: The XBP-1 gene was overexpressed in four cases out of five primary colorectal carcinomas and in four cases out of six colorectal adenomas.
  • Immunohistochemical staining demonstrated that XBP-1 protein was strongly stained in the cytoplasms of cancer cells, whereas it was unreactive in the normal colon epithelial cells and stromal cells.
  • CONCLUSION: These data indicate that increased expression of XBP-1 gene may play some role in human colon carcinogenesis through impairment of cell differentiation regulation.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma / metabolism. Colorectal Neoplasms / metabolism. DNA-Binding Proteins / biosynthesis. Nuclear Proteins / biosynthesis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17352224.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / RNA, Messenger; 0 / Transcription Factors; 0 / regulatory factor X transcription factors
  •  go-up   go-down


31. Nusko G, Hahn EG, Mansmann U: Characteristics of metachronous colorectal adenomas found during long-term follow-up: analysis of four subsequent generations of adenoma recurrence. Scand J Gastroenterol; 2009;44(6):736-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics of metachronous colorectal adenomas found during long-term follow-up: analysis of four subsequent generations of adenoma recurrence.
  • OBJECTIVE: Because of the high recurrence rates of colorectal adenomas, regular surveillance by colonoscopy has been recommended, but there is still a dearth of information on the long-term results of follow-up colonoscopy after polypectomy.
  • The aims of this study were to determine the differences between initial adenomas and metachronous lesions, to evaluate the effect of long-term surveillance and to describe the hypothetical origin of the colorectal adenoma-carcinoma sequence.
  • MATERIAL AND METHODS: Between 1978 and 2003 a total of 1091 patients undergoing periodic surveillance examinations were prospectively documented at the Erlangen Registry of Colorectal Polyps.
  • Statistical analysis using chi(2) testing of adenoma characteristics found in four subsequent recurrence periods was carried out, and the relative risk (RR) for the development of metachronous adenomas of advanced pathology was calculated.
  • RESULTS: In comparison with the initial findings, metachronous adenomas are generally significantly smaller lesions (p<0.00001), usually tubular in shape (p<0.00001) and bearing high-grade dysplasia less often (p<0.00001) and are usually located in the right colon (p<0.00001).
  • These differences are found between the initial and four subsequent generations of metachronous adenomas.
  • The number of synchronous adenomas is reduced only in the first recurrence (p<0.001); in the further generations equal proportions of multiplicity are found, as in the baseline examination.
  • Patients with adenomas of advanced pathology, i.e. large, tubulovillous or villous adenomas at baseline, have a significantly higher risk for large (RR 2.73; 95% CI 1.77-4.20), tubulovillous or villous (RR 1.55; 95% CI 1.06-2.25) or multiple (RR 2.45; 95% CI 1.83-3.29) metachronous adenomas at the first recurrence.
  • CONCLUSIONS: Metachronous adenomas show the uniform characteristics of being small tubular lesions rarely bearing high-grade dysplasia, usually located in the right colon.
  • [MeSH-major] Adenoma / pathology. Colorectal Neoplasms / pathology. Neoplasms, Second Primary

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19277927.001).
  • [ISSN] 1502-7708
  • [Journal-full-title] Scandinavian journal of gastroenterology
  • [ISO-abbreviation] Scand. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  •  go-up   go-down


32. Landau D, Garrett C, Chodkiewicz C: A case of primary squamous cell colon cancer. J Oncol Pharm Pract; 2007 Mar;13(1):47-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of primary squamous cell colon cancer.
  • Carcinomas of the colon are a common cancer seen in both inpatient and outpatient settings with approximately 145,000 new cases being diagnosed every year in the USA.
  • Despite the frequency of these cancers being seen, it continues to be a rarity to see a primary squamous cell cancer of the colon.
  • While the exact aetiology of this rare tumour is currently still not completely understood, various aetiologies include chronic irritation leading to squamous differentiation, embryonic migration of ectodermal cells to the colon, or adenomas undergoing squamous transformation.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Colonic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17621567.001).
  • [ISSN] 1078-1552
  • [Journal-full-title] Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
  • [ISO-abbreviation] J Oncol Pharm Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


33. Crispin A, Birkner B, Munte A, Nusko G, Mansmann U: Process quality and incidence of acute complications in a series of more than 230,000 outpatient colonoscopies. Endoscopy; 2009 Dec;41(12):1018-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Colon preparation resulted in clear bowels in 76.31 % of patients, liquid residues in 22.22 %, and dirty bowels in 1.47 %.
  • [MeSH-minor] Acute Disease. Adenoma / diagnosis. Aged. Colon / injuries. Colonic Neoplasms / diagnosis. Colonic Polyps / surgery. Female. Heart Diseases / etiology. Hemorrhage / etiology. Humans. Intestinal Perforation / etiology. Male. Middle Aged. Respiration Disorders / etiology. Risk Factors

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Georg Thieme Verlag KG Stuttgart New York.
  • (PMID = 19856246.001).
  • [ISSN] 1438-8812
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


34. Fadare O, Parkash V, Fiedler PN, Mayerson AB, Asiyanbola B: Tumor-to-tumor metastasis to a thyroid follicular adenoma as the initial presentation of a colonic adenocarcinoma. Pathol Int; 2005 Sep;55(9):574-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor-to-tumor metastasis to a thyroid follicular adenoma as the initial presentation of a colonic adenocarcinoma.
  • Herein is described the case of a 59-year-old woman whose thyroid nodule (a follicular adenoma) was resected and found to contain foci of a well-differentiated adenocarcinoma with a morphologic and immunohistochemical profile consistent with origination from the lower gastrointestinal tract.
  • Subsequent diagnostic work-up revealed a sigmoid colon tumor with metastases to the liver.
  • This is, to the authors' knowledge, the first reported example of a colon adenocarcinoma whose initial clinical manifestation was a metastasis to a thyroid neoplasm and only the third reported example of a colonic adenocarcinoma metastatic to a thyroid tumor.
  • [MeSH-major] Adenocarcinoma / secondary. Adenoma / pathology. Colonic Neoplasms / pathology. Thyroid Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for follicular adenoma .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16143033.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor
  • [Number-of-references] 23
  •  go-up   go-down


35. Schulz AC, Bojarski C, Buhr HJ, Kroesen AJ: Occurrence of adenomas in the pouch and small intestine of FAP patients after proctocolectomy with ileoanal pouch construction. Int J Colorectal Dis; 2008 Apr;23(4):437-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occurrence of adenomas in the pouch and small intestine of FAP patients after proctocolectomy with ileoanal pouch construction.
  • PURPOSE: Proctocolectomy with ileoanal pouch construction is the standard therapy for patients with familial adenomatous polyposis coli (FAP) to prevent the genesis of colorectal carcinomas.
  • In our patient population, we observed the postoperative development of adenomas not only in the pouch but also in the remaining small intestine.
  • The exact incidence of these ileal polyps is still unknown, since the diagnostic possibilities of examining the small intestine are limited.
  • METHODS: We performed wireless capsule endoscopy (CE) in patients who developed postoperative pouch adenomas (PA) to record the simultaneous occurrence of small bowel adenomas and PA.
  • Eight PA patients (all with PA) also had adenomas in the small intestine diagnosed by CE.
  • CONCLUSIONS: Since jejunal and ileal adenomas occur in all patients with PA, we recommend regular follow-up examinations, which include pouch endoscopy at 3 months and annually after surgery in the presence of PA after proctocolectomy and pouch creation.
  • [MeSH-major] Adenoma / epidemiology. Adenomatous Polyposis Coli / surgery. Colonic Pouches / adverse effects. Intestine, Small / pathology. Proctocolectomy, Restorative / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 2005 Apr;48(4):816-23 [15747076.001]
  • [Cites] Dis Colon Rectum. 1994 Nov;37(11):1126-9 [7956581.001]
  • [Cites] Int J Colorectal Dis. 2006 May;21(4):301-7 [16163544.001]
  • [Cites] Dis Colon Rectum. 1995 Aug;38(8):813-30 [7634976.001]
  • [Cites] Gastrointest Endosc. 2005 Jul;62(1):62-70 [15990821.001]
  • [Cites] Int J Colorectal Dis. 2007 Apr;22(4):449-51 [16710723.001]
  • [Cites] J Clin Pathol. 2005 Jan;58(1):97-101 [15623495.001]
  • [Cites] Gastroenterology. 2002 Mar;122(3):641-5 [11874996.001]
  • [Cites] Gastroenterol Clin Biol. 2006 Apr;30(4):594-7 [16733384.001]
  • [Cites] Br J Surg. 2007 Apr;94(4):478-82 [17310506.001]
  • [Cites] Chirurg. 2002 Aug;73(8):855-8 [12425165.001]
  • [Cites] Surgery. 1996 Jun;119(6):615-23 [8650601.001]
  • [Cites] Dis Colon Rectum. 2001 Mar;44(3):456-8 [11289297.001]
  • [Cites] Am J Gastroenterol. 2005 Jan;100(1):27-37 [15654777.001]
  • [Cites] Int J Colorectal Dis. 2006 Jan;21(1):79-83 [16676398.001]
  • [Cites] Mt Sinai J Med. 2004 Nov;71(6):384-91 [15592657.001]
  • [Cites] Gut. 2002 Jun;50(6):845-50 [12010888.001]
  • [Cites] Int J Colorectal Dis. 2006 Dec;21(8):847-50 [16525781.001]
  • [Cites] Int J Colorectal Dis. 2006 Oct;21(7):632-41 [16511680.001]
  • [Cites] Dis Colon Rectum. 2001 Mar;44(3):347-53 [11289279.001]
  • [Cites] Ann Surg. 2001 Mar;233(3):360-4 [11224623.001]
  • [Cites] Dis Colon Rectum. 1998 May;41(5):552-6; discussion 556-7 [9593235.001]
  • [Cites] Tech Coloproctol. 2005 Dec;9(3):187-92 [16328131.001]
  • [Cites] Surgery. 2004 Oct;136(4):795-803 [15467664.001]
  • (PMID = 18193239.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


36. Waye JD: Improving lesion detection during colonoscopy. Gastroenterol Hepatol (N Y); 2010 Oct;6(10):647-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Colonoscopy has changed since it was first introduced 50 years ago, with glass fibers being replaced by video electronics, the addition of water jets, better illumination, and the use of filters to enhance visual identification of polyps.
  • In spite of these improvements, polyps and tumors of the colon are still overlooked even by the most meticulous examiner.
  • The Third Eye Retroscope is a device that, in conjunction with the video colonoscope, may be able to find virtually all lesions in the colon.
  • This novel device is described here and presents a new way to look into the colon.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21103444.001).
  • [ISSN] 1554-7914
  • [Journal-full-title] Gastroenterology & hepatology
  • [ISO-abbreviation] Gastroenterol Hepatol (N Y)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2978415
  • [Keywords] NOTNLM ; Retroscope / Third Eye Retroscope / adenoma / colonoscopy / polyps / retroversion / screening / surveillance
  •  go-up   go-down


37. Hornick JL, Farraye FA, Odze RD: Clinicopathologic and immunohistochemical study of small apparently "de novo" colorectal adenocarcinomas. Am J Surg Pathol; 2007 Feb;31(2):207-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic and immunohistochemical study of small apparently "de novo" colorectal adenocarcinomas.
  • Rarely, adenocarcinomas of the colorectum develop as small (< or =1.0 cm) rapidly invasive tumors without an obvious adenomatous or "in situ" component.
  • These tumors have been termed "de novo" carcinomas.
  • The aim of this study was to evaluate and compare the pathologic features, biologic characteristics, and natural history of small apparently de novo invasive colorectal adenocarcinomas with conventional large (>1.0 cm) carcinomas.
  • Routinely processed specimens from 20 patients (M/F ratio: 13/7; mean age: 65 y) with small apparently de novo invasive colorectal adenocarcinomas (all < or =1.0 cm in size) were evaluated for a variety of clinical and pathologic features.
  • Small apparently de novo invasive adenocarcinomas were present in the left colon, transverse colon, and right colon in 85%, 10%, and 5% of cases, respectively.
  • Upon complete sectioning of the tissue blocks of tumor, residual foci of adenomatous epithelium were present in 16/20 (80%) cases, of which 75% contained foci of high-grade dysplasia.
  • In our patient population, true small de novo colorectal adenocarcinomas, tumors that lack an identifiable adenomatous component, are exceedingly rare, because complete tissue sectioning reveals residual adenomatous tissue in the majority of cases.
  • The biologic characteristics and natural history of small carcinomas with a minimal dysplastic component, and those with no identifiable adenomatous component, are similar to conventional large (>1 cm) adenocarcinomas, and, thus, they should probably be treated similarly.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma / pathology. Colorectal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17255765.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


38. Phelps RA, Broadbent TJ, Stafforini DM, Jones DA: New perspectives on APC control of cell fate and proliferation in colorectal cancer. Cell Cycle; 2009 Aug 15;8(16):2549-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Aberrant Wnt/beta-catenin signaling following loss of the tumor suppressor adenomatous polyposis coli (APC) is thought to initiate colon adenoma formation.
  • However, examination of tumors from familial adenomatous polyposis coli (FAP) patients has failed to confirm the presence of nuclear beta-catenin in early lesions following APC loss despite robust staining in later lesions.
  • This observation presents the possibility that colon adenomas arise through a beta-catenin-independent function of APC.
  • Though there are currently contrasting models to explain colon tumorigenesis, our goal is to begin to reconcile data from multiple different model systems and provide a functional view into the initiation and progression of colon cancer.
  • [MeSH-major] Adenomatous Polyposis Coli / pathology. Cell Differentiation / physiology. Colorectal Neoplasms / pathology

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19597346.001).
  • [ISSN] 1551-4005
  • [Journal-full-title] Cell cycle (Georgetown, Tex.)
  • [ISO-abbreviation] Cell Cycle
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 94
  •  go-up   go-down


39. Khatibzadeh N, Ziaee SA, Rahbar N, Molanie S, Arefian L, Fanaie SA: The indirect role of site distribution in high-grade dysplasia in adenomatous colorectal polyps. J Cancer Res Ther; 2005 Oct-Dec;1(4):204-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The indirect role of site distribution in high-grade dysplasia in adenomatous colorectal polyps.
  • BACKGROUND: The appropriate application of Endoscopic modalities for polypectomy depends on the likelihood that the adenoma in question harbors invasive cancer.
  • While prior studies have evaluated polyp size and morphology in assessing the risk of malignancy, in recent decay some authorities have paid more attention to dysplasia.
  • All in all, the relative risk of cancer based on polyp distribution in correlation with dysplasia has not been statistically studied which is done in our study.
  • METHODS AND MATERIALS: Between June 2001 and March 2004, the distribution of 130 adenomatous polyps was compared with synchronous invasive or in situ cancer.
  • Factors such as Patient age, Patients gender, location of lesion, size of polyp, histological subtype of adenoma on biopsy, degree of dysplasia, synchronous cancer, color of polyp, and number of polyps were included in the data collection.
  • CONCLUSION: Lesions greater than 1 cm in diameter with high-grade dysplasia after splenic flexure should be managed as presumptive malignancies with segmental colon resection.
  • [MeSH-major] Adenomatous Polyps / pathology. Colorectal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17998654.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


40. Burkart AL, Sheridan T, Lewin M, Fenton H, Ali NJ, Montgomery E: Do sporadic Peutz-Jeghers polyps exist? Experience of a large teaching hospital. Am J Surg Pathol; 2007 Aug;31(8):1209-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Do sporadic Peutz-Jeghers polyps exist? Experience of a large teaching hospital.
  • Most types of sporadic gastrointestinal (GI) polyps vastly outnumber their syndromic counterparts.
  • In contrast, the incidence of sporadic Peutz-Jeghers polyps (PJP) is unknown.
  • The pathology database of a large hospital was searched for "Peutz-Jeghers polyp(s)," yielding 121 polyps from 38 patients.
  • The polyps were reviewed by 3 pathologists to confirm the diagnosis.
  • Of the 102 polyps included after histologic review, 94 polyps arose in patients meeting the World Health Organization criteria for PJS.
  • These PJS polyps were eliminated from further analysis.
  • Of the 8 potential sporadic PJP, only 3 polyps from 3 patients had unequivocal PJP histologic features, all from the small intestine.
  • The 5 remaining patients each had a colonic polyp with features suggestive, but not definitely diagnostic of, PJP.
  • One patient had a history of high-grade dysplasia in a tubulovillous adenoma in the colon at 53 years, but no family cancer history.
  • Another had a history of pituitary adenoma at age 39, and the last had ductal breast carcinoma diagnosed 4 years before the discovery of the polyp.
  • [MeSH-major] Hospitals, Teaching. Intestinal Polyps / pathology. Peutz-Jeghers Syndrome / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17667545.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Lee EJ, Park CK, Kim JW, Chang DK, Kim KM: Deletion mutation of BRAF in a serrated adenoma from a patient with familial adenomatous polyposis. APMIS; 2007 Aug;115(8):982-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Deletion mutation of BRAF in a serrated adenoma from a patient with familial adenomatous polyposis.
  • BRAF gene mutations in the colorectum have been associated with serrated adenomas and less frequently with hyperplastic polyps, villous adenomas, tubular adenomas, and carcinomas.
  • Most BRAF mutations in the colon have been reported as a V600E substitution.
  • We report a case with a very rare deletion mutation of BRAF (c.1799-1801delTGA, p.Val600_Lys601delinsGlu) in a serrated adenoma; the patient has familial adenomatous polyposis with a germline mutation of the APC gene (c.3578delA, p.Gln1193ArgfsX1264).
  • Genetic studies on fundic gland polyps and tubular adenomas from the same patient failed to demonstrate BRAF mutation.
  • This case is the first reported with a deletion mutation of BRAF found in the colon.
  • [MeSH-major] Adenomatous Polyposis Coli / genetics. Gene Deletion. Proto-Oncogene Proteins B-raf / genetics

  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • Genetic Alliance. consumer health - Familial Polyposis.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17696956.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  •  go-up   go-down


42. Douma KF, Aaronson NK, Vasen HF, Bleiker EM: Psychosocial issues in genetic testing for familial adenomatous polyposis: a review of the literature. Psychooncology; 2008 Aug;17(8):737-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Psychosocial issues in genetic testing for familial adenomatous polyposis: a review of the literature.
  • OBJECTIVES: Familial adenomatous polyposis (FAP) is characterized by the development of multiple adenomas in the colon that can lead to colorectal cancer.
  • [MeSH-major] Adenomatous Polyps / genetics. Adenomatous Polyps / psychology. Colonic Neoplasms / genetics. Colonic Neoplasms / psychology. Genetic Techniques / instrumentation


43. Shelton DN, Sandoval IT, Eisinger A, Chidester S, Ratnayake A, Ireland CM, Jones DA: Up-regulation of CYP26A1 in adenomatous polyposis coli-deficient vertebrates via a WNT-dependent mechanism: implications for intestinal cell differentiation and colon tumor development. Cancer Res; 2006 Aug 1;66(15):7571-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Up-regulation of CYP26A1 in adenomatous polyposis coli-deficient vertebrates via a WNT-dependent mechanism: implications for intestinal cell differentiation and colon tumor development.
  • Mutations in the adenomatous polyposis coli (APC) tumor suppressor gene seem to underlie the initiation of many colorectal carcinomas.
  • Paradoxically, however, previous studies found that dietary supplementation of Apc(MIN) mice with retinoic acid failed to abrogate adenoma formation.
  • While investigating the above finding, we found that expression of CYP26A1, a major retinoic acid catabolic enzyme, was up-regulated in Apc(MIN) mouse adenomas, human FAP adenomas, human sporadic colon carcinomas, and in the intestine of apc(mcr) mutant zebrafish embryos.
  • [MeSH-major] Adenomatous Polyposis Coli Protein / deficiency. Colonic Neoplasms / metabolism. Cytochrome P-450 Enzyme System / biosynthesis. Intestines / pathology. Wnt Proteins / metabolism

  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • ZFIN. ZFIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16885356.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adenomatous Polyposis Coli Protein; 0 / Cytochrome P-450 Enzyme Inhibitors; 0 / Morpholines; 0 / Oligonucleotides; 0 / Wnt Proteins; 5688UTC01R / Tretinoin; 9035-51-2 / Cytochrome P-450 Enzyme System; EC 1.14.14.1 / retinoic acid 4-hydroxylase
  •  go-up   go-down


44. Obtulowicz T, Swoboda M, Speina E, Gackowski D, Rozalski R, Siomek A, Janik J, Janowska B, Ciesla JM, Jawien A, Banaszkiewicz Z, Guz J, Dziaman T, Szpila A, Olinski R, Tudek B: Oxidative stress and 8-oxoguanine repair are enhanced in colon adenoma and carcinoma patients. Mutagenesis; 2010 Sep;25(5):463-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oxidative stress and 8-oxoguanine repair are enhanced in colon adenoma and carcinoma patients.
  • Oxidative stress is involved in the pathogenesis of colon cancer.
  • In the examined groups of patients with colorectal cancer (CRC, n = 89), benign adenoma (AD, n = 77) and healthy volunteers (controls, n = 99), we measured: vitamins A, C and E in blood plasma, 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxodG) and 8-oxo-7,8-dihydroguanine (8-oxoGua) in leukocytes and urine, leukocyte 8-oxoGua excision activity, mRNA levels of APE1, OGG1, 8-oxo-7,8-dihydrodeoxyguanosine 5'-triphosphate pyrophosphohydrolase (MTH1) and OGG1 polymorphism.
  • The vitamin levels decreased gradually in AD and CRC patients.
  • 8-OxodG increased in leukocytes and urine of CRC and AD patients.
  • 8-OxoGua excision was higher in CRC patients than in controls, in spite of higher frequency of the OGG1 Cys326Cys genotype, encoding a glycosylase with decreased activity. mRNA levels of OGG1 and APE1 increased in CRC and AD patients, which could explain increased 8-oxoGua excision rate in CRC patients.
  • The results suggest that oxidative stress occurs in CRC and AD individuals.
  • [MeSH-major] Adenoma / metabolism. Carcinoma / metabolism. Colonic Neoplasms / metabolism. DNA Repair / genetics. Deoxyguanosine / analogs & derivatives. Oxidative Stress / genetics
  • [MeSH-minor] Adenomatous Polyps / blood. Adenomatous Polyps / metabolism. Adult. Aged. Aging / genetics. Antioxidants / metabolism. Case-Control Studies. DNA Glycosylases / genetics. DNA Glycosylases / metabolism. DNA Repair Enzymes / genetics. DNA Repair Enzymes / metabolism. DNA, Neoplasm / metabolism. DNA-(Apurinic or Apyrimidinic Site) Lyase / genetics. DNA-(Apurinic or Apyrimidinic Site) Lyase / metabolism. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Middle Aged. Neoplasm Staging. Phosphoric Monoester Hydrolases / genetics. Phosphoric Monoester Hydrolases / metabolism. Polymorphism, Single Nucleotide / genetics. RNA, Messenger / genetics. RNA, Messenger / metabolism. Sex Characteristics. Smoking / adverse effects. Smoking / genetics

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20534734.001).
  • [ISSN] 1464-3804
  • [Journal-full-title] Mutagenesis
  • [ISO-abbreviation] Mutagenesis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antioxidants; 0 / DNA, Neoplasm; 0 / RNA, Messenger; 88847-89-6 / 8-oxo-7-hydrodeoxyguanosine; EC 3.1.3.- / Phosphoric Monoester Hydrolases; EC 3.1.6.- / 8-oxodGTPase; EC 3.2.2.- / DNA Glycosylases; EC 3.2.2.- / oxoguanine glycosylase 1, human; EC 4.2.99.18 / APEX1 protein, human; EC 4.2.99.18 / DNA-(Apurinic or Apyrimidinic Site) Lyase; EC 6.5.1.- / DNA Repair Enzymes; G9481N71RO / Deoxyguanosine
  •  go-up   go-down


45. Miyoshi N, Ohue M, Noura S, Yano M, Sasaki Y, Kishi K, Yamada T, Miyashiro I, Ohigashi H, Iishi H, Ishikawa O, Imaoka S: Surgical usefulness of indocyanine green as an alternative to India ink for endoscopic marking. Surg Endosc; 2009 Feb;23(2):347-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: India ink has been commonly used for preoperative colonic tattooing, but various complications have been reported.
  • [MeSH-major] Adenoma / surgery. Carcinoma / surgery. Colonoscopy. Colorectal Neoplasms / surgery. Coloring Agents. Indocyanine Green

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. INDOCYANINE GREEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Sci. 1961 Aug;21:43-57 [13689739.001]
  • [Cites] J Clin Gastroenterol. 2000 Oct;31(3):233-6 [11034004.001]
  • [Cites] Am J Surg Pathol. 1996 Oct;20(10):1266-70 [8827034.001]
  • [Cites] Arch Surg. 2005 Mar;140(3):285-8 [15781794.001]
  • [Cites] Am J Ophthalmol. 2006 Nov;142(5):765-70 [17056360.001]
  • [Cites] Gastrointest Endosc. 1991 Jan-Feb;37(1):56-8 [1706283.001]
  • [Cites] Gastrointest Endosc. 1975 Aug;22(1):42-3 [1205106.001]
  • [Cites] Surgery. 2001 Mar;129(3):335-40 [11231462.001]
  • [Cites] Endoscopy. 2006 Feb;38(2):190-2 [16479428.001]
  • [Cites] Surg Endosc. 2003 Mar;17(3):521 [12488998.001]
  • [Cites] Gastrointest Endosc. 2005 Jan;61(1):186-7 [15672088.001]
  • [Cites] Endoscopy. 2001 Aug;33(8):687-91 [11490385.001]
  • [Cites] Gastrointest Endosc. 1991 Jan-Feb;37(1):65-8 [1706285.001]
  • [Cites] Am J Surg. 2003 Jan;185(1):88-9 [12531454.001]
  • [Cites] Gastrointest Endosc. 2000 Apr;51(4 Pt 1):438-42 [10744816.001]
  • [Cites] Am Surg. 1993 Mar;59(3):205-10 [8476162.001]
  • [Cites] Endoscopy. 1999 Mar;31(3):271-3 [10344435.001]
  • [Cites] Gastrointest Endosc. 2003 May;57(6):735-7 [12709711.001]
  • [Cites] Ophthalmology. 1994 Mar;101(3):529-33 [8127574.001]
  • [Cites] Gastrointest Endosc. 1991 Jan-Feb;37(1):68-71 [1706286.001]
  • [Cites] Gastrointest Endosc. 2002 Sep;56(3):339-42 [12196769.001]
  • [Cites] Am Surg. 1989 Jul;55(7):457-61 [2472762.001]
  • [Cites] Dis Colon Rectum. 2003 Jul;46(7):987 [12847379.001]
  • [Cites] Surg Endosc. 1999 Apr;13(4):397-400 [10094755.001]
  • (PMID = 18443867.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Coloring Agents; IX6J1063HV / Indocyanine Green
  •  go-up   go-down


46. Ahlawat S, Al-Kawas FH: Invagination of the muscularis propria in a polyp stalk: a rare cause of post-polypectomy perforation of the colon. Endoscopy; 2007 Feb;39 Suppl 1:E78-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invagination of the muscularis propria in a polyp stalk: a rare cause of post-polypectomy perforation of the colon.
  • [MeSH-major] Adenoma, Villous / surgery. Colonic Diseases / etiology. Colonic Polyps / surgery. Colonoscopy. Intestinal Mucosa. Intestinal Perforation / etiology. Intussusception / complications. Postoperative Complications / etiology


47. Weng SW, Liu JW, Chen WJ, Wang PW: Recurrent Klebsiella pneumoniae liver abscess in a diabetic patient followed by Streptococcus bovis endocarditis--occult colon tumor plays an important role. Jpn J Infect Dis; 2005 Apr;58(2):70-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent Klebsiella pneumoniae liver abscess in a diabetic patient followed by Streptococcus bovis endocarditis--occult colon tumor plays an important role.
  • The patient later developed Streptococcus bovis bacteremia originating from a colon tumor with complications of endocarditis, osteomyelitis, and silent splenic abscess.
  • Occult colon tumor may have played an important role in our case, with recurrent infection arising from colonizers of the gastrointestinal tract.
  • As our case shows, the possible association between occult colon tumor and K. pneumoniae liver abscess in diabetic patients should be surveyed.
  • [MeSH-major] Colonic Neoplasms / complications. Endocarditis, Bacterial / microbiology. Klebsiella Infections / etiology. Liver Abscess / microbiology. Streptococcal Infections / etiology
  • [MeSH-minor] Adenoma, Villous / complications. Aged. Anti-Bacterial Agents / therapeutic use. Diabetes Mellitus, Type 2 / complications. Humans. Klebsiella pneumoniae / isolation & purification. Male. Streptococcus bovis / isolation & purification

  • Genetic Alliance. consumer health - Endocarditis.
  • Genetic Alliance. consumer health - Klebsiella.
  • MedlinePlus Health Information. consumer health - Streptococcal Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15858282.001).
  • [ISSN] 1344-6304
  • [Journal-full-title] Japanese journal of infectious diseases
  • [ISO-abbreviation] Jpn. J. Infect. Dis.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down


48. García Sánchez Mdel V, González R, Iglesias Flores E, Gómez Camacho F, Casais Juanena L, Cerezo Ruiz A, Montero Pérez-Barquero M, Muntané J, de Dios Vega JF: [Diagnostic value of fecal calprotectin in predicting an abnormal colonoscopy]. Med Clin (Barc); 2006 Jun 10;127(2):41-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Precisión diagnóstica de la calprotectina fecal para predecir una colonoscopia patológica.
  • The colonoscopy is the gold standard method of detecting an organic pathology in the colon.
  • Fecal calprotectin (FCP) is a marker that may detect organic pathologies of the colon.
  • People were divided in: normal colonoscopy: 117 people, and 28 colon adenomas, 20 colorectal cancer (CRC) and 25 IBD.
  • 217 mg/kg was the best cut-off for discriminating patients with organic colon disorders.
  • The measurement of FCP is a non-invasive, inexpensive, reliable and easily measured test.
  • [MeSH-major] Colonic Diseases / diagnosis. Colonic Neoplasms / diagnosis. Colonoscopy. Feces / chemistry. Inflammatory Bowel Diseases / diagnosis. Leukocyte L1 Antigen Complex / analysis

  • MedlinePlus Health Information. consumer health - Bowel Movement.
  • MedlinePlus Health Information. consumer health - Colonic Diseases.
  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16801001.001).
  • [ISSN] 0025-7753
  • [Journal-full-title] Medicina clínica
  • [ISO-abbreviation] Med Clin (Barc)
  • [Language] spa
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Leukocyte L1 Antigen Complex
  •  go-up   go-down


49. Togashi K, Shimura K, Konishi F, Miyakura Y, Koinuma K, Horie H, Yasuda Y: Prospective observation of small adenomas in patients after colorectal cancer surgery through magnification chromocolonoscopy. Dis Colon Rectum; 2008 Feb;51(2):196-201
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective observation of small adenomas in patients after colorectal cancer surgery through magnification chromocolonoscopy.
  • PURPOSE: This study was designed to confirm the safety of not removing small adenoma in patients who undergo colorectal cancer surgery.
  • Benign adenomas of 6 mm or less in size, diagnosed based on both nonmagnified and magnified observation, were left unresected with a maximum of three polyps per patient.
  • The sites of the polyps were marked by tattooing.
  • In follow-up, polyps were removed if they grew larger than 6 mm, were suspicious for high-grade dysplasia, or the patients requested to have polyps removal.
  • RESULTS: Five hundred polyps in 284 patients met the above criteria and were not resected, and 412 polyps were followed by repeat colonoscopy.
  • At the final colonoscopy, 71 percent of 412 polyps showed no change in size, 15 percent increased, 3 percent decreased, and 11 percent could not be identified.
  • Eighty-eight polyps were resected endoscopically, and histology showed neither cancer nor adenomas with high-grade dysplasia.
  • Two hundred fifty-five polyps detected in the same patient cohort during index/repeat colonoscopy were removed, including four adenomas with high-grade dysplasia and two T1 cancers.
  • CONCLUSIONS: Leaving small polyps is safe even in patients who have undergone colorectal cancer surgery, provided that careful observation is guaranteed.
  • [MeSH-major] Adenoma / diagnosis. Colonic Polyps / surgery. Colonoscopy / methods. Digestive System Surgical Procedures / methods. Neoplasms, Second Primary / diagnosis. Postoperative Care / methods


50. Yuan B, Jin X, Zhu R, Zhang X, Liu J, Wan H, Lu H, Shen Y, Wang F: Cronkhite-Canada syndrome associated with rib fractures: a case report. BMC Gastroenterol; 2010;10:121
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Esophagogastroduodenoscopy, video capsule endoscopy and colonoscopy revealed various sizes of generalized gastrointestinal polyps.
  • Histological examination of the biopsy specimens obtained from the stomach and the colon showed adenomatous polyp and inflammatory polyp respectively.

  • MedlinePlus Health Information. consumer health - Chest Injuries and Disorders.
  • MedlinePlus Health Information. consumer health - Osteoporosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastrointest Endosc. 2001 Sep;54(3):388-91 [11522989.001]
  • [Cites] Aliment Pharmacol Ther. 2002 Mar;16(3):333-42 [11876685.001]
  • [Cites] Expert Opin Pharmacother. 2003 Mar;4(3):385-9 [12614190.001]
  • [Cites] Am J Gastroenterol. 2003 Jun;98(6):1444-6 [12818298.001]
  • [Cites] Gastrointest Endosc. 2008 Mar;67(3):570-2 [18294523.001]
  • [Cites] Medicine (Baltimore). 1982 Sep;61(5):293-309 [7109958.001]
  • [Cites] Gastrointest Endosc. 1997 Dec;46(6):537-41 [9434222.001]
  • [Cites] N Engl J Med. 1955 Jun 16;252(24):1011-5 [14383952.001]
  • [Cites] Digestion. 2007;75(2-3):96-7 [17510553.001]
  • [Cites] Digestion. 2004;69(1):57-62 [14755154.001]
  • (PMID = 20955587.001).
  • [ISSN] 1471-230X
  • [Journal-full-title] BMC gastroenterology
  • [ISO-abbreviation] BMC Gastroenterol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2972238
  •  go-up   go-down


51. Lefevre JH, Colas C, Coulet F, Bonilla C, Mourra N, Flejou JF, Tiret E, Bodmer W, Soubrier F, Parc Y: MYH biallelic mutation can inactivate the two genetic pathways of colorectal cancer by APC or MLH1 transversions. Fam Cancer; 2010 Dec;9(4):589-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MYH associated polyposis is a hereditary syndrome responsible for early colorectal cancer with a distinct genetic pathway from the Familial Adenomatous Polyposis or the Hereditary Non Polyposis Colorectal Cancer syndrome.
  • One patient who developed colon cancer had loss of expression of MLH1 on tumoral tissue and microsatellite instability (MSI) phenotype.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / genetics. Adenoma / genetics. Adenomatous Polyposis Coli / genetics. Colorectal Neoplasms / genetics. DNA Glycosylases / genetics. Genes, APC. Mutation / genetics. Nuclear Proteins / genetics

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Hum Genet. 2003 Jan;72(1):88-100 [12474140.001]
  • [Cites] Cancer Res. 2003 Nov 15;63(22):7595-9 [14633673.001]
  • [Cites] Nat Genet. 2002 Feb;30(2):227-32 [11818965.001]
  • [Cites] Nat Genet. 1994 Dec;8(4):405-10 [7894494.001]
  • [Cites] Cancer Res. 1998 Aug 1;58(15):3455-60 [9699680.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10 (1 Pt 1):191-5 [14734469.001]
  • [Cites] Int J Cancer. 2006 Mar 15;118(6):1465-70 [16206289.001]
  • [Cites] Genet Test. 2005 Summer;9(2):138-46 [15943554.001]
  • [Cites] Cancer Res. 1997 Mar 1;57(5):808-11 [9041175.001]
  • [Cites] Hum Genet. 2006 Mar;119(1-2):9-22 [16341550.001]
  • [Cites] Ann Surg. 2006 Dec;244(6):874-9; discussion 879-80 [17122612.001]
  • [Cites] Curr Biol. 2002 Jun 4;12(11):912-8 [12062055.001]
  • [Cites] J Clin Pathol. 2001 Jun;54(6):484-7 [11376026.001]
  • [Cites] Gut. 2004 Mar;53(3):371-5 [14960518.001]
  • [Cites] Mutat Res. 2003 Oct 29;531(1-2):231-51 [14637258.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):659-64 [16423994.001]
  • [Cites] Oncogene. 2007 Apr 12;26(17):2513-7 [17043646.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jun 9;95(12 ):6870-5 [9618505.001]
  • [Cites] J Biol Chem. 2002 Mar 29;277(13):11135-42 [11801590.001]
  • [Cites] J Med Genet. 2004 Sep;41(9):664-8 [15342696.001]
  • [Cites] Br J Cancer. 2006 Nov 6;95(9):1239-43 [17031395.001]
  • (PMID = 20640893.001).
  • [ISSN] 1573-7292
  • [Journal-full-title] Familial cancer
  • [ISO-abbreviation] Fam. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / DNA, Neoplasm; 0 / MLH1 protein, human; 0 / Nuclear Proteins; EC 3.2.2.- / DNA Glycosylases; EC 3.2.2.- / mutY adenine glycosylase; EC 3.6.1.3 / MutL Protein Homolog 1
  •  go-up   go-down


52. Javeri K, Williams TR, Bonnett JW: An overview of the method, application, and various findings of computed tomographic colonography in patients after incomplete colonoscopy. Curr Probl Diagn Radiol; 2010 Nov-Dec;39(6):262-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Colon cancer is the third most common malignancy in the USA with 154,000 new cases and 52,000 deaths in 2007.
  • Routine CT colonography imaging of the insufflated colon was performed in both the supine and the prone positions with oral contrast.
  • Each patient was classified into groups based on the quality/adequacy of the examination, presence, number, and size of polyps.
  • [MeSH-major] Colonic Neoplasms / radiography. Colonography, Computed Tomographic. Colonoscopy
  • [MeSH-minor] Adenocarcinoma / radiography. Adenoma / radiography. Colitis / radiography. Colonic Polyps / pathology. Colonic Polyps / surgery. Humans. Hyperplasia. Image Processing, Computer-Assisted. Lipoma / radiography. Patient Acceptance of Health Care

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Mosby, Inc. All rights reserved.
  • (PMID = 20875613.001).
  • [ISSN] 1535-6302
  • [Journal-full-title] Current problems in diagnostic radiology
  • [ISO-abbreviation] Curr Probl Diagn Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


53. He JJ: [Meta analysis of 2025 cases with multiple primary colorectal carcinoma]. Zhonghua Wei Chang Wai Ke Za Zhi; 2006 May;9(3):225-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 30.9% of the lesions were located in the rectum, 19.9% in the sigmoid, 9.0% in the descending colon, 5.2% the in splenic flexure, 9.1% in the transverse colon, 6.1% in the hepatic flexure, 11.8% in the ascending colon,and 8.1% in the caecum.
  • 37.6% of the cases were complicated with extra- intestinal lesions,and 43.7% adenoma or polyps.
  • Histological type was the same in 60.6% of the cases,and adenocarcinoma accounted for 89.2% and cancerization of adenoma 8.4%.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16721683.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Meta-Analysis
  • [Publication-country] China
  •  go-up   go-down


54. Chakravarti B, Dwivedi SK, Mithal A, Chattopadhyay N: Calcium-sensing receptor in cancer: good cop or bad cop? Endocrine; 2009 Jun;35(3):271-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One situation is loss of CaR expression, resulting in loss of growth suppressing effects of elevated extracellular Ca(2+) by CaR, reported in parathyroid adenoma and in colon carcinoma.
  • CaR signaling and effects have been studied in several cancers including ovarian cancers, gastrinomas, and gliomas in addition to comparatively detailed studies in breast, prostate, and colon cancers.
  • Pharmacological agonists and antagonists of CaR hold therapeutic promise depending on whether activation of CaR is required such as in case of colon cancer or inactivating the receptor is required as in the case of breast- and prostate tumors.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem J. 2003 Jun 15;372(Pt 3):787-97 [12628005.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Sep 16;94(19):10330-4 [9294210.001]
  • [Cites] Am J Obstet Gynecol. 1998 Feb;178(2):305-13 [9500491.001]
  • [Cites] J Clin Invest. 2004 Feb;113(4):598-608 [14966569.001]
  • [Cites] N Engl J Med. 1985 Feb 21;312(8):474-83 [3881673.001]
  • [Cites] J Biol Chem. 2000 Mar 17;275(11):7553-7 [10713061.001]
  • [Cites] Br J Cancer. 2004 Mar 22;90(6):1293-4; author reply 1295 [15026815.001]
  • [Cites] Cancer. 2003 Feb 1;97(3 Suppl):779-84 [12548575.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2001 Dec;281(6):E1267-74 [11701443.001]
  • [Cites] Cancer. 1997 Oct 15;80(8 Suppl):1588-94 [9362426.001]
  • [Cites] Brain Pathol. 1993 Jul;3(3):255-68 [8293185.001]
  • [Cites] Cancer Res. 1993 Apr 15;53(8):1724-6 [8467485.001]
  • [Cites] Endocrinology. 2003 Dec;144(12):5188-93 [12970167.001]
  • [Cites] Hum Pathol. 1996 Dec;27(12):1319-23 [8958305.001]
  • [Cites] Endocr Rev. 1996 Dec;17(6):698-714 [8969974.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Sep;88(9):4455-64 [12970324.001]
  • [Cites] Cancer Res. 2003 Jan 1;63(1):67-71 [12517779.001]
  • [Cites] Bone. 2004 Sep;35(3):664-72 [15336602.001]
  • [Cites] Breast. 2004 Dec;13 Suppl 1:S19-28 [15585379.001]
  • [Cites] Acta Neuropathol. 1986;70(1):17-21 [3727931.001]
  • [Cites] Neurol Med Chir (Tokyo). 1995 Sep;35(9):631-8 [7566395.001]
  • [Cites] Metabolism. 1984 Jan;33(1):50-3 [6690886.001]
  • [Cites] Am J Pathol. 1999 Dec;155(6):2057-66 [10595935.001]
  • [Cites] Rev Endocr Metab Disord. 2000 Nov;1(4):253-63 [11706739.001]
  • [Cites] Science. 1997 Mar 21;275(5307):1784-7 [9065401.001]
  • [Cites] AJR Am J Roentgenol. 1990 Sep;155(3):587-93 [2167004.001]
  • [Cites] Cancer Metastasis Rev. 1998 Mar;17(1):107-18 [9544426.001]
  • [Cites] Nat Med. 2002 Jan;8(1):35-40 [11786904.001]
  • [Cites] Arq Bras Endocrinol Metabol. 2006 Aug;50(4):685-93 [17117294.001]
  • [Cites] Curr Osteoporos Rep. 2007 Sep;5(3):120-7 [17925193.001]
  • [Cites] Oncogene. 2006 Dec 4;25(57):7531-7 [17143297.001]
  • [Cites] Int J Oncol. 2003 Apr;22(4):779-86 [12632068.001]
  • [Cites] Cell Calcium. 2004 Mar;35(3):217-28 [15200145.001]
  • [Cites] N Engl J Med. 1997 Nov 20;337(21):1506-10 [9366582.001]
  • [Cites] Br J Cancer. 1999 Oct;81(3):496-502 [10507776.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Dec;85(12):4789-94 [11134144.001]
  • [Cites] J Bone Miner Res. 2001 Nov;16(11):2092-102 [11697806.001]
  • [Cites] Carcinogenesis. 2000 Jun;21(6):1149-55 [10837003.001]
  • [Cites] Tidsskr Nor Laegeforen. 1992 Aug 10;112(18):2346-8 [1329263.001]
  • [Cites] J Biol Chem. 2001 Sep 14;276(37):34871-9 [11390379.001]
  • [Cites] Cell Biochem Biophys. 2000;33(1):63-95 [11322513.001]
  • [Cites] Oncol Rep. 1998 Nov-Dec;5(6):1389-94 [9769374.001]
  • [Cites] J Cell Biol. 2002 Jul 22;158(2):221-6 [12119356.001]
  • [Cites] Exp Cell Res. 2005 Aug 15;308(2):439-45 [15950968.001]
  • [Cites] J Bone Miner Res. 2002 Nov;17 Suppl 2:N141-5 [12412791.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2005 Apr;10(2):169-80 [16025223.001]
  • [Cites] J Urol. 1996 Nov;156(5):1691-5 [8863572.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2003 Feb;284(2):E435-42 [12388158.001]
  • [Cites] Curr Opin Nephrol Hypertens. 1996 Jul;5(4):307-15 [8823527.001]
  • [Cites] J Biol Chem. 1998 Jan 9;273(2):1114-20 [9422777.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Mar;45(3):220-30 [16281261.001]
  • [Cites] Cancer Res. 1998 Mar 15;58(6):1130-4 [9515795.001]
  • [Cites] Ann N Y Acad Sci. 1999;889:120-7 [10668488.001]
  • [Cites] J Neuropathol Exp Neurol. 1997 Mar;56(3):243-54 [9056538.001]
  • [Cites] Hum Pathol. 1982 May;13(5):454-8 [6281168.001]
  • [Cites] Int J Oncol. 2004 May;24(5):1111-9 [15067332.001]
  • [Cites] Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6213s-6216s [17062703.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Nov 2;264(3):615-8 [10543980.001]
  • [Cites] Prostate. 1997 May 15;31(3):168-74 [9167768.001]
  • [Cites] Endocr Pathol. 2003 Spring;14(1):61-70 [12746564.001]
  • [Cites] J Physiol. 1998 Dec 1;513 ( Pt 2):411-24 [9806992.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Jul;85(13):4857-60 [3387442.001]
  • [Cites] J Lab Clin Med. 1994 Apr;123(4):547-55 [8145003.001]
  • [Cites] Oncogene. 2005 Mar 24;24(13):2144-54 [15735754.001]
  • [Cites] Semin Oncol. 1998 Jun;25(3):281-304 [9633841.001]
  • [Cites] Endocrinology. 2002 Feb;143(2):596-606 [11796515.001]
  • [Cites] J Musculoskelet Neuronal Interact. 2004 Sep;4(3):308-18 [15615499.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Apr;88(4):1603-9 [12679445.001]
  • [Cites] J Comp Neurol. 1986 May 15;247(3):275-96 [3522658.001]
  • [Cites] Nature. 1999 Dec 23-30;402(6764):884-8 [10622253.001]
  • [Cites] Eur J Oncol Nurs. 2007;11 Suppl 2:S32-7 [17804294.001]
  • [Cites] Lancet Oncol. 2001 Mar;2(3):149-56 [11902565.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 14;101(37):13566-71 [15347804.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3812-8 [12097294.001]
  • [Cites] In Vitro Cell Dev Biol. 1989 Jul;25(7):643-9 [2753852.001]
  • [Cites] Glia. 1996 May;17(1):39-51 [8723841.001]
  • [Cites] J Cell Biol. 2004 Mar 1;164(5):769-79 [14993236.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Apr;81(4):1312-7 [8636323.001]
  • [Cites] Am J Physiol Renal Physiol. 2001 Feb;280(2):F291-302 [11208605.001]
  • [Cites] Annu Rev Cell Dev Biol. 2004;20:781-810 [15473860.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2006 May;290(5):E761-70 [16603723.001]
  • [Cites] Ther Apher Dial. 2005 Aug;9 Suppl 1:S27-34 [16109139.001]
  • [Cites] Am J Hum Genet. 1998 Dec;63(6):1588-93 [9837810.001]
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5031-6 [11016624.001]
  • [Cites] Glia. 1999 Mar;26(1):64-72 [10088673.001]
  • [Cites] Gan To Kagaku Ryoho. 2007 Jan;34(1):1-10 [17220661.001]
  • [Cites] Gastroenterology. 2004 Jan;126(1):148-58 [14699496.001]
  • [Cites] Int J Clin Oncol. 2008 Feb;13(1):18-23 [18307015.001]
  • [Cites] J Cell Biochem. 1991 Jul;46(3):250-4 [1774225.001]
  • [Cites] J Biol Chem. 2004 Aug 27;279(35):36865-75 [15215241.001]
  • [Cites] Semin Oncol. 1991 Jun;18(3):177-85 [2042059.001]
  • [Cites] Lab Invest. 1994 Oct;71(4):510-8 [7967506.001]
  • [Cites] Science. 1986 Oct 10;234(4773):161-6 [3018928.001]
  • [Cites] Hum Mutat. 2000 Oct;16(4):281-96 [11013439.001]
  • [Cites] Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6258s-6263s [17062710.001]
  • [Cites] J Bone Miner Res. 2005 Feb;20(2):318-29 [15647826.001]
  • [Cites] Mol Genet Metab. 1999 Oct;68(2):328-31 [10527684.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Apr;81(4):1598-606 [8636374.001]
  • [Cites] Oncogene. 2004 Jan 29;23(4):991-9 [14647423.001]
  • [Cites] J Biol Chem. 1991 Aug 25;266(24):15771-81 [1874734.001]
  • [Cites] Nat Genet. 1995 Dec;11(4):389-94 [7493018.001]
  • [Cites] Cancer Metastasis Rev. 1989 Aug;8(2):98-101 [2673568.001]
  • [Cites] N Engl J Med. 1986 Apr 24;314(17):1094-101 [2870434.001]
  • [Cites] Curr Opin Cell Biol. 1999 Apr;11(2):177-83 [10209148.001]
  • [Cites] J Clin Endocrinol Metab. 1983 Mar;56(3):572-81 [6822654.001]
  • [Cites] Endocrinology. 1991 Jun;128(6):2999-3004 [2036974.001]
  • [Cites] Am J Physiol Cell Physiol. 2000 Sep;279(3):C691-9 [10942719.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Feb;86(2):867-74 [11158059.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Dec 13;299(4):532-8 [12459170.001]
  • [Cites] J Endocrinol. 1989 Jul;122(1):219-27 [2788697.001]
  • [Cites] EMBO J. 2006 Jul 12;25(13):2978-88 [16763551.001]
  • [Cites] Cancer Res. 2006 Sep 15;66(18):9065-73 [16982748.001]
  • [Cites] Clin Calcium. 2008 Jan;18(1):32-6 [18175869.001]
  • [Cites] Cytometry. 1996 May 1;24(1):64-73 [8723904.001]
  • [Cites] Cancer Res. 1980 Nov;40(11):3982-7 [6162540.001]
  • [Cites] J Comput Assist Tomogr. 1992 Nov-Dec;16(6):856-9 [1385498.001]
  • [Cites] Cancer Res. 2004 Apr 1;64(7):2482-9 [15059902.001]
  • [Cites] Cell. 1996 Oct 18;87(2):159-70 [8861899.001]
  • [Cites] J Neurosci Res. 1997 Apr 15;48(2):122-7 [9130140.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2003 Aug;285(2):E329-37 [12700162.001]
  • [Cites] Biochem Soc Trans. 2003 Dec;31(Pt 6):1203-8 [14641026.001]
  • [Cites] Eur J Endocrinol. 2003 Apr;148(4):403-11 [12656660.001]
  • [Cites] Growth Factors. 2005 Jun;23(2):117-23 [16019433.001]
  • [Cites] Prostate. 2001 May 15;47(3):212-21 [11351351.001]
  • [Cites] Biochem J. 2000 Dec 1;352 Pt 2:353-61 [11085928.001]
  • [Cites] Int J Cancer. 2007 Oct 1;121(7):1455-62 [17557293.001]
  • [Cites] Am J Respir Cell Mol Biol. 1994 Dec;11(6):701-6 [7946399.001]
  • [Cites] Diabetes. 2000 Mar;49(3):409-17 [10868962.001]
  • [Cites] J Biol Chem. 1995 May 26;270(21):12919-25 [7759551.001]
  • [Cites] J Bone Miner Res. 1999 Jun;14(6):878-82 [10352095.001]
  • [Cites] Endocrinology. 1986 Nov;119(5):2284-9 [3464413.001]
  • [Cites] Endocrinology. 2000 May;141(5):1882-92 [10803599.001]
  • [Cites] J Biol Chem. 1998 Aug 14;273(33):21267-75 [9694886.001]
  • [Cites] Biochem J. 1986 Sep 15;238(3):905-12 [2432886.001]
  • [Cites] Acta Diabetol Lat. 1979 Jan-Mar;16(1):9-18 [377879.001]
  • [Cites] Cancer Treat Rev. 2003 Jun;29(3):189-98 [12787713.001]
  • [Cites] News Physiol Sci. 2002 Apr;17:62-7 [11909994.001]
  • [Cites] J Histochem Cytochem. 2000 May;48(5):595-602 [10769043.001]
  • [Cites] Clin Endocrinol (Oxf). 2000 Mar;52(3):339-48 [10718832.001]
  • [Cites] Physiol Rev. 2002 Jan;82(1):245-89 [11773614.001]
  • [Cites] J Biol Chem. 2002 Jul 5;277(27):24571-8 [11964407.001]
  • [Cites] Endocrinology. 2005 Apr;146(4):1727-36 [15637291.001]
  • [Cites] Cancer Res. 2002 Jan 15;62(2):409-16 [11809689.001]
  • [Cites] Cancer Cell. 2002 Apr;1(3):279-88 [12086864.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Oct;82(10):3481-6 [9329389.001]
  • [Cites] J Cell Biochem. 2004 Mar 1;91(4):718-29 [14991763.001]
  • [Cites] Eur J Endocrinol. 2000 May;142(5):500-5 [10802529.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2005 Jun;288(6):E1206-13 [15657090.001]
  • [Cites] Histol Histopathol. 2003 Jan;18(1):245-51 [12507303.001]
  • [Cites] Annu Rev Cell Dev Biol. 2004;20:695-723 [15473857.001]
  • [Cites] Oncologist. 2007 Sep;12(9):1035-43 [17914073.001]
  • [Cites] J Cell Biol. 2003 Sep 1;162(5):899-908 [12952940.001]
  • [Cites] Curr Opin Genet Dev. 2007 Feb;17(1):40-4 [17188489.001]
  • [Cites] Brain Res. 1999 Dec 18;851(1-2):116-24 [10642834.001]
  • [Cites] J Clin Endocrinol Metab. 1977 Jul;45(1):105-13 [874057.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jul 23;320(2):455-60 [15219850.001]
  • [Cites] Bone. 2004 Aug;35(2):479-88 [15268900.001]
  • [Cites] CA Cancer J Clin. 1997 Jan-Feb;47(1):5-27 [8996076.001]
  • [Cites] Acta Neurochir (Wien). 1994;127(1-2):48-54 [7942181.001]
  • [Cites] Physiol Rev. 2001 Jan;81(1):239-297 [11152759.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10439-48 [17079465.001]
  • [Cites] Breast Cancer. 1999 Oct 25;6(4):292-297 [11091732.001]
  • [Cites] Eur J Surg Oncol. 2006 Jun;32(5):511-5 [16564154.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2007 Jul;293(1):G403-11 [17463182.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Feb;83(2):703-7 [9467597.001]
  • [Cites] J Biol Chem. 1999 Apr 9;274(15):10173-83 [10187801.001]
  • [Cites] Clin Breast Cancer. 2005 Feb;5 Suppl(2):S46-53 [15807924.001]
  • [Cites] Support Care Cancer. 2007 Nov;15(11):1243-9 [17393190.001]
  • [Cites] J Biol Chem. 1997 Jan 31;272(5):2620-8 [9006895.001]
  • [Cites] Exp Cell Res. 2000 Jul 10;258(1):1-11 [10912782.001]
  • [Cites] Endocrinology. 1999 Jun;140(6):2908-16 [10342884.001]
  • [Cites] Front Biosci. 2003 May 01;8:s377-90 [12700051.001]
  • [Cites] Mol Endocrinol. 1997 Apr;11(4):433-41 [9092795.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Mar 16;269(2):427-32 [10708570.001]
  • [Cites] Oncogene. 2002 Nov 7;21(51):7839-49 [12420221.001]
  • [Cites] Cancer Res. 2000 Mar 15;60(6):1753-60 [10749150.001]
  • [Cites] J Bone Miner Res. 1989 Dec;4(6):839-44 [2610020.001]
  • [Cites] J Clin Invest. 1997 Jan 1;99(1):88-96 [9011580.001]
  • [Cites] Endocrinology. 2000 Dec;141(12):4357-64 [11108243.001]
  • [Cites] Annu Rev Nutr. 1999;19:545-86 [10448536.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Mar 6;232(1):80-3 [9125156.001]
  • [Cites] Neuroepidemiology. 1990;9(1):2-16 [2330068.001]
  • [Cites] Endocrinology. 1995 Dec;136(12):5416-22 [7588290.001]
  • [Cites] J Natl Med Assoc. 2007 Jan;99(1):35-45 [17304967.001]
  • [Cites] Endocrinology. 2004 Mar;145(3):1211-7 [14645111.001]
  • [Cites] Nihon Rinsho. 1998 Jun;56(6):1419-24 [9648458.001]
  • [Cites] Br J Urol. 1996 Jan;77(1):102-6 [8653278.001]
  • [Cites] In Vitro. 1984 Aug;20(8):652-62 [6500605.001]
  • [Cites] Endocrinology. 1993 Apr;132(4):1658-64 [8462465.001]
  • [Cites] Virchows Arch. 2001 Dec;439(6):725-51 [11787845.001]
  • [Cites] J Bone Miner Res. 2002 Jul;17(7):1164-70 [12096830.001]
  • [Cites] Biochem Biophys Res Commun. 1975 Nov 17;67(2):525-9 [812497.001]
  • [Cites] Subcell Biochem. 2007;45:405-27 [18193646.001]
  • [Cites] Ann Oncol. 2007 Jun;18 Suppl 6:vi164-7 [17591815.001]
  • [Cites] J Steroid Biochem Mol Biol. 2004 May;89-90(1-5):355-60 [15225800.001]
  • [Cites] J Biol Chem. 2001 Sep 14;276(37):34880-7 [11390380.001]
  • [Cites] Hosp Pract (Off Ed). 1992 Nov 15;27(11):51-8 [1331139.001]
  • [Cites] J Cell Physiol. 2007 Dec;213(3):589-602 [17786953.001]
  • [Cites] Cell Calcium. 2004 Mar;35(3):229-37 [15200146.001]
  • [Cites] J Bone Miner Res. 2003 Dec;18(12):2200-5 [14672355.001]
  • (PMID = 19011996.001).
  • [ISSN] 1355-008X
  • [Journal-full-title] Endocrine
  • [ISO-abbreviation] Endocrine
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Calcium-Sensing
  • [Number-of-references] 203
  •  go-up   go-down


55. Dundar M, Caglayan AO, Saatci C, Karaca H, Baskol M, Tahiri S, Ozkul Y: How the I1307K adenomatous polyposis coli gene variant contributes in the assessment of risk of colorectal cancer, but not stomach cancer, in a Turkish population. Cancer Genet Cytogenet; 2007 Sep;177(2):95-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] How the I1307K adenomatous polyposis coli gene variant contributes in the assessment of risk of colorectal cancer, but not stomach cancer, in a Turkish population.
  • Germline and somatic truncating mutations of the adenomatous polyposis coli gene (APC) are thought to initiate colorectal tumor formation in familial adenomatous polyposis syndrome and sporadic colorectal carcinogenesis, respectively.
  • Genomic DNA was extracted from patients by obtaining all stomach and colon malign polipose tissues using nuclei lysis methods.
  • The APC I1307K allele was identified in 7 of 57 stomach carcinoma patients (12.3%; P > 0.05) and 30 of 56 colon carcinoma patients (53.6%; P < 0.05) using antigen-anticor interaction methods.
  • Furthermore, APC I1307K carriers had greater numbers of adenomas and colorectal cancers per patient than noncarriers.
  • The conclusion is that the APC I1307K variant leads to increased adenoma formation and colorectal cancer.
  • The estimated relative risk for carriers may justify specific clinical screening for Turkish people expected to harbor this allele, and genetic testing in the long term may significantly promote colorectal cancer prevention in this population.
  • [MeSH-major] Adenomatous Polyposis Coli Protein / genetics. Colorectal Neoplasms / genetics. Genes, APC. Stomach Neoplasms / genetics


56. Pisello F, Geraci G, Arnone E, Modica G, Stassi F, Sciumè C: [Endoscopic surveillance of colon-rectum in the narrow band imaging era]. G Chir; 2009 Oct;30(10):440-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Endoscopic surveillance of colon-rectum in the narrow band imaging era].
  • [Transliterated title] Sorveglianza endoscopica del colon-retto. Ruolo del Narrow Band Imaging (NBI).
  • BACKGROUND AND AIMS: Colonoscopic surveillance is an established method of colorectal cancer (CRC) screening that reduces death rates, but has an adenoma miss rate of 10-20%.
  • Narrow band imaging (NBI), a novel endoscopic technology, highlights superficial mucosal capillaries and improves contrast for small adenomas.
  • This study evaluated the role of NBI in the improving colon adenoma detection.
  • PATIENTS AND METHODS: White light colonoscope was compared with NBI for adenoma detection during colonoscopy.
  • The outcome parameter was the difference in the adenoma detection rate between the two techniques.
  • All polyps detected were removed for histopathological analysis.
  • RESULTS: Adenomas were detected more frequently in the NBI group (51) than in the control group (49); however, the difference was not statistically significant (p = 0.128).
  • CONCLUSIONS: In our experience, the NBI did not increased the adenomas detection rate compared to white light by an endoscopist with a known high detection rate using white light.
  • [MeSH-major] Adenoma / diagnosis. Colonoscopy / methods. Colorectal Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19954587.001).
  • [ISSN] 0391-9005
  • [Journal-full-title] Il Giornale di chirurgia
  • [ISO-abbreviation] G Chir
  • [Language] ita
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] Italy
  •  go-up   go-down


57. Ravizza D, Fiori G, Trovato C, Maisonneuve P, Bocciolone L, Crosta C: Is colonoscopy a suitable investigation in the preoperative staging of ovarian cancer patients? Dig Liver Dis; 2005 Jan;37(1):57-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS: The aim of this study was to evaluate the utility of preoperative colonoscopy in ovarian cancer patients and the prevalence of adenomas in this population.
  • All the polyps observed were removed.
  • Thirty-six adenomas were removed in 26 (20%) women.
  • An increased prevalence of adenomas was not observed in this population.
  • [MeSH-major] Colonic Neoplasms / secondary. Colonoscopy. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adenoma / pathology. Adenoma / surgery. Adult. Aged. Aged, 80 and over. Colon / pathology. Female. Humans. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Retrospective Studies. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15702861.001).
  • [ISSN] 1590-8658
  • [Journal-full-title] Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • [ISO-abbreviation] Dig Liver Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


58. Micheletto G, Sciannamea I, Zanoni A, Panizzo V, Rubino B, Danelli P: [Intestinal neuroendocrine tumor. Case report and review of the literature]. Ann Ital Chir; 2009 Jul-Aug;80(4):319-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Symptoms are non specific; the most common are abdominal pain, nausea and vomiting, weight loss and gastrointestinal (GI) blood loss.
  • Here we report a case of a 73-year-old male with an adenomatous colonic polyp, not suitable of endoscopic treatment, and a synchronous carcinoid of small intestine discovered during surgical procedure.
  • [MeSH-major] Adenoma. Carcinoid Tumor. Colonic Polyps. Ileal Neoplasms. Neoplasms, Multiple Primary. Sigmoid Neoplasms


59. Hurst NG, Stocken DD, Wilson S, Keh C, Wakelam MJ, Ismail T: Elevated serum matrix metalloproteinase 9 (MMP-9) concentration predicts the presence of colorectal neoplasia in symptomatic patients. Br J Cancer; 2007 Oct 8;97(7):971-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Early detection of polyps or colorectal carcinoma can reduce colorectal carcinoma-associated deaths.
  • A total of 27 significant adenomas and 63 malignancies were identified.
  • [MeSH-major] Adenoma / diagnosis. Biomarkers, Tumor / blood. Colorectal Neoplasms / diagnosis. Matrix Metalloproteinase 9 / blood

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2004 Dec 23;351(26):2704-14 [15616205.001]
  • [Cites] Cancer Chemother Pharmacol. 1999;43 Suppl:S56-60 [10357560.001]
  • [Cites] BMJ. 2004 Oct 9;329(7470):849-51 [15472270.001]
  • [Cites] J Thorac Cardiovasc Surg. 1973 Aug;66(2):320-8 [4352772.001]
  • [Cites] Cancer. 1975 Dec;36(6):2251-70 [1203876.001]
  • [Cites] Cancer. 1978 Sep;42(3 Suppl):1484-91 [709519.001]
  • [Cites] Arch Surg. 1979 May;114(5):563-7 [444049.001]
  • [Cites] Dtsch Med Wochenschr. 1983 Apr 22;108(16):610-4 [6839982.001]
  • [Cites] Dis Colon Rectum. 1984 Dec;27(12):803-10 [6499620.001]
  • [Cites] Semin Oncol. 1987 Jun;14(2):102-38 [2438773.001]
  • [Cites] Gastroenterology. 1987 Nov;93(5):1009-13 [3653628.001]
  • [Cites] Nature. 1990 Dec 20-27;348(6303):699-704 [1701851.001]
  • [Cites] J Cancer Res Clin Oncol. 1991;117(2):144-50 [1848860.001]
  • [Cites] Int J Cancer. 1991 Nov 11;49(5):666-72 [1657796.001]
  • [Cites] Am J Surg Pathol. 1992 May;16(5):500-7 [1318001.001]
  • [Cites] Ann N Y Acad Sci. 1999 Jun 30;878:413-9 [10415745.001]
  • [Cites] BMC Cancer. 2006;6:251 [17059590.001]
  • [Cites] BMC Cancer. 2006;6:258 [17076885.001]
  • [Cites] Am J Pathol. 1992 Aug;141(2):389-96 [1323219.001]
  • [Cites] Int J Biol Markers. 1992 Jul-Sep;7(3):160-6 [1431339.001]
  • [Cites] Crit Rev Oral Biol Med. 1993;4(2):197-250 [8435466.001]
  • [Cites] Cancer Res. 1995 Aug 1;55(15):3263-6 [7614460.001]
  • [Cites] Int J Cancer. 1995 Aug 9;62(4):407-13 [7635566.001]
  • [Cites] Surg Oncol. 1995;4(2):111-9 [7551259.001]
  • [Cites] J Pathol. 1997 Jul;182(3):347-55 [9349239.001]
  • [Cites] BMJ. 1998 Aug 29;317(7158):559-65 [9721111.001]
  • [Cites] Br J Cancer. 1998 Dec;78(11):1495-502 [9836483.001]
  • [Cites] J Biol Chem. 1999 Mar 26;274(13):8925-32 [10085137.001]
  • [Cites] Carcinogenesis. 1999 May;20(5):749-55 [10334190.001]
  • [Cites] Cancer Chemother Pharmacol. 1999;43 Suppl:S42-51 [10357558.001]
  • [CommentIn] Br J Cancer. 2008 May 6;98(9):1593; author reply 1594 [18414416.001]
  • [CommentIn] Br J Cancer. 2008 Aug 5;99(3):553-4; author reply 555 [18648367.001]
  • (PMID = 17912241.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.24.35 / Matrix Metalloproteinase 9
  • [Other-IDs] NLM/ PMC2360395
  •  go-up   go-down


60. Armah HB, Krasinskas AM, Parwani AV: Tubular adenoma with high-grade dysplasia in the ileal segment 34 years after augmentation ileocystoplasty: report of a first case. Diagn Pathol; 2007;2:29
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tubular adenoma with high-grade dysplasia in the ileal segment 34 years after augmentation ileocystoplasty: report of a first case.
  • We present the case of a 39-year-old male with a tubular adenoma with high-grade dysplasia in the ileal segment 34 years after augmentation ileocystoplasty to enlarge a post-chemoradiation-induced shrunken bladder.
  • Histologic examination revealed a tubular adenoma with high-grade dysplasia.
  • There are only two previous reports of tubulovillous adenoma in ileal segment after ileocystoplasty, both without high-grade dysplasia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 2002 Jan;167(1):84-8 [11743281.001]
  • [Cites] BJU Int. 2001 Aug;88(3):187-91 [11488727.001]
  • [Cites] Scand J Urol Nephrol. 2003;37(3):202-4 [12775277.001]
  • [Cites] Int J Urol. 2003 Sep;10(9):495-7 [12941129.001]
  • [Cites] J Clin Pathol. 1992 Oct;45(10):928-9 [1430267.001]
  • [Cites] World J Urol. 2004 Sep;22(3):227-34 [15316739.001]
  • [Cites] J Urol. 1992 Apr;147(4):1013-6 [1552576.001]
  • [Cites] Int J Urol. 2006 Aug;13(8):1134-5 [16903947.001]
  • [Cites] Urology. 2006 Dec;68(6):1343.e9-10 [17141834.001]
  • [Cites] J Urol. 1991 Sep;146(3):862-6 [1714971.001]
  • [Cites] Urol Int. 1991;46(1):22-6 [2024366.001]
  • [Cites] J Urol. 1990 Apr;143(4):671-8 [2179579.001]
  • [Cites] J Urol. 1990 Sep;144(3):607-10 [2201791.001]
  • [Cites] J Urol. 1990 Nov;144(5):1110-4 [2231881.001]
  • [Cites] Br J Urol. 1989 Nov;64(5):489-92 [2611620.001]
  • [Cites] J Urol. 1989 Jan;141(1):178-81 [2908946.001]
  • [Cites] Urol Clin North Am. 1986 May;13(2):201-5 [3515722.001]
  • [Cites] J Urol. 1984 Dec;132(6):1108-11 [6502797.001]
  • [Cites] Science. 1980 Mar 7;207(4435):1079-80 [7355272.001]
  • [Cites] Urol Res. 1995;23(1):21-5 [7618231.001]
  • [Cites] J Urol. 1997 Feb;157(2):482-5; discussion 485-6 [8996339.001]
  • [Cites] Urol Clin North Am. 1997 Nov;24(4):723-8 [9391525.001]
  • [Cites] Br J Urol. 1998 Jan;81(1):55-61 [9467477.001]
  • [Cites] J Urol. 1998 Aug;160(2):490-1 [9679906.001]
  • [Cites] Eur Urol. 1999 Feb;35(2):98-101 [9933802.001]
  • [Cites] Eur Urol. 1999 Dec;36(6):588-94 [10559613.001]
  • [Cites] Dis Colon Rectum. 1999 Dec;42(12):1632-8 [10613486.001]
  • [Cites] Urology. 1999 Sep;54(3):561 [10754137.001]
  • [Cites] Urol Int. 2000;64(1):31-2 [10782030.001]
  • [Cites] Cochrane Database Syst Rev. 2003;(1):CD003306 [12535469.001]
  • (PMID = 17697327.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1995190
  •  go-up   go-down


61. Scott RH, Mansour S, Pritchard-Jones K, Kumar D, MacSweeney F, Rahman N: Medulloblastoma, acute myelocytic leukemia and colonic carcinomas in a child with biallelic MSH6 mutations. Nat Clin Pract Oncol; 2007 Feb;4(2):130-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Medulloblastoma, acute myelocytic leukemia and colonic carcinomas in a child with biallelic MSH6 mutations.
  • Background A 13-year-old girl presented with rectal bleeding and was found to have two colonic carcinomas (stage Dukes' C) and multiple colonic polyps.
  • A three-generation family history identified no relatives with colonic carcinomas or polyposis.
  • Investigations Immunohistochemical analysis was performed on a sample of colonic adenoma.
  • [MeSH-major] Cerebellar Neoplasms / genetics. Colonic Neoplasms / genetics. DNA-Binding Proteins / genetics. Leukemia, Myeloid, Acute / genetics. Medulloblastoma / genetics


62. Paulsen JE, Knutsen H, Ølstørn HB, Løberg EM, Alexander J: Identification of flat dysplastic aberrant crypt foci in the colon of azoxymethane-treated A/J mice. Int J Cancer; 2006 Feb 1;118(3):540-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of flat dysplastic aberrant crypt foci in the colon of azoxymethane-treated A/J mice.
  • The role of aberrant crypt foci (ACF) as preneoplastic lesions in colon carcinogenesis is not clear.
  • At weeks 7-14, we examined the luminal surface of unsectioned colon preparations stained with methylene blue in the inverse light microscope.
  • In conclusion, our data indicate a development from flat ACF to adenoma characterized by aberrant activation of the Wnt signaling pathway and fast crypt multiplication.
  • [MeSH-major] Azoxymethane / toxicity. Carcinogens / toxicity. Colonic Neoplasms / pathology. Hyperplasia / pathology. Precancerous Conditions / pathology

  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 16094649.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 0 / beta Catenin; 136601-57-5 / Cyclin D1; MO0N1J0SEN / Azoxymethane
  •  go-up   go-down


63. Kitade Y, Akao Y: MicroRNAs and their therapeutic potential for human diseases: microRNAs, miR-143 and -145, function as anti-oncomirs and the application of chemically modified miR-143 as an anti-cancer drug. J Pharmacol Sci; 2010;114(3):276-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • miRs) in colorectal tumors (63 cancer specimens and 65 adenoma specimens) compared to adjacent non-tumorous tissues.
  • Decreased expression of miR-143 and -145 was frequently observed in the adenoma and cancer samples.
  • As the down-regulation of miR-143 and -145 was observed even in the early phase of adenoma formation, their decreased expression would appear to contribute mainly to the initiation of tumorigenesis.
  • [MeSH-minor] Adenoma / genetics. Adenoma / metabolism. Adenoma / pathology. Animals. Cell Line, Tumor. Colon / physiopathology. Down-Regulation. Growth Inhibitors. Humans. Mice. Xenograft Model Antitumor Assays

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20953119.001).
  • [ISSN] 1347-8648
  • [Journal-full-title] Journal of pharmacological sciences
  • [ISO-abbreviation] J. Pharmacol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Growth Inhibitors; 0 / MIRN143 microRNA, human; 0 / MIRN145 microRNA, human; 0 / MicroRNAs
  •  go-up   go-down


64. Batlle E, Bacani J, Begthel H, Jonkheer S, Gregorieff A, van de Born M, Malats N, Sancho E, Boon E, Pawson T, Gallinger S, Pals S, Clevers H: EphB receptor activity suppresses colorectal cancer progression. Nature; 2005 Jun 23;435(7045):1126-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here we show that, although Wnt signalling remains constitutively active, most human colorectal cancers lose expression of EphB at the adenoma-carcinoma transition.
  • Furthermore, reduction of EphB activity accelerates tumorigenesis in the colon and rectum of Apc(Min/+) mice, and results in the formation of aggressive adenocarcinomas.
  • [MeSH-minor] Adenoma / metabolism. Adenoma / pathology. Animals. Cell Line, Tumor. Disease Progression. Down-Regulation. Gene Expression Regulation, Neoplastic. Genes, APC. Genes, Dominant / genetics. Humans. Intercellular Signaling Peptides and Proteins / metabolism. Mice. Mice, Transgenic. Mutation / genetics. RNA, Messenger / genetics. RNA, Messenger / metabolism. Signal Transduction. Wnt Proteins


65. Rohde F, Rimkus C, Friederichs J, Rosenberg R, Marthen C, Doll D, Holzmann B, Siewert JR, Janssen KP: Expression of osteopontin, a target gene of de-regulated Wnt signaling, predicts survival in colon cancer. Int J Cancer; 2007 Oct 15;121(8):1717-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of osteopontin, a target gene of de-regulated Wnt signaling, predicts survival in colon cancer.
  • We analyzed 13 normal colon tissues, 9 adenomas, 120 primary colon tumors, and 10 liver metastases by quantitative reverse-transcription PCR.
  • OPN expression was strongly elevated in primary colon cancer and liver metastasis, but not in pre-cancerous lesions and UICC stage I tumors.
  • Thus, OPN is a transcriptional target of aberrant Wnt signaling, and OPN expression alone predicts survival in human colon cancer.
  • [MeSH-major] Biomarkers, Tumor / analysis. Biomarkers, Tumor / genetics. Colonic Neoplasms / chemistry. Colonic Neoplasms / mortality. Osteopontin / analysis. Osteopontin / genetics. Wnt Proteins / genetics
  • [MeSH-minor] Adenoma / chemistry. Adenoma / mortality. Aged. Animals. Colon / chemistry. Female. Gene Expression Regulation, Neoplastic. Genes, APC. Humans. Liver Neoplasms / chemistry. Liver Neoplasms / mortality. Liver Neoplasms / secondary. Male. Mice. Middle Aged. Mutation. Precancerous Conditions / chemistry. Precancerous Conditions / mortality. Predictive Value of Tests. Prognosis. Reverse Transcriptase Polymerase Chain Reaction. Signal Transduction. Survival Analysis. Up-Regulation. beta Catenin / analysis. beta Catenin / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17565744.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Wnt Proteins; 0 / beta Catenin; 106441-73-0 / Osteopontin
  •  go-up   go-down


66. Leman ES, Schoen RE, Magheli A, Sokoll LJ, Chan DW, Getzenberg RH: Evaluation of colon cancer-specific antigen 2 as a potential serum marker for colorectal cancer. Clin Cancer Res; 2008 Mar 1;14(5):1349-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of colon cancer-specific antigen 2 as a potential serum marker for colorectal cancer.
  • PURPOSE: A blood test to detect colon cancer at a preventable stage would represent a major advancement.
  • We have previously identified colon cancer-specific markers using focused proteomics analysis of nuclear structural proteins.
  • Two of these markers, colon cancer-specific antigen (CCSA)-3 and CCSA-4, have been developed into blood-based markers that are able to distinguish individuals with colorectal cancer from those without.
  • CCSA-2 is a distinct novel colon cancer marker identified using focused proteomics.
  • EXPERIMENTAL DESIGN: Using an indirect ELISA on serum samples obtained from two institutions, we evaluated CCSA-2 as a serum-based colon cancer marker.
  • A total of 111 serum samples from individuals who underwent colonoscopy and were subsequently diagnosed as either being normal or having hyperplastic polyps, nonadvanced adenomas, advanced adenomas, and colorectal cancer were evaluated.
  • CCSA-2 at a cutoff of 10.8 mug/mL has overall specificity of 78.4% [95% confidence interval (95% CI), 67.3-87.1%] and sensitivity of 97.3% (95% CI, 85.8-99.5%) in separating individuals with advanced adenomas and colorectal cancer from normal, hyperplastic, and nonadvanced adenoma populations.
  • CONCLUSION: Our initial study shows that CCSA-2 is a potential serum-based marker for colon cancer detection with high sensitivity and specificity.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [RetractionIn] Schoen RE, Magheli A, Sokoll LJ, Chan DW, Getzenberg RH. Clin Cancer Res. 2013 Jan 15;19(2):508 [23271798.001]
  • (PMID = 18316554.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA084968; United States / NCI NIH HHS / CA / U01 CA084968-01; United States / NCI NIH HHS / CA / CA084968
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Retracted Publication
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / colon cancer-specific antigen 2, human; 0 / colon-specific antigen
  • [Other-IDs] NLM/ NIHMS371863; NLM/ PMC4664476
  •  go-up   go-down


67. Bhattacharya S, Mathew G, Jayne DG, Pelengaris S, Khan M: 15-lipoxygenase-1 in colorectal cancer: a review. Tumour Biol; 2009;30(4):185-99
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of these enzymes, 15-LOX-1 is expressed in colon.
  • [MeSH-minor] Adenoma / enzymology. Adenoma / metabolism. Animals. Anticarcinogenic Agents / blood. Anticarcinogenic Agents / metabolism. Arachidonic Acid / metabolism. Cyclic GMP-Dependent Protein Kinases / metabolism. Disease Models, Animal. GATA6 Transcription Factor / metabolism. Humans. Intestinal Mucosa / enzymology. Intestinal Mucosa / metabolism. PPAR alpha / metabolism. PPAR delta / metabolism. PPAR gamma / genetics. PPAR gamma / metabolism. PPAR-beta / metabolism. Reference Values. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Colorectal cancer 1.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19752603.001).
  • [ISSN] 1423-0380
  • [Journal-full-title] Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  • [ISO-abbreviation] Tumour Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / GATA6 Transcription Factor; 0 / PPAR alpha; 0 / PPAR delta; 0 / PPAR gamma; 0 / PPAR-beta; 27YG812J1I / Arachidonic Acid; EC 1.13.11.33 / ALOX15B protein, human; EC 1.13.11.33 / Arachidonate 15-Lipoxygenase; EC 2.7.11.12 / Cyclic GMP-Dependent Protein Kinases
  • [Number-of-references] 110
  •  go-up   go-down


68. Ito H, Matsuo K, Hosono S, Watanabe M, Kawase T, Suzuki T, Hirai T, Yatabe Y, Tanaka H, Tajima K: Association between CYP7A1 and the risk of proximal colon cancer in Japanese. Int J Mol Epidemiol Genet; 2010;1(1):35-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association between CYP7A1 and the risk of proximal colon cancer in Japanese.
  • Recently, an association between a polymorphism (-204A>C, rs3808607) in CYP7A1 and proximal colon cancer/adenoma has been reported, which was not observed with distal colon or rectal cancer/adenoma.
  • In this case-control study, we examined the association between haplotypes of CYP7A1 and proximal or distal colon/rectal cancer risk in a Japanese population.
  • Subjects were 96 cases of proximal colon cancer, 357 of distal colon/rectal cancer and 961 age- and sex-matched non-cancer controls at Aichi Cancer Center.
  • In locus-specific analyses, we saw no association with rs3808607 for any site.
  • Haplotype analyses revealed that the TAAGG haplotype was positively associated with proximal colon cancer [confounder-adjusted odds ratio: 1.72 (95% confidence interval: 1.10-2.71), p=0.018] but not with distal colon and rectal cancer combined.
  • Our results indicate that CYP7A1 plays a role in the carcinogenesis of colorectal cancer specifically in the proximal colon.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genet Anal. 1999 Feb;14(5-6):143-9 [10084106.001]
  • [Cites] J Lipid Res. 1999 Oct;40(10):1883-9 [10508208.001]
  • [Cites] Am J Med Genet. 2002 Jul 1;110(3):234-42 [12116231.001]
  • [Cites] J Natl Cancer Inst. 1976 Feb;56(2):441-2 [1255778.001]
  • [Cites] Nature. 2003 Dec 18;426(6968):789-96 [14685227.001]
  • [Cites] Cancer Res. 2005 Apr 1;65(7):2979-82 [15805302.001]
  • [Cites] Carcinogenesis. 2005 Dec;26(12):2164-71 [16051637.001]
  • [Cites] Genet Epidemiol. 2005 Sep;29(2):108-27 [16080203.001]
  • [Cites] Atherosclerosis. 2005 Sep;182(1):37-45 [16115473.001]
  • [Cites] Cancer Sci. 2006 May;97(5):406-10 [16630139.001]
  • [Cites] Cancer. 2007 May 15;109(10):2116-23 [17410537.001]
  • [Cites] Am J Epidemiol. 1986 Jul;124(1):17-27 [3521261.001]
  • [Cites] Eur J Cancer. 1995 Jul-Aug;31A(7-8):1067-70 [7576993.001]
  • [Cites] J Clin Invest. 1995 Aug;96(2):700-9 [7635963.001]
  • [Cites] J Clin Epidemiol. 1997 Jan;50(1):69-77 [9048692.001]
  • [Cites] J Clin Invest. 1998 Mar 15;101(6):1283-91 [9502769.001]
  • [Cites] Curr Opin Lipidol. 1998 Apr;9(2):113-8 [9559267.001]
  • [Cites] J Lipid Res. 1998 Sep;39(9):1833-43 [9741696.001]
  • [Cites] J Natl Cancer Inst. 1974 Oct;53(4):1093-7 [4427390.001]
  • [Cites] J Epidemiol. 2005 Jul;15(4):135-45 [16141632.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):1009-13 [16702384.001]
  • [Cites] BMC Genet. 2006;7:29 [16709249.001]
  • [Cites] J Epidemiol. 2007 May;17(3):100-7 [17545697.001]
  • (PMID = 21537451.001).
  • [ISSN] 1948-1756
  • [Journal-full-title] International journal of molecular epidemiology and genetics
  • [ISO-abbreviation] Int J Mol Epidemiol Genet
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3076754
  • [Keywords] NOTNLM ; CYP7A1 / Japanese / polymorphisms / proximal colon cancer
  •  go-up   go-down


69. Katznelson L: Approach to the patient with persistent acromegaly after pituitary surgery. J Clin Endocrinol Metab; 2010 Sep;95(9):4114-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Acromegaly is a chronic and insidious disease that is associated with multisystem comorbidities, including cardiovascular disease, hypertension, sleep apnea syndrome, colon polyposis, arthropathy, and metabolic complications including glucose intolerance and type 2 diabetes mellitus.
  • [MeSH-major] Acromegaly / therapy. Adenoma / surgery. Algorithms. Growth Hormone-Secreting Pituitary Adenoma / surgery. Postoperative Complications / therapy

  • Genetic Alliance. consumer health - Acromegaly.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20823464.001).
  • [ISSN] 1945-7197
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 59
  •  go-up   go-down


70. Johnson PM, Gallinger S, McLeod RS: Surveillance colonoscopy in individuals at risk for hereditary nonpolyposis colorectal cancer: an evidence-based review. Dis Colon Rectum; 2006 Jan;49(1):80-93; discussion 94-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, given the potential for rapid progression from adenoma to carcinoma and missing lesions at colonoscopy, there is consensus that screening more frequently than every three years is required.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Hereditary Cancer.
  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Dis Colon Rectum. 2006 Nov;49(11):1797-8; author reply 1799 [17053868.001]
  • (PMID = 16284887.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] United States
  •  go-up   go-down


71. Femia AP, Dolara P, Giannini A, Salvadori M, Biggeri A, Caderni G: Frequent mutation of Apc gene in rat colon tumors and mucin-depleted foci, preneoplastic lesions in experimental colon carcinogenesis. Cancer Res; 2007 Jan 15;67(2):445-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequent mutation of Apc gene in rat colon tumors and mucin-depleted foci, preneoplastic lesions in experimental colon carcinogenesis.
  • Mucin-depleted foci (MDF) are microscopic dysplastic lesions induced in the colon of rodents by specific colon carcinogens.
  • Because Apc is a member of the Wnt pathway and the most frequent mutated gene in human colon cancer, we tested whether MDF harbor Apc mutations.
  • We screened a segment of the Apc gene comprising the region homologous to the mutation cluster region (MCR) of human APC, which frequently shows mutations in experimental colon tumors.
  • These results show that Apc mutations are present in MDF with a frequency similar to that of tumors, strengthening the evidence that they are precancerous lesions in colon carcinogenesis.
  • [MeSH-major] Colonic Neoplasms / genetics. Genes, APC. Mucins / deficiency. Mutation. Precancerous Conditions / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenoma / genetics. Adenoma / metabolism. Animals. Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / metabolism. Male. Rats. Rats, Inbred F344

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17234750.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mucins
  •  go-up   go-down


72. Robertson DJ, Greenberg ER, Beach M, Sandler RS, Ahnen D, Haile RW, Burke CA, Snover DC, Bresalier RS, McKeown-Eyssen G, Mandel JS, Bond JH, Van Stolk RU, Summers RW, Rothstein R, Church TR, Cole BF, Byers T, Mott L, Baron JA: Colorectal cancer in patients under close colonoscopic surveillance. Gastroenterology; 2005 Jul;129(1):34-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We determined the incidence of CRC in patients under colonoscopic surveillance and examined the circumstances and risk factors for CRC and adenoma with high-grade dysplasia.
  • METHODS: Patients were drawn from 3 adenoma chemoprevention trials.
  • All underwent baseline colonoscopy with removal of at least one adenoma and were deemed free of remaining lesions.
  • We identified patients subsequently diagnosed with invasive cancer or adenoma with high-grade dysplasia.
  • The cancers were located in all regions of the colon; 10 were at or proximal to the hepatic flexure.
  • Seven patients were diagnosed with adenoma with high-grade dysplasia during follow-up.
  • Older patients and those with a history of more adenomas were at higher risk of being diagnosed with invasive cancer or adenoma with high-grade dysplasia.
  • [MeSH-major] Adenoma / diagnosis. Adenoma / epidemiology. Colonoscopy. Colorectal Neoplasms / diagnosis. Colorectal Neoplasms / epidemiology


73. Suzui M, Inamine M, Kaneshiro T, Morioka T, Yoshimi N, Suzuki R, Kohno H, Tanaka T: Indole-3-carbinol inhibits the growth of human colon carcinoma cells but enhances the tumor multiplicity and volume of azoxymethane-induced rat colon carcinogenesis. Int J Oncol; 2005 Nov;27(5):1391-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Indole-3-carbinol inhibits the growth of human colon carcinoma cells but enhances the tumor multiplicity and volume of azoxymethane-induced rat colon carcinogenesis.
  • The purpose of this study was to examine the effects of I3C on colon carcinogenesis, cell proliferation, cell-cycle progression and apoptosis, and on the levels of expression of several cell-cycle control molecules.
  • We used a long-term rat model by using azoxymethane (AOM) to induce tumors (adenomas and adenocarcinomas) in the colon.
  • In addition, the tumor multiplicity of adenoma plus adenocarcinoma and the volume of adenocarcinoma were also increased by 2.0- (P<0.00001) and 2.1-fold (P<0.05) respectively, compared to the control.
  • I3C significantly increased the proliferating cell nuclear antigen labeling index (PCNA LI) (P<0.008) and decreased the apoptotic index (P<0.05) of the colon adenocarcinoma.
  • In contrast, in HCT 116 and HT29 human colon carcinoma cells, I3C inhibited growth and induced G1-phase cell-cycle arrest and apoptosis.
  • These results suggest that I3C inhibits the growth of human colon carcinoma cells, at least in part, by inducing p27KIP1 and p21CIP1-mediated G1 cell-cycle arrest but dietary I3C promotes AOM-induced rat colon carcinogenesis by inhibiting the apoptosis of colon tumors.
  • [MeSH-major] Adenocarcinoma / pathology. Antioxidants / pharmacology. Colonic Neoplasms / pathology. Indoles / pharmacology

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16211236.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Indoles; C11E72455F / indole-3-carbinol
  •  go-up   go-down


74. Cirocchi R, Coccetta M, De Sol A, Morelli U, Spizzirri A, Cattorini L, Farinella E, Giustozzi G, Sciannameo F: [Minimally invasive treatment of synchronous colorectal tumours]. Chir Ital; 2008 Mar-Apr;60(2):237-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Trattamento mini-invasivo delle neoplasie sincrone del colon-retto.
  • In patients with colorectal cancers synchronous neoplastic lesions are an increasingly frequent finding at preoperative staging; 3% of the cases are other cancers while 33-35% of the synchronous lesions are villous adenomas.
  • The treatment of most colorectal adenomas can be performed by endoscopic poplypectomy.
  • Surgical timing involved performing a sequential exeresis characterised by a cancer resection, followed by resection of the voluminous adenoma: TEM for rectal cancer followed by a laparoscopic right hemicolectomy with an extracorporeal anastomosis for a voluminous villous adenoma (1 patient) and laparoscopic right hemicolectomy with an extracorporeal anastomosis for cancer followed by TEM for a voluminous villous adenoma (2 patients).
  • One patient with left colon cancer associated with a voluminous villous rectal adenoma first underwent TEM for the rectal adenoma and then a left laparoscopic hemicolectomy with an extracorporeal anastomosis in order to ease the transit of the circular mechanical stapler.
  • Another patient with rectal and right colon adenomas first underwent TEM for a voluminous rectal sessile adenoma and later a right hemicolectomy.
  • [MeSH-major] Adenoma / surgery. Colectomy / methods. Colorectal Neoplasms / surgery. Laparoscopy. Microsurgery

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18689172.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


75. Bini EJ, Park J, Francois F: Use of flexible sigmoidoscopy to screen for colorectal cancer in HIV-infected patients 50 years of age and older. Arch Intern Med; 2006 Aug 14-28;166(15):1626-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The prevalence of neoplastic lesions (adenomas or adenocarcinomas) in the distal colon was significantly higher in HIV-infected patients than in control subjects (25.5% vs 13.1%, P<.001), and the odds of HIV-infected patients having a neoplastic lesion was significantly higher even after adjustment for potential confounding variables (odds ratio, 2.34; 95% confidence interval, 1.60-3.44).
  • The prevalence of adenomas of any size (25.5% vs 12.9%, P<.001) and advanced neoplasia (7.3% vs 3.8%, P = .03) in the distal colon was significantly higher in HIV-infected patients.
  • Among individuals with positive results on flexible sigmoidoscopy, proximal colonic neoplastic lesions on follow-up colonoscopy were more common in HIV-infected patients after adjustment for age, sex, and race/ethnicity (odds ratio, 1.88; 95% confidence interval, 1.02-3.46).
  • CONCLUSIONS: Patients infected with HIV are more likely to have colonic neoplasms on screening flexible sigmoidoscopy than those without HIV, and these individuals should be offered colorectal cancer screening.
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adenoma / epidemiology. Aged. Female. Health Status. Humans. Male. Middle Aged


76. Worrell RT, Best A, Crawford OR, Xu J, Soleimani M, Matthews JB: Apical ammonium inhibition of cAMP-stimulated secretion in T84 cells is bicarbonate dependent. Am J Physiol Gastrointest Liver Physiol; 2005 Oct;289(4):G768-78
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Normal human colonic luminal (NH(4)(+)) concentration ([NH(4)(+)]) ranges from approximately 10 to 100 mM.
  • However, the nature of the effects of NH(4)(+) on transport, as well as NH(4)(+) transport itself, in colonic epithelium is poorly understood.
  • We elucidate here the effects of apical NH(4)(+) on cAMP-stimulated Cl(-) secretion in colonic T84 cells.
  • However, apical NH(4)(+) inhibition of current was prevented by 10 min of pretreatment of the apical surface with 500 microM DIDS, 100 microM 4,4'-dinitrostilbene-2,2'-disulfonic acid (DNDS), or 25 microM niflumic acid, suggesting a role for NH(4)(+) action through an apical anion exchanger. mRNA and protein for the apical anion exchangers SLC26A3 [downregulated in adenoma (DRA)] and SLC26A6 [putative anion transporter (PAT1)] were detected in T84 cells by RT-PCR and Northern and Western blots.
  • [MeSH-major] Bicarbonates / metabolism. Colon / metabolism. Cyclic AMP / antagonists & inhibitors. Cyclic AMP / pharmacology. Quaternary Ammonium Compounds / pharmacology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 4,4'-DINITRO-2,2'-STILBENEDISULFONIC ACID .
  • Hazardous Substances Data Bank. CARBACHOL CHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16002564.001).
  • [ISSN] 0193-1857
  • [Journal-full-title] American journal of physiology. Gastrointestinal and liver physiology
  • [ISO-abbreviation] Am. J. Physiol. Gastrointest. Liver Physiol.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK-051630; United States / NIDDK NIH HHS / DK / DK-62809
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiporters; 0 / Bicarbonates; 0 / Carbonic Anhydrase Inhibitors; 0 / Chloride Channels; 0 / Membrane Transport Proteins; 0 / Muscarinic Agonists; 0 / Quaternary Ammonium Compounds; 0 / SLC26A6 protein, human; 0 / Slc26a3 protein, rat; 0 / Stilbenes; 128-42-7 / 4,4'-dinitro-2,2'-stilbenedisulfonic acid; 8Y164V895Y / Carbachol; E0399OZS9N / Cyclic AMP; Q1O6DSW23R / 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid
  •  go-up   go-down


77. Jalving M, de Jong S, Koornstra JJ, Boersma-van Ek W, Zwart N, Wesseling J, de Vries EG, Kleibeuker JH: TRAIL induces apoptosis in human colorectal adenoma cell lines and human colorectal adenomas. Clin Cancer Res; 2006 Jul 15;12(14 Pt 1):4350-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TRAIL induces apoptosis in human colorectal adenoma cell lines and human colorectal adenomas.
  • The aim of this study was to investigate whether it is possible to induce apoptosis in human adenoma cell lines and human adenomas using rhTRAIL.
  • EXPERIMENTAL DESIGN: Two human adenoma cell lines were exposed to 0.1 microg/mL of rhTRAIL for 5 hours.
  • Short-term explant cultures were established from freshly removed human adenomas (n = 38) and biopsies of normal colon epithelium (n = 15), and these were incubated for 5 hours in the presence or absence of 1 microg/mL of rhTRAIL.
  • RESULTS: In the adenoma cell lines, rhTRAIL induced up to 55% apoptosis.
  • This coincided with caspase-8 and caspase-3 activation and could be inhibited by a pan-caspase inhibitor. rhTRAIL induced caspase-dependent apoptosis in adenomas with high-grade dysplasia (n = 21) compared with the paired untreated counterparts (apoptotic index, 34 +/- 5% versus 17 +/- 2%, mean +/- SE; P = 0.002), but not in adenomas with low-grade dysplasia (n = 17) or in normal colon epithelium (n = 15).
  • CONCLUSIONS: Colorectal adenoma cell lines and adenomas with high-grade dysplasia are sensitive to rhTRAIL-induced apoptosis, whereas normal colon epithelium is not.
  • This suggests the potential application of rhTRAIL in the treatment of adenomas with high-grade dysplasia.
  • [MeSH-major] Adenoma / metabolism. Adenoma / pathology. Apoptosis. Colorectal Neoplasms / metabolism. Colorectal Neoplasms / pathology. TNF-Related Apoptosis-Inducing Ligand / physiology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4132-6 [16857782.001]
  • (PMID = 16857810.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Apoptosis Regulatory Proteins; 0 / Ligands; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / TNFSF10 protein, human; EC 3.4.22.- / Caspases
  •  go-up   go-down


78. Sillars-Hardebol AH, Carvalho B, de Wit M, Postma C, Delis-van Diemen PM, Mongera S, Ylstra B, van de Wiel MA, Meijer GA, Fijneman RJ: Identification of key genes for carcinogenic pathways associated with colorectal adenoma-to-carcinoma progression. Tumour Biol; 2010 Apr;31(2):89-96
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of key genes for carcinogenic pathways associated with colorectal adenoma-to-carcinoma progression.
  • Colorectal adenomas form a biologically and clinically distinct intermediate stage in development of colorectal cancer (CRC) from normal colon epithelium.
  • Only 5% of adenomas progress into adenocarcinomas, indicating that malignant transformation requires other biological alterations than those involved in adenoma formation.
  • The present study aimed to explore which cancer-related biological processes are affected during colorectal adenoma-to-carcinoma progression and to identify key genes within these pathways that can serve as tumor markers for malignant transformation.
  • The activity of 12 cancer-related biological processes was compared between 37 colorectal adenomas and 31 adenocarcinomas, using the pathway analysis tool Gene Set Enrichment Analysis.
  • Expression of six gene sets was significantly increased in CRCs compared to adenomas, representing chromosomal instability, proliferation, differentiation, invasion, stroma activation, and angiogenesis.
  • For AURKA and PDGFRB, increased mRNA expression levels were verified at the protein level by immunohistochemical analysis of a series of adenomas and CRCs.
  • [MeSH-major] Adenoma / genetics. Carcinoma / genetics. Colorectal Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Carcinogenesis. 2008 Oct;29(10):1930-7 [18667445.001]
  • [Cites] Cancer Lett. 2007 Dec 18;258(2):223-9 [17977645.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Cancer. 2000 Apr 15;88(8):1820-7 [10760758.001]
  • [Cites] Nat Cell Biol. 2000 Sep;2(9):672-6 [10980711.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3230-9 [11309271.001]
  • [Cites] Bioinformatics. 2001 Jun;17(6):520-5 [11395428.001]
  • [Cites] Gastroenterology. 2002 Oct;123(4):1109-19 [12360473.001]
  • [Cites] Oncogene. 2003 Oct 16;22(46):7155-69 [14562044.001]
  • [Cites] PLoS Biol. 2004 Feb;2(2):E7 [14737219.001]
  • [Cites] Int J Oncol. 2004 May;24(5):1279-88 [15067352.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 22;101(25):9309-14 [15184677.001]
  • [Cites] Cancer. 1974 Sep;34(3):suppl:878-88 [4853616.001]
  • [Cites] N Engl J Med. 1986 Dec 25;315(26):1650-9 [3537791.001]
  • [Cites] Cell. 1990 Jun 1;61(5):759-67 [2188735.001]
  • [Cites] Nat Genet. 1998 Oct;20(2):189-93 [9771714.001]
  • [Cites] Oncogene. 2005 Feb 10;24(7):1212-9 [15592519.001]
  • [Cites] J Clin Invest. 2005 Apr;115(4):978-85 [15761500.001]
  • [Cites] Int J Cancer. 2005 Jul 20;115(6):935-42 [15723354.001]
  • [Cites] J Pathol. 2005 Jul;206(3):291-304 [15906272.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50 [16199517.001]
  • [Cites] Oncogene. 2005 Dec 15;24(56):8240-51 [16091733.001]
  • [Cites] Cell Cycle. 2006 Feb;5(3):296-303 [16418575.001]
  • [Cites] Clin Cancer Res. 2006 Feb 15;12(4):1121-7 [16489064.001]
  • [Cites] Nat Rev Cancer. 2006 Feb;6(2):99-106 [16491069.001]
  • [Cites] Blood. 2006 Mar 1;107(5):2112-22 [16269622.001]
  • [Cites] Adv Immunol. 2006;90:51-81 [16730261.001]
  • [Cites] Nat Genet. 2006 Sep;38(9):1043-8 [16921376.001]
  • [Cites] Oncogene. 2006 Dec 4;25(57):7531-7 [17143297.001]
  • [Cites] Am J Pathol. 2006 Dec;169(6):2054-65 [17148668.001]
  • [Cites] Eur J Cancer. 2006 Dec;42(18):3274-86 [16979889.001]
  • [Cites] Cell Oncol. 2007;29(5):387-98 [17726261.001]
  • [Cites] Gut. 2009 Jan;58(1):79-89 [18829976.001]
  • (PMID = 20358421.001).
  • [ISSN] 1423-0380
  • [Journal-full-title] Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  • [ISO-abbreviation] Tumour Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Proto-Oncogene Proteins; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor beta; EC 2.7.11.1 / AURKA protein, human; EC 2.7.11.1 / Aurora Kinase A; EC 2.7.11.1 / Aurora Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / polo-like kinase 1
  • [Other-IDs] NLM/ PMC2848338
  •  go-up   go-down


79. Popivanova BK, Li YY, Zheng H, Omura K, Fujii C, Tsuneyama K, Mukaida N: Proto-oncogene, Pim-3 with serine/threonine kinase activity, is aberrantly expressed in human colon cancer cells and can prevent Bad-mediated apoptosis. Cancer Sci; 2007 Mar;98(3):321-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proto-oncogene, Pim-3 with serine/threonine kinase activity, is aberrantly expressed in human colon cancer cells and can prevent Bad-mediated apoptosis.
  • Because Pim-3 protein was not detected in normal colon mucosal tissues, we evaluated Pim-3 expression in malignant lesions of human colon, another endoderm-derived organ.
  • Pim-3 was detected immunohistochemically in well-differentiated (43/68 cases) and moderately differentiated (23/41 cases) but not poorly differentiated colon adenocarcinomas (0/5 cases).
  • Moreover, Pim-3 proteins were detected in adenoma (35/40 cases) and normal mucosa (26/111 cases), which are adjacent to adenocarcinoma.
  • Furthermore, in human colon cancer tissues, Pim-3 co-localized with Bad in all cases (9/9) and with phospho-Ser(112)Bad in most cases (6/9).
  • These observations suggest that Pim-3 can inactivate Bad by phosphorylating its Ser(112) in human colon cancer cells and thus may prevent apoptosis and promote progression of human colon cancer.
  • [MeSH-major] Colonic Neoplasms / enzymology. Colonic Neoplasms / genetics. Protein-Serine-Threonine Kinases / genetics. Protein-Serine-Threonine Kinases / metabolism. Proto-Oncogene Proteins / genetics. Proto-Oncogene Proteins / metabolism. bcl-Associated Death Protein / antagonists & inhibitors

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17270021.001).
  • [ISSN] 1347-9032
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins; 0 / bcl-Associated Death Protein; EC 2.7.11.1 / PIM3 protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


80. Park HW, Kang HC, Kim IJ, Jang SG, Kim K, Yoon HJ, Jeong SY, Park JG: Correlation between hypermethylation of the RASSF2A promoter and K-ras/BRAF mutations in microsatellite-stable colorectal cancers. Int J Cancer; 2007 Jan 1;120(1):7-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using methylation-specific PCR and bisulfite sequencing, we analyzed the methylation status in primary CRC, adenomas and corresponding normal tissues and then compared it with the presence of K-ras and BRAF mutations.
  • In primary CRC, the frequency of RASSF2A methylation was 72.6%, and it was found in 16 of 16 (100%) adenomas.
  • [MeSH-minor] Adenoma / genetics. Adenoma / pathology. Case-Control Studies. Cell Line, Tumor. Colon / metabolism. DNA Mutational Analysis. DNA Repair. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Microsatellite Instability. Middle Aged. Neoplasm Staging. Promoter Regions, Genetic / genetics. Rectum / metabolism. Tumor Suppressor Proteins

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17013898.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proteins; 0 / RASSF2 protein, human; 0 / Tumor Suppressor Proteins; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  •  go-up   go-down


81. Tonelli F, Garcea A, Batignani G: Different role of the colonic pouch for low anterior resection and coloanal anastomosis. Tech Coloproctol; 2005 Apr;9(1):15-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Different role of the colonic pouch for low anterior resection and coloanal anastomosis.
  • BACKGROUND: Functional outcome after sphincter-saving operations can be improved by colonic pouch compared to the straight procedure.
  • However, it is not clear whether the colonic pouch has a different behavior in patients treated by low anterior resection with colorectal (LAR) or coloanal anastomosis (CAA).
  • METHODS: We evaluated the 1-year results of 75 patients who underwent a sphincter-saving operation for rectal carcinoma or villous tumor of the middle or lower third of the rectum: 18 patients underwent coloanal anastomosis (CAA), in 13 patients we performed a coloanal anastomosis with a colonic pouch (PCAA), 20 patients had low anterior resection (LAR) and 24 had LAR with pouch construction (PLAR).
  • CONCLUSIONS: Colonic J-pouch provides an advantage over straight anastomosis in sphincter-saving operations by reducing the daily number of defecations, and the frequencies of fecal soiling and urgency.
  • [MeSH-major] Anal Canal / surgery. Colon / surgery. Colonic Pouches
  • [MeSH-minor] Adenoma, Villous / surgery. Adult. Aged. Aged, 80 and over. Anastomosis, Surgical. Carcinoma / surgery. Female. Humans. Male. Manometry. Middle Aged. Rectal Neoplasms / surgery. Rectum / surgery

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15868493.001).
  • [ISSN] 1123-6337
  • [Journal-full-title] Techniques in coloproctology
  • [ISO-abbreviation] Tech Coloproctol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  •  go-up   go-down


82. Roy HK, Turzhitsky V, Kim YL, Goldberg MJ, Muldoon JP, Liu Y, Brand RE, Hall C, Hasabou N, Jameel M, Backman V: Spectral slope from the endoscopically-normal mucosa predicts concurrent colonic neoplasia: a pilot ex-vivo clinical study. Dis Colon Rectum; 2008 Sep;51(9):1381-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spectral slope from the endoscopically-normal mucosa predicts concurrent colonic neoplasia: a pilot ex-vivo clinical study.
  • METHODS: Subjects (n = 127) undergoing colonoscopy had spectral slope determined from two endoscopically normal midtransverse colonic biopsies using four-dimensional elastic light-scattering fingerprinting and correlated with clinical findings.
  • There was a corresponding decrease in spectral slope values from the endoscopically normal mucosa in subjects harboring adenomas (n = 41) and advanced adenomas (n = 10), compared to neoplasia-free subjects (P </= 0.00001).
  • These factors did not appear to be confounded by either age or adenoma location.
  • For detecting advanced adenomas, spectral slope had a negative and positive predictive value of 95 percent and 50 percent respectively.
  • CONCLUSIONS: We demonstrate, for the first time, that spectral slope in "normal" mucosa can accurately risk-stratify patients for colonic neoplasia.

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jul;14(7):1639-45 [16030095.001]
  • [Cites] Gastroenterology. 2005 Sep;129(3):1083-103 [16143145.001]
  • [Cites] Am J Gastroenterol. 2006 Feb;101(2):343-50 [16454841.001]
  • [Cites] Arch Intern Med. 2006 Mar 27;166(6):629-34 [16567601.001]
  • [Cites] Cancer Res. 2006 Jul 1;66(13):6553-62 [16818627.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Cancer Res. 1999 May 15;59(10):2353-7 [10344743.001]
  • [Cites] N Engl J Med. 2000 Jul 20;343(3):169-74 [10900275.001]
  • [Cites] Nature. 2000 Jul 6;406(6791):35-6 [10894529.001]
  • [Cites] Gastroenterology. 2003 Feb;124(2):544-60 [12557158.001]
  • [Cites] Science. 2003 Mar 14;299(5613):1753-5 [12637750.001]
  • [Cites] Gastroenterology. 2004 Apr;126(4):1071-81; discussion 948 [15057746.001]
  • [Cites] Clin Gastroenterol Hepatol. 2003 May;1(3):195-201 [15017491.001]
  • [Cites] Cancer Res. 2003 Apr 15;63(8):1727-30 [12702551.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3694-700 [15150130.001]
  • [Cites] Mol Cancer Ther. 2004 Sep;3(9):1159-65 [15367710.001]
  • [Cites] Gut. 1993 Apr;34(4):525-30 [8491402.001]
  • [Cites] N Engl J Med. 1998 Oct 29;339(18):1277-84 [9791143.001]
  • [Cites] N Engl J Med. 2004 Dec 23;351(26):2704-14 [15616205.001]
  • (PMID = 18536963.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA112315; United States / NCI NIH HHS / CA / U01 CA111257; United States / NIBIB NIH HHS / EB / EB003682-01A2; United States / NCI NIH HHS / CA / CA112315-01A1; United States / NCI NIH HHS / CA / R01 CA112315-01A1; United States / NCI NIH HHS / CA / R01 CA109861; United States / NIBIB NIH HHS / EB / R01 EB003682-01A2; United States / NIBIB NIH HHS / EB / R01 EB003682
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS58195; NLM/ PMC2913285
  •  go-up   go-down


83. Kirimlioglu H, Kirimlioglu V, Yilmaz S, Sagir V, Coban S, Turkmen E, Hilmioglu F: Role of matrix metalloproteinase-7 in colorectal adenomas. Dig Dis Sci; 2006 Nov;51(11):2068-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of matrix metalloproteinase-7 in colorectal adenomas.
  • They are known to be overexpressed as normal mucosa progresses to adenomas and carcinomas.
  • In our prospective study we measured the overexpression of MMP-7 immunohistochemically in various types of colonic adenomas.
  • Although MMP-7 has already been shown to be overexpressed in various types of colonic adenomas, tubular versus villous adenomas had not been further seperated to date.
  • Seventy-six patients had either normal mucosa (n=15) or tubular (n=32), tubulovillous (n=16), or villous (n=13) colonic adenoma.
  • Each adenoma was graded according to the percentage of strongly stained areas in the adenoma as G0, G1, G2, or G3.
  • Sixty-nine percent of villous adenomas showed grade 3 staining of MMP-7, versus none of the tubular adenomas.
  • G0 and G1 staining was not detected in the villous adenomas.
  • The results of the study show that the degrees of overexpression of the three subtypes of colonic adenomas were statistically significantly different.
  • In conclusion, MMP-7 overexpression is thought to be an early event in the adenoma-carcinoma pathway.
  • [MeSH-major] Adenoma / enzymology. Colorectal Neoplasms / enzymology. Matrix Metalloproteinase 7 / physiology
  • [MeSH-minor] Adenoma, Villous / enzymology. Adenoma, Villous / pathology. Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. Male. Middle Aged. Prospective Studies

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2001 Jun;233(6):786-92 [11371737.001]
  • [Cites] Eur J Cancer. 1999 Mar;35(3):335-51 [10448282.001]
  • [Cites] Clin Cancer Res. 2002 Jan;8(1):144-8 [11801551.001]
  • [Cites] Oncogene. 1999 May 6;18(18):2883-91 [10362259.001]
  • [Cites] J Pathol. 2003 Dec;201(4):528-34 [14648655.001]
  • [Cites] Mol Carcinog. 1994 Aug;10(4):199-206 [8068180.001]
  • [Cites] Cancer Metastasis Rev. 2004 Jan-Jun;23(1-2):101-17 [15000152.001]
  • [Cites] Br J Surg. 1997 Feb;84(2):160-6 [9052425.001]
  • [Cites] Mol Carcinog. 1999 Mar;24(3):177-87 [10204802.001]
  • [Cites] Gastrointest Endosc. 2004 Mar;59(3):385-92 [14997136.001]
  • [Cites] Science. 1997 Mar 21;275(5307):1787-90 [9065402.001]
  • [Cites] APMIS. 1999 Jan;107(1):102-10 [10190286.001]
  • [Cites] Br J Surg. 1976 May;63(5):384-8 [1268479.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1998;5(4):392-401 [9931388.001]
  • [Cites] Am J Pathol. 1996 Jul;149(1):273-82 [8686751.001]
  • [Cites] Cancer Res. 1994 Sep 1;54(17):4805-12 [8062282.001]
  • [Cites] Gastroenterology. 2002 Jan;122(1):60-71 [11781281.001]
  • [Cites] Mod Pathol. 2000 Sep;13(9):925-33 [11007031.001]
  • [Cites] J Biol Chem. 2003 Mar 7;278(10):7910-9 [12482850.001]
  • [Cites] Dis Colon Rectum. 2002 Apr;45(4):537-43 [12006939.001]
  • (PMID = 17009118.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.24.23 / MMP7 protein, human; EC 3.4.24.23 / Matrix Metalloproteinase 7
  •  go-up   go-down


84. Wargovich MJ: What do diet-induced alterations in colorectal polyps and aberrant crypts indicate for risk? J Nutr; 2006 Oct;136(10):2679S-80S
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] What do diet-induced alterations in colorectal polyps and aberrant crypts indicate for risk?
  • [MeSH-major] Colon / pathology. Colonic Neoplasms. Colonic Polyps. Diet. Rectal Neoplasms
  • [MeSH-minor] Adenoma / pathology. Adenoma / prevention & control. Animals. Calcium, Dietary / administration & dosage. Fruit. Humans. Precancerous Conditions / pathology. Vegetables

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16988147.001).
  • [ISSN] 0022-3166
  • [Journal-full-title] The Journal of nutrition
  • [ISO-abbreviation] J. Nutr.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Calcium, Dietary
  •  go-up   go-down


85. Park JK, Hong R, Kim KJ, Lee TB, Lim SC: Significance of p-STAT3 expression in human colorectal adenocarcinoma. Oncol Rep; 2008 Sep;20(3):597-604
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A total of 127 invasive CRA, 20 colorectal adenomas and 20 normal mucosae were obtained.
  • The statistically significant difference of immunoreactivity for p-STAT3 between the CRA and adenoma, and between the CRA and normal mucosae was identified.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / secondary. Adenoma / genetics. Adenoma / metabolism. Adenoma / pathology. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Carcinoma in Situ / genetics. Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. Colon / metabolism. Colon / pathology. Humans. Immunoenzyme Techniques. Neoplasm Invasiveness. Neoplasm Staging. Phosphorylation. Prognosis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18695911.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / STAT3 Transcription Factor; 0 / STAT3 protein, human
  •  go-up   go-down


86. Dong K, Li B, Li BH, Guan QL, Huo YZ: [Clinical analysis of Peutz-Jeghers syndrome:a report of 6 cases]. Zhonghua Wei Chang Wai Ke Za Zhi; 2005 Jul;8(4):336-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Repeated abdominal pain, intussusception and intestinal polyp with bleeding were main manifestations.
  • Case 4 and case 5 underwent laparotomy for many times because of intussusceptions caused by polyps or recurrent abdominal pain.
  • Case 1 and case 4 had polyps synchronous with adenoma, and case 2 had polyp with gastric cancer.
  • Main treatment included polyp resection and partial small intestinal and colon resection.
  • CONCLUSIONS: Patients with PJS have family history of cancer and a high incidence of polyp recurrence of small intestine.

  • Genetic Alliance. consumer health - Peutz Jeghers syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16167257.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


87. Park DH, Kim HS, Kim WH, Kim TI, Kim YH, Park DI, Kim HJ, Yang SK, Byeon JS, Lee MS, Chung IK, Jung SA, Jeen YT, Choi JH, Choi H, Han DS: Clinicopathologic characteristics and malignant potential of colorectal flat neoplasia compared with that of polypoid neoplasia. Dis Colon Rectum; 2008 Jan;51(1):43-9; discussion 49
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A prospective, cross-sectional study of 3,360 patients diagnosed with adenomas via total colonoscopy and polypectomy was performed at 11 tertiary medical centers between July 2003 and July 2004.
  • If multiple adenomas were identified, then only the adenoma with the most advanced degree of histology was recorded for the patient.
  • Patients with flat neoplasias tended to be older (59.6 vs. 57.1, P < 0.01), with the neoplasia located more frequently in the right colon than polypoid neoplasias (49.3 percent vs. 32 percent, P < 0.01).
  • Multivariate analysis revealed that a size of > or =11 mm (odds ratio, 6.8; 95 percent confidence interval, 4.8-9.7) and location in the left colon (odds ratio, 1.6; 95 percent confidence interval, 1.1-2.4) were significant determinants for the malignancy potential of colonic neoplasias.
  • CONCLUSIONS: The clinicopathologic indices for the propensity of malignant transformation in colorectal neoplasias were a size > or =11 mm and location in the left colon rather than flat gross morphology.
  • [MeSH-major] Adenoma / pathology. Colonic Polyps / pathology. Colorectal Neoplasms / pathology. Precancerous Conditions / pathology

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18034359.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


88. Soon MS, Soon A, Lin TY, Lin OS: Distribution of colon neoplasia in Chinese patients: implications for endoscopic screening strategies. Eur J Gastroenterol Hepatol; 2008 Jul;20(7):642-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distribution of colon neoplasia in Chinese patients: implications for endoscopic screening strategies.
  • OBJECTIVES: Our aim was to measure the prevalence and distribution of colonic neoplasia in Chinese adults, and to estimate the sensitivity of sigmoidoscopic screening strategies for detecting those with advanced neoplasia.
  • The prevalence and distribution of colonic neoplasia and advanced neoplasia (defined as an adenoma >or=10 mm or with villous, high-grade dysplastic, or malignant features) were reviewed retrospectively and the outcomes of various sigmoidoscopic screening strategies estimated.
  • Overall, 24 patients had advanced neoplasia in the proximal colon, of whom four had synchronous distal neoplasia.
  • [MeSH-minor] Adenoma / diagnosis. Adenoma / ethnology. Adenoma / pathology. Age Distribution. Aged. Colonoscopy. Epidemiologic Methods. Female. Humans. Male. Middle Aged. Sex Distribution. Taiwan / epidemiology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18679066.001).
  • [ISSN] 0954-691X
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


89. Pellisé M, Fernández-Esparrach G, Cárdenas A, Sendino O, Ricart E, Vaquero E, Gimeno-García AZ, de Miguel CR, Zabalza M, Ginès A, Piqué JM, Llach J, Castells A: Impact of wide-angle, high-definition endoscopy in the diagnosis of colorectal neoplasia: a randomized controlled trial. Gastroenterology; 2008 Oct;135(4):1062-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND & AIMS: It is essential to optimize standard colonoscopy technique to be able to increase polyp detection.
  • Morphology, size, location, and pathologic diagnosis of each polyp were recorded.
  • Pathology examination was feasible in 418 lesions (272 adenomas, 109 hyperplastic polyps, and 37 inflammatory lesions).
  • Both techniques detected a similar number and type of lesions, and there were no differences in the distribution along the colon, in the degree of dysplasia, or morphology of adenomas.
  • The per-patient basis analyses demonstrated that there were no differences between the 2 arms of the study in the detection rates of polyps (SC, 0.84 +/- 1.59; HDE, 0.83 +/- 1.30), adenomas (0.45 +/- 1.07 vs 0.43 +/- 0.87), small adenomas (0.22 +/- 0.71 vs 0.28 +/- 0.78), flat adenomas (0.30 +/- 0.91 vs 0.21 +/- 0.63), or hyperplastic polyps (0.16 +/- 0.50 vs 0.18 +/- 0.54).
  • [MeSH-major] Adenomatous Polyps / pathology. Colorectal Neoplasms / pathology. Endoscopes, Gastrointestinal. Endoscopy, Gastrointestinal / methods. Endoscopy, Gastrointestinal / standards
  • [MeSH-minor] Adenoma / pathology. Adult. Aged. Female. Humans. Male. Middle Aged. Patient Selection. Reproducibility of Results

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gastroenterology. 2008 Oct;135(4):1035-7 [18786535.001]
  • (PMID = 18725223.001).
  • [ISSN] 1528-0012
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] United States
  •  go-up   go-down


90. Ma DF, Kondo T, Nakazawa T, Niu DF, Mochizuki K, Kawasaki T, Yamane T, Katoh R: Hypoxia-inducible adenosine A2B receptor modulates proliferation of colon carcinoma cells. Hum Pathol; 2010 Nov;41(11):1550-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypoxia-inducible adenosine A2B receptor modulates proliferation of colon carcinoma cells.
  • In this study, we examined the expression pattern of adenosine receptors in various colorectal tissues and human colon carcinoma cell lines and investigated the biologic functions regarding colon carcinogenesis.
  • Using reverse transcriptase polymerase chain reaction and Western blotting, we found that adenosine receptor A2B (ADORA2B) was consistently up-regulated in colorectal carcinoma tissues and colon cancer cell lines compared with normal colorectal mucosa.
  • In immunohistochemistry, we observed diffuse immunopositivity of ADORA2B in 67% of colorectal adenocarcinomas (39/58), 17% of tubular adenomas (5/30), and 0% of normal colon glands (0/62).
  • During a hypoxic state, there was also a significant induction of ADORA2B expression in the messenger RNA level at 8 hours of incubation and in the protein level at 24 hours of incubation in colon carcinoma cell lines.
  • To examine the function of ADORA2B, we applied an ADORA2B-selective antagonist (MRS1754) to the colon carcinoma cells, which significantly inhibited cell growth in a dose-dependent manner as demonstrated with a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide cell proliferation assay.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma / pathology. Colorectal Neoplasms / pathology. Receptor, Adenosine A2B / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20619442.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Acetamides; 0 / Adenosine A2 Receptor Antagonists; 0 / Antineoplastic Agents; 0 / N-(4-cyanophenyl)-2-(4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)-phenoxy)acetamide; 0 / Purines; 0 / RNA, Messenger; 0 / Receptor, Adenosine A2B
  •  go-up   go-down


91. Kalady MF, McGannon E, Vogel JD, Manilich E, Fazio VW, Church JM: Risk of colorectal adenoma and carcinoma after colectomy for colorectal cancer in patients meeting Amsterdam criteria. Ann Surg; 2010 Sep;252(3):507-11; discussion 511-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of colorectal adenoma and carcinoma after colectomy for colorectal cancer in patients meeting Amsterdam criteria.
  • Therefore, when colon cancer is diagnosed, total rather than segmental colectomy is advocated.
  • However, information about adenoma and carcinoma risk after index surgery is still underreported.
  • Metachronous colorectal adenoma and carcinoma development were the primary end points.
  • In 74 patients (33%), 256 adenomas were detected, including 140 high-risk adenomas in 48 patients (22%).
  • By comparison, 4 of 38 patients (11%) who underwent total colectomy developed subsequent high-risk adenomas and 3 (8%) developed metachronous cancer.
  • CONCLUSIONS: Amsterdam patients undergoing partial colectomy have a high rate of metachronous high-risk adenomas and carcinomas.
  • For either surgical option, yearly endoscopic surveillance is essential to remove premalignant adenomas.
  • [MeSH-major] Adenoma / epidemiology. Carcinoma / epidemiology. Colectomy / methods. Colorectal Neoplasms, Hereditary Nonpolyposis / pathology. Colorectal Neoplasms, Hereditary Nonpolyposis / surgery. Neoplasms, Second Primary / epidemiology


92. Paik SS, Jang SM, Jang KS, Lee KH, Choi D, Jang SJ: Leptin expression correlates with favorable clinicopathologic phenotype and better prognosis in colorectal adenocarcinoma. Ann Surg Oncol; 2009 Feb;16(2):297-303
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Leptin expression was evaluated on the tissue microarray of 44 normal colon mucosal tissues, 44 adenomatous polyps, and 437 colorectal adenocarcinomas by immunohistochemistry.
  • Frequency of leptin expression was dramatically increased from normal colonic mucosa (2/44, 4.5%) to adenomas (13/44, 29.5%) and adenocarcinomas (321/437, 73.5%) as neoplastic progression.
  • We conclude that leptin was gradually expressed during the normal-adenoma-adenocarcinoma sequence, suggesting an association in colorectal carcinogenesis.
  • [MeSH-minor] Adenoma / metabolism. Adenoma / pathology. Adenomatous Polyps / metabolism. Adenomatous Polyps / pathology. Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Child. Colon / metabolism. Colon / pathology. Female. Humans. Immunoenzyme Techniques. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Phenotype. Survival Rate. Tissue Array Analysis. Young Adult

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19050975.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Leptin
  •  go-up   go-down


93. Løvig T, Andersen SN, Clausen OP, Rognum TO: Microsatellite instability in long-standing ulcerative colitis. Scand J Gastroenterol; 2007 May;42(5):586-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Ulcerative colitis (UC) is a chronic inflammatory disease of the colon associated with a high risk of developing colorectal cancer.
  • RESULTS: High-level MSI (MSI-H) was detected in one villous adenoma with high-grade dysplasia and right-sided location.
  • CONCLUSIONS: This study suggests that MSI is rare in UC-related neoplasia as well as non-neoplastic lesions, and does not contribute to the development of dysplasia.

  • Genetic Alliance. consumer health - Ulcerative Colitis.
  • MedlinePlus Health Information. consumer health - Ulcerative Colitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17454879.001).
  • [ISSN] 0036-5521
  • [Journal-full-title] Scandinavian journal of gastroenterology
  • [ISO-abbreviation] Scand. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / BAT26 microsatellite DNA; 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Genetic Markers
  •  go-up   go-down


94. Daniel P, Wagrowska-Danilewicz M, Danilewicz M, Stasikowska O, Malecka-Panas E: Transforming growth factor beta 1 and metalloproteinase-9 overexpression in colorectal cancer (CC) and adenoma. Int J Colorectal Dis; 2007 Oct;22(10):1165-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transforming growth factor beta 1 and metalloproteinase-9 overexpression in colorectal cancer (CC) and adenoma.
  • The aim of the study was to determine the pattern of immunohistochemical expression of TGFbeta1, MMP-9, and Ki-67 in CC and adenomatous polyps.
  • PATIENT/METHODS: The study group comprised 50 patients with colorectal polyps and 33 patients with CC.
  • Endoscopically removed polyps and CC biopsies had been evaluated with histopatologic examination and immunohistochemistry.
  • RESULTS: Among 62 adenomas, 33 high-grade dysplasia (HGD) and 29 low-grade dysplasia (LGD) had been detected.
  • Mean TGFbeta1, MMP-9, and Ki-67 LI in CC were significantly higher (p < 0.01, 0.01, and 0.01, respectively) than in HGD polyps.
  • Mean TGFbeta1, MMP-9, and Ki-67 LI in HGD polyps were significantly higher than in LGD polyps (p < 0.01, 0.01, and 0.01, respectively).
  • CONCLUSION: The increased expression of TGFbeta1, MMP-9 observed in colorectal adenomas seems to be related to the grade of dysplasia.
  • [MeSH-major] Adenoma / metabolism. Colorectal Neoplasms / metabolism. Matrix Metalloproteinase 9 / metabolism. Transforming Growth Factor beta1 / metabolism

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Colorectal cancer 1.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1995 Sep;72(3):575-82 [7669564.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2000 Sep;8(3):175-82 [10981868.001]
  • [Cites] Surgery. 2003 May;133(5):568-79 [12773985.001]
  • [Cites] Gastroenterology. 1994 Nov;107(5):1488-95 [7926512.001]
  • [Cites] Mod Pathol. 1991 Mar;4(2):239-46 [1646457.001]
  • [Cites] Future Oncol. 2006 Dec;2(6):743-63 [17155901.001]
  • [Cites] Clin Exp Metastasis. 1993 Mar;11(2):183-9 [8444010.001]
  • [Cites] Cancer Res. 1990 Jul 1;50(13):3872-7 [2162246.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):607-14 [10080606.001]
  • [Cites] J Natl Cancer Inst. 1993 Apr 7;85(7):574-8 [8384265.001]
  • [Cites] Br J Cancer. 1996 Sep;74(5):753-8 [8795578.001]
  • [Cites] Biochem Biophys Res Commun. 1989 Jan 16;158(1):228-34 [2536277.001]
  • [Cites] Pathol Oncol Res. 1999;5(4):273-9 [10607921.001]
  • [Cites] Br J Cancer. 1998 Dec;78(11):1495-502 [9836483.001]
  • [Cites] Cancer Res. 1996 Jul 15;56(14):3366-70 [8764135.001]
  • [Cites] Oncol Rep. 2003 Nov-Dec;10(6):1741-5 [14534689.001]
  • [Cites] Br J Cancer. 1999 Apr;80(1-2):194-205 [10389996.001]
  • [Cites] Carcinogenesis. 1999 May;20(5):749-55 [10334190.001]
  • [Cites] World J Gastroenterol. 2005 Jun 7;11(21):3245-9 [15929175.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8621-3 [12861075.001]
  • [Cites] Biochim Biophys Acta. 2007 Jan;1775(1):21-62 [16904831.001]
  • [Cites] Oncol Rep. 2005 Jan;13(1):115-20 [15583811.001]
  • [Cites] Cancer Res. 1999 Jan 15;59(2):320-4 [9927040.001]
  • [Cites] J Clin Gastroenterol. 1992 Dec;15(4):317-20 [1294637.001]
  • [Cites] Eur J Surg Oncol. 2002 Feb;28(1):24-9 [11869009.001]
  • [Cites] Eur J Cancer. 2001 Jan;37(2):224-33 [11166150.001]
  • [Cites] Dis Colon Rectum. 1997 Mar;40(3):322-5 [9118748.001]
  • [Cites] Annu Rev Biochem. 1998;67:753-91 [9759503.001]
  • [Cites] J Neurooncol. 1994;18(2):105-9 [7964973.001]
  • [Cites] N Engl J Med. 2000 May 4;342(18):1350-8 [10793168.001]
  • [Cites] Mol Carcinog. 2006 Oct;45(10):786-94 [16921482.001]
  • [Cites] J Exp Clin Cancer Res. 1997 Sep;16(3):281-8 [9387902.001]
  • [Cites] Dis Colon Rectum. 1996 Nov;39(11):1255-64 [8918435.001]
  • [Cites] World J Gastroenterol. 2002 Aug;8(4):674-8 [12174377.001]
  • [Cites] J Natl Cancer Inst. 1997 Sep 3;89(17):1260-70 [9293916.001]
  • [Cites] APMIS. 1997 Sep;105(9):730-4 [9350218.001]
  • [Cites] Br J Cancer. 1993 Jul;68(1):137-9 [8318404.001]
  • [Cites] Biochim Biophys Acta. 2004 Dec 17;1705(2):69-89 [15588763.001]
  • [Cites] Br J Surg. 2005 Aug;92(8):1002-7 [15931661.001]
  • [Cites] Hum Pathol. 1989 Jul;20(7):696-700 [2661411.001]
  • [Cites] Oncogene. 1998 Oct 15;17 (15):1969-78 [9788440.001]
  • [Cites] Cancer Res. 1996 Jul 15;56(14):3359-65 [8764134.001]
  • [Cites] Cancer. 1989 Dec 15;64(12):2501-5 [2684387.001]
  • [Cites] Int J Cancer. 1994 Jul 1;58(1):50-6 [8014015.001]
  • [Cites] Adv Cancer Res. 1997;71:165-207 [9111866.001]
  • [Cites] Neoplasma. 2005;52(5):420-4 [16151588.001]
  • (PMID = 17394006.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Transforming Growth Factor beta1; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


95. Oberwalder M, Zitt M, Wöntner C, Fiegl H, Goebel G, Zitt M, Köhle O, Mühlmann G, Ofner D, Margreiter R, Müller HM: SFRP2 methylation in fecal DNA--a marker for colorectal polyps. Int J Colorectal Dis; 2008 Jan;23(1):15-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SFRP2 methylation in fecal DNA--a marker for colorectal polyps.
  • INTRODUCTION: DNA methylation of secreted frizzled-related proteins (SFRPs) can be detected in colorectal cancer (CRC) tissue, in tissue of adenomas, and in aberrant crypt foci, whereas in normal colorectal mucosa tissue, SFRP genes are unmethylated.
  • The purpose of this study was to clarify whether SFRP2 methylation in fecal DNA can be found in stool of individuals with hyperplastic and adenomatous colorectal polyps.
  • MATERIALS AND METHODS: Patients who were diagnosed with colorectal polyps or showed negative colonoscopy were included in this study.
  • RESULTS: Stool samples from 68 individuals were checked for DNA content; 23% of the samples (6 of 26) from healthy controls, 46% of the samples (6 of 13) from patients with hyperplastic polyps, and 45% of the samples (13 of 29) from patients with adenomas were positive for human DNA.
  • SFRP2 methylation in stool samples was found in none of the healthy controls, in 33% (2 of 6) patients with hyperplastic polyps, and in 46% (6 of 13) patients with adenomas.
  • Statistical analysis revealed that the frequency of SFRP2 methylation increased significantly (P=0.028) from healthy controls to patients with hyperplastic polyps and to patients with adenomas.
  • CONCLUSIONS: In the current study, we report for the first time that SFRP2 methylation in fecal DNA increases significantly from healthy controls to patients with hyperplastic polyps and to patients with adenomas.
  • SFRP2 methylation may serve as a marker for molecular stool-based adenoma and CRC screening.
  • [MeSH-major] Adenomatous Polyps / genetics. Biomarkers, Tumor / genetics. Colonic Polyps / genetics. Colorectal Neoplasms / genetics. DNA Methylation. Gene Expression Regulation, Neoplastic. Membrane Proteins / genetics. Precancerous Conditions / genetics

  • MedlinePlus Health Information.